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The human immune system has evolved to fulfil a myriad of functions. It has to confer protection 
from potentially harmful infectious agents including bacteria, viruses and parasites and fight malignant 
cells, but tolerate self-tissue and foreign, but harmless substances introduced via e.g. the lungs or 
the digestive system. This is reflected in the complexity of the immune system, with various innate and 
adaptive, often highly specialized effector functions at interplay. Helminth (greek: ‘intestinal worm’) 
infections are likely as old as humanity itself. The co-evolution of helminths and humans has not only 
resulted in specified immune responses against helminths, but also in the development of immune 
evasion mechanisms by these parasites and even a selective pressure to alter the host’s genetic 
composition and thereby shape the immune system 1-3. 
1. an IntroductIon to schIstosoma
Schistosoma (S.) spp. are parasitic flatworms of the genus trematode. In humans, they cause an 
acute and chronic disease known as schistosomiasis/bilharzia. The species causing most human 
schistosomiasis cases are S. mansoni, S. japonicum and S. haematobium 3. In 2016, an estimated 
206.4 million people, mainly in poor and rural communities of tropical and subtropical areas, required 
preventative treatment 4. Schistosoma spp. parasites can cause severe disease, but can also survive in 
the human host up to 20 years, meaning both mortality and morbidity are major concerns. 
1.1. Immunity to schistosoma spp.  
Many features of schistosomiasis and the underlying immunological processes can be replicated well in 
animal models, most commonly infected with S. mansoni or S. japonicum. The immunological response 
to Schistosoma can be divided into an acute and a chronic phase. The acute phase, in response to 
premature life cycle stages that penetrate the host skin and subsequently migrate through several 
tissues including the lung, is initially characterized by a type 1 immune response. A much stronger 
type 2 immune response is however induced in response to eggs released by mating adult worm pairs 
starting 5-6 weeks post infection. S. mansoni and S. japonicum adult worm pairs reside in the mesenteric 
vein, and part of the released eggs penetrate through the tissue into the intestinal lumen where they 
are released into the environment with the faeces. Importantly, many eggs are transported with 
the blood flow into the liver and other organs. Tissue-entrapped eggs and the resulting inflammatory 
granulomatous response are the main drivers of pathology 5. The egg-specific type 2 response 
predominates the earlier type 1 response 6. In the chronic phase of infection, regulatory responses are 
induced which contribute to limiting immunopathology despite the continuous release of eggs, and 
allow long-term parasite survival in the host.
Type 2 immune responses have a major role in both the host defence against helminths or venoms 
and in allergic disorders. The central features of a type 2 response shared by immune responses to 
helminth and allergens include the induction of CD4+ T helper (Th) 2 cells and their innate counterpart, 
type-2 innate lymphoid cells (ILC2s), which both produce the type 2 cytokines interleukin-4 (IL-4), IL-5, 
IL-9 and IL-13, the induction of B cell IgE production and the recruitment and activation of granulocytes 
and alternatively activated macrophages (AAMs) 7. The type 2 immune response to helminth is diverse 
and adapted to the type of helminth, with the classical ‘weep and sweep’ response including increased 
smooth-muscle-cell contractility, intestinal permeability and goblet-cell mucus production that 
has developed to expel intestinal helminths 8. The type 2 response to Schistosoma spp., resident in 
the vasculature, is induced in response to antigens released by the eggs 6, 9. Characteristic for this type 2 
response is the formation of granulomas around tissue-entrapped eggs, which mainly consist of CD4+ 
Th2 cells, ILC2s as well as eosinophils and macrophages. The central, and dichotomous, role of type 
2 immunity in schistosomiasis becomes apparent in transgenic mouse models. Mice deficient in IL-4 




onset 10, 11, highlighting the modulatory and host-protective role of Th2 responses especially during 
the acute stage of disease. Mice deficient in IL-13 or IL4Rα, the shared receptor for both IL-4 and 
IL-13, do not develop severe hepatic fibrosis as wild-type (WT) animals do, resulting in prolonged 
survival 10, 12. This in turn demonstrates that prolonged type 2 responses during chronic infection 
contribute to morbidity.
1.2. schistosoma spp. eggs & egg antigens
In the context of experimental intraperitoneal (i.p.) administration, eggs can be considered as ‘antigen 
reservoirs’. After intravenous (i.v.) injections, eggs transported with the blood stream get trapped in 
the lung 13, which serves as a model to study lung inflammation in response to Schistosoma spp. In 
contrast, eggs likely remain in the peritoneal cavity after i.p. injection. S. mansoni soluble egg antigens 
(SEA), which is the soluble fraction of homogenized eggs, is a complex mixture of hundreds of antigens, 
many of which are glycoproteins 14, 15. The S. mansoni egg excretory-secretory product (ES), which 
represents the entirety of molecules released by cultured eggs, has been described to still contain 
188 proteins 16. Some of the most abundant proteins, including IPSE/alpha-1 17-21 and omega-1 22-27, 
have been well-characterized and described to fulfil distinct functions. Others, such as kappa-5 28, 29, 
lyso-PS 30 or SmCKBP 31 are less well characterized, and for many the function is completely unknown. 
Some immunomodulatory molecules of Schistosoma spp. life cycle stages other than eggs have 
been described, including Smteg, Sm22.6, PIII and Sm29, all of which have been described to prevent 
allergic airway inflammation (AAI) 32, 33, and cyclophilin A 34. The only description of a Schistosoma spp. 
egg-derived molecule inhibiting AAI is the S. japonicum molecule SjP40 35. Schistosoma spp. single 
molecules and their described functions are summarized in table 1.
1.3. the regulatory network 
The immune regulatory network, induced during the chronic phase of infection, suppresses the host 
immune system to allow parasite survival while preventing excessive tissue damage. Immunomodulation 
is thus advantageous for both the parasite and the host. The induction of regulatory T (Treg) cells, 
the most prominent component of the regulatory network, by Schistosoma spp. has been described 
in both human and murine studies 36-38. Treg cells suppress effector T cell responses in murine 
schistosomiasis 38, 39, and depletion of Treg cells during the acute or chronic phase of infection results 
in increased granulomatous immunopathology 40, 41. An adoptive transfer of S. mansoni-primed Treg 
cells or a retroviral transfer of the Foxp3 gene suppresses granuloma formation and ameliorates 
immunopathology 40-42. More recently, additional members of the regulatory network, such as regulatory 
B (Breg) cells (see section 2) and AAMs 43, have been described. Importantly, cells of the regulatory 
network are interrelated and synergize, e.g. Breg cells induce Treg cell generation. The aforementioned 
regulatory immune cells possess various effector functions. One of the most prominent ones is immune 
modulation through the regulatory cytokine IL-10 44, 45. As a result of the induced regulatory network, 
both antigen-specific and non-specific, more generalized immune modulation occurs. Importantly, 
the regulatory network also results in ‘spill-over suppression’ and diminished responses to allergens 
(see section 3), vaccinations and co-infections 46. Another member of the regulatory network are 
AAMs, which play a central role in tissue remodelling 47. This rapid wound healing response is a central 
component of type 2 immunity, as it prevents excessive host tissue damage and pathology caused by 
large, multicellular parasites such as helminths 48. 
2. reGulatory b cells
The first description of B cells with suppressive capacities stems from 1974, when it was observed that B 






































































































































































































































































































































































































































































































































































































































































































































































of suppressive B cells in murine models of autoimmune diseases were published 51-53 and the term 
‘regulatory B cell’ introduced. 
2.1. Phenotype & origin
Breg cells is an umbrella term for a heterogeneous group of B cells that comprise immunomodulatory 
capacity. Various Breg cell subsets have been described both in humans and mice, depending on their 
origin, the tissue they reside in, their phenotype and mode of action. To date, it is unknown whether 
Breg cells develop from a committed precursor or whether any B cell can acquire suppressive capacity 
in response to certain environmental stimuli, and different models are discussed in the literature 54, 55. 
Extensive overviews over different Breg cell subsets and the range of described suppressor mechanisms 
has also been provided in the literature 44, 55, 56. In brief, both murine B cell lineages, innate-like B1 B 
cells abundant in peritoneal and pleural cavity 57 and B2 B cells that populate secondary lymphoid 
organs, can give rise to Breg cells. Of B2 B cells, especially marginal zone (MZ) B cells 58, 59 and their 
precursors (transitional type MZ precursors, T2-MZP) 60, 61 have been described to acquire regulatory 
functions. More recently, plasma blasts and plasma cells have also been acknowledged to produce 
regulatory cytokines and act suppressive 62, 63. In humans, Breg cells are mainly characterized within 
the CD24hiCD38hi immature B cell and the CD24hiCD27+ B cell compartment 64, 65. Suppressive functions 
of Breg cells other than IL-10 production, include e.g. the release of other regulatory cytokines including 
IL-35 and transforming growth factor beta (TGF-β), the induction of Treg cells and suppression of 
effector T cells through expression of ligands such as FasL, ICAM-1/LFA-1, GITRL or PD-L1 66. 
2.2. signals for the induction and expansion of breg cells
Breg cells are present in naïve individuals and mice, but often expand and display increased suppressive 
activity in the context of autoimmunity and infection 44, 67, 68. Various signals have been described to 
play a role in Breg cell development and activation, of which stimulation through the B cell receptor 
(BCR) 53, 69, 70, CD40 53, 60, 71, 72, and Toll-like receptors (TLRs; especially TLR4 73-75, TLR7 76 and TLR9 58, 73) are 
considered most central. Moreover, different cytokines including IL-15 77, IL-21 78, IL-35 62, 79, BAFF 80, 
APRIL 81 and type I interferons 63 have been described to support Breg cell development and activation.
Recently, it has also been acknowledged that microbiota-derived signals contribute to Breg cell 
activation. The microbiome induces Breg cells in the spleen and the mesenteric lymph node (LN) in 
an IL-1β- and IL-6-dependent manner. Mice with a disrupted microbiome have an impaired Breg cell 
compartment and develop exacerbated autoimmunity 82. Other studies confirmed that alterations of 
the gut microbiome, either by increased estrogen levels or housing animals under specific-pathogen-
fee conditions, induce IL-10-producing Breg cells in the spleen and the mesenteric LN 83, 84.
It is likely that more than one stimuli and converging signalling pathways are needed to achieve 
maximal Breg cell development and activation. A two-step model has been proposed for the acquisition 
of regulatory properties by B cells, with the exposure to innate stimuli (e.g. TLR ligands) as first step 
initiating IL-10 production, and BCR or CD40 ligation as a second step promoting B cell survival and 
activation and thus amplifying suppression 61, 73. Other studies suggest that TLR and CD40 ligation 
may enable B cell IL-10 expression by promoting differentiation into IL-10-competent plasmablasts or 
plasma cells 62, 63. 
It is worth noting that the signals required for the development and activation of Breg cells likely 
differ in vivo and in vitro. During an inflammatory response in vivo, multiple processes occur in parallel 
at any given time, while in vitro systems allow to dissect the role of individual signals and pathways, 
but often fail to mimic the complexity in vivo.
12
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2.3. breg cells in helminth infection
The first indication that B cells with regulatory properties are induced during helminth infection has 
been made 20 years ago in µMT mice lacking mature B cells, which develop augmented pathology 
following S. mansoni infection 85. Subsequently, different helminth species have been shown to induce 
Breg cells 86-89. These helminth-elicited Breg cells have immunomodulatory capacities in a variety 
of autoimmune and inflammatory conditions, including anaphylaxis 90, experimental autoimmune 
encephalomyelitis (EAE) 87, 91 and AAI 86, 87, 92. In humans, Breg cells have also been identified in helminth-
infected individuals 88, 93.
Options of how helminth or their products induce Breg cells are a) the direct ligation of above 
mentioned receptors, e.g. the BCR or TLRs on B cells by helminth molecules, and b) signals derived 
from accessory cells (e.g. via the ligation of CD40) or the general inflammatory environment (e.g. 
cytokines) induced by helminth infection. That Breg cells can be directly induced by Schistosoma 
spp. products in both mice and humans has been shown by in vitro co-culture of murine, purified 
splenic B cells with living S. mansoni worms 86, and by in vitro stimulation of PBMC-derived B cells with 
SEA 94, respectively. S. mansoni infection has been described to induce the expression of Tlr7 in Breg 
cells. TLR7 ligation was moreover found to facilitate IL-10 production, it remains unclear however 
whether this is the consequence of direct TLR7 ligation by a S. mansoni molecule 76. Despite these 
studies suggesting a direct Breg cell induction by helminths and their products is possible, it is plausible 
that in vivo, Breg cells also receive signals from accessory cells and their environment.
The description of helminth-specific signals that induce Breg cells is limited. In the context of 
Schistosoma spp., in vitro exposure of murine splenocytes to live worms 86, 90 and of human peripheral 
blood B cells from helminth-infected individuals to SEA 94 has been reported to induce IL-10-producing 
Breg cells. In all these cases the molecular identity of the stimulus has however not been identified. 
The milk oligosaccharide lacto-N-fucopentaose III (LNFP-III), which carries a glycosylation pattern that 
also occurs on Schistosoma spp. products and is therefore cross-reactive, has been described to induce 
B cell IL-10 production 95. Except for the stimulation of isolated human B cells from helminth-infected 
individuals with SEA 94, which may be a recall reaction of memory B cells, it remains unclear whether 
the observed Breg cell induction is the result of a direct interaction of with receptors on B cells. For 
helminth other than Schistosoma spp., the glycoprotein ES-62 from Acanthocheilonema viteae and an 
extract from Brugia malayi, both filarial nematodes, also induce IL-10 production by B cells 96, 97. 
2.4. breg cell transcriptomics
Transcriptomics allows to study the complete set of genes transcribed at a certain time point and 
potentially allows insight into the whole breadth of cellular processes at interplay. To date, only 
few studies have utilized transcriptomics approaches to gain insight into the signals required for 
the development and activation of Breg cells. Khan et al. reported that Tlr7 is significantly upregulated 
on S. mansoni-induced CD19+CD1dhi B cells compared to naïve control cells and CD19+CD1dlo B cells 
from infected animals, and that TLR7 ligation increases their IL-10 production 76. Another study by Sun 
et al. identifies CD9 as a marker of murine IL-10-competent, CD19+CD1dhiCD5+ Breg cells induced by 
in vitro polyclonal stimulation. Although the exact role of CD9 remains unclear, the study also suggests 
that CD9 might play a role in the immunosuppressive function of Breg cells, as blocking CD9 in vitro 
impaired their ability to suppress T cell proliferation 98. CD9+ B cells have subsequently been described 
to suppress house dust mite-induced AAI 99.
3. allerGy and asthma
Asthma is an atopic, chronic inflammatory disorder that is estimated to affect 315 million people 




and airway obstruction, resulting in episodes of wheezing and breathlessness. First episodes of atopic 
disease often occur during childhood following sensitization to inhaled allergen, and infants who suffer 
from atopic disease often develop allergic asthma later in life. Recent studies suggest that the incidence 
of asthma has now reached a plateau in high prevalence countries 101. The global burden of asthma 
however continues to rise as incidence rates in Africa, South America, and parts of Asia still rapidly 
increase 102. Asthma is a multivariable disease in which genetic predispositions are certainly important 
risk factors. Genome-wide association studies (GWAS) have identified different susceptibility loci, most 
prominently the chromosome 17q21 region and various genes of the type 2/IgE cluster, including 
e.g. Il33 and Tslp (thymic stromal lymphopoeitin), which are genes encoding type 2 innate cytokines 
produced by bronchial epithelial cells 103, 104. However, the rapid increase in incidence rates over the last 
few decades points toward a strong contribution of environmental factors to disease development. 
3.1. hygiene & old friends hypothesis, epidemiological evidence  
The ‘hygiene hypothesis’ already postulated in 1989 105 suggests that a decrease in childhood exposure 
to infectious agents as a result of increasing sanitation standards, improved health care, and life style 
changes contributes to the increase in incidence of allergies and asthma. This conceptual framework 
has been developed further into the ‘old friends hypothesis’, suggesting an evolutionary adaptation of 
our immune system to the continuous encounter with microbes and infectious agents, and a tendency 
towards an over-reactive immune system in their absence. Both concepts suggest that a reduction 
in infectious pressure over time leads to an immune system imbalance promoting allergic and other 
immune-mediated disorders such as inflammatory bowel disease (IBD) or multiple sclerosis (MS) 106.
The increase in asthma and other immune-mediated diseases correlates with urbanization 
and economic development, but a causal link has not been demonstrated so far. As one possible 
factor, changes in the exposure to pathogenic microbes, including helminths, have been suggested. 
The incidence of helminth infections is inversely correlated with increasing asthma rates in westernized 
countries. The ability of helminths to establish chronic infections and induce regulatory immunity 
has generated strong interest in the possibility that helminths or their products suppress hyper-
inflammation and could be used as new anti-inflammatory treatment strategy 107. 
The association between helminth infections and the reduced incidence of allergic disorders has 
been addressed in numerous epidemiological studies, yielding heterogeneous results. Meta-analyses 
show that there is no overall effect of helminth infections on asthma, but that hookworm infections do 
protect against allergic sensitization 108-110. Individual studies have also suggested that infections with 
S. mansoni reduce the severity of asthma 111 and allergic skin reactions 112, 113. While early clinical trials 
using eggs of the pig whipworm Trichuris suis (TSO) or experimental hookworm infections, both of 
which are intestinal helminths, resulted in promising safety and efficacy data in patients with intestinal 
inflammatory diseases, efficacy could not be demonstrated in larger studies or studies with allergic or 
asthmatic subjects 107. Potential reasons for the heterogeneity in results from epidemiological studies 
and clinical trials, apart from the helminth species, include a range of other factors such as time, 
location, intensity and chronicity of infection and host genetics 114.
3.2. Immunity in asthma
The asthmatic immune response is complex, with a multitude of innate and adaptive, cellular and 
humoral processes at interplay. During allergic sensitization, epithelial cells produce cytokines including 
TSLP, IL-25 and IL-33, which activate DCs and ILC2s to induce Th2 cell polarization. Upon renewed 
allergen exposure, Th2 cells and ILC2s quickly produce large amounts of type 2 cytokines including IL-4, 
IL-5 and IL-13, which in turn cause class-switching of B cells to IgE and the recruitment and activation 
of eosinophils, mast cells and basophils 115, 116. Mast cells and basophils release inflammatory mediators 
14
CHAPTER 1
such as histamines following cross-linking of allergen-specific IgE bound to surface IgE Fc-receptors, 
amplifying the allergic response and resulting in an acute reaction including mucus production 
and bronchoconstriction 115, 117. 
3.3. helminth-mediated protection against aaI
Helminths have developed various strategies to modulate the host immune system. They amplify 
the natural immune regulatory network of the host and modify pro-inflammatory immunity, thereby 
preventing exaggerated immune responses to ubiquitous antigens such as allergens.
Early insight into the protective effects of helminth infections stems from research using a variety 
rodent and human nematodes and Schistosoma spp. The latter provides a unique model of helminth 
infection as it, in contrast to the other models of mainly gastrointestinal nematodes used, allows to study 
both the role of egg deposition and chronicity of infection on protection against AAI. The literature 
published thus far on the protective effect of Schistosoma spp. infections is summarized in table 2. 
Building up on this work, several groups have successfully employed excretory-secretory products (ES) 
or, in the case of Schistosoma spp., SEA and eggs instead of natural infections. Ultimately, a range 
of single molecules that harbour protective effects against AAI have already been identified and 
their mode of action characterized, including Ancylostoma caninum AIP-2, Anisakis simplex MIF-like 
protein, Ascaris suum PAS-1, Acanthocheilonema vitae cystatin and ES-62 as well as Heligmosomoides 
polygyrus HpARI. For schistosomes, S. mansoni Smteg, Sm22.6, Sm29 and PIII as well as S. japonicum 
SjP40 have been described in the literature as single molecules with protective effects against AAI. 
The literature published thus far on the protective effect of helminth-derived molecules is summarized 
in table 3.
3.4. mechanisms of protection
A range of different mechanisms by which helminths and their molecules protect against AAI have 
been described, including the induction of Treg cells, regulatory macrophages and regulatory 
cytokines (IL-10, TGF-β), the induction of Th1 responses and IFN-γ which result in a shift in the Th1/
Th2 balance, as well as the inhibition of pro-inflammatory processes such as IL-33 release and mast cell 
degranulation (also see table 2 and table 3). 
Different mechanisms of protection have been suggested to be involved in conferring Schistosoma 
spp.-mediated protection from AAI. Schistosoma spp. provides an especially interesting model for 
experimental studies as its life cycle in the host includes the formation of adult worm pairs and 
continuous deposition of eggs. Infections with either mixed sex worms or only male worms allows 
to dissect the contribution of eggs to protection. Various studies identified Treg cells and Breg cells, 
respectively, as mediators of protection 32, 86, 88, 92, 118-120. Only some of these studies however provide 
functional experiments to formally prove their role in protection rather than solely showing an 
association between reduced AAI and elevated numbers or activity of these cells. One recent study 
links protective effects against AAI to an increased IFN-γ production 35.
The variety of proposed mechanisms most likely reflects the variety of different species, molecules 
and models studied. It is plausible that helminths have evolved distinct ways of altering the host 
immune response and promote their own survival.
3.5. development of novel therapies & outlook
Despite the drastic worldwide increase in asthma prevalence, not many novel therapies have 
been developed. The current treatment of asthmatic patients still consists of inhaled steroids and 
bronchodilators, which only alleviates symptoms and is impeded by the development of steroid 




tolerance are needed. Exploiting the modulatory capacities of evolutionary conserved ‘old friends’ like 
helminths might serve as a promising strategy towards the development of novel treatment options. 
Although early clinical trials investigating the use of natural helminth infections initially showed 
promising results in intestinal inflammatory diseases 121, 122, follow-up studies have shown little effect in 
allergy 123, 124 and efforts to use live infections as treatment strategies have since diminished. Treatment 
with live helminth infections also bears risks, and efforts have therefore intensified to identify single, 
helminth-derived molecules that mediate protection. 
4. scoPe of thIs thesIs
The induction of Breg cells by helminth parasites and the implication of helminth-induced immune 
modulation for providing protection from hyper-inflammatory disorders such as allergies has been 
extensively studied over the last decades. However, due to the complex immunity to helminth infections, 
it proved difficult to a) dissect the molecular signals for induction of Breg cells, and b) fully characterize 
cellular mechanisms of protection in allergic airway inflammation. Experimental S. mansoni infection 
and isolated S. mansoni eggs have provided us with tools to further address these research areas. 
The first part of this thesis focusses on the role of Breg cells in protection from AAI by chronic S. 
mansoni infections and aims at identifying molecular signals required for schistosome-induced Breg 
cell development.
In chapter 2 we build up on previous work and show that not only splenic B cells, but also 
pulmonary B cells induced during chronic S. mansoni infection can provide protection against airway 
inflammation. In chapter 3, we sought to identify S. mansoni-derived antigens that induce Breg cells 
and describe that the egg glycoprotein IPSE/alpha-1 directly interacts with splenic MZ B cells, induces 
IL-10 production and promotes Treg cell expansion. In chapter 4, we aimed to identify molecular 
signals contributing to Breg cell induction in vivo by performing transcriptomics on splenic B cell 
subsets from chronically infected mice. In chapter 5, we describe that type I interferons enhance Breg 
cell IL-10 production in response to S. mansoni antigens in vitro, but are dispensable in vivo. 
In the second part of this thesis, we build up on earlier work by us and others showing a protective 
effect of S. mansoni on experimental AAI, and aimed to identify protective, single S. mansoni-derived 
molecules.
chapter 6 summarizes and discusses the evidence for helminth-induced protection from AAI, 
mechanisms of protection, efforts towards the identification of protective, single helminth-derived 
molecules and the implications for the development of novel treatment strategies (as of 2014). 
In chapter 7, we describe that isolated S. mansoni eggs and the single egg-derived glycoprotein 
omega-1, in the absence of adult worms, also protect from AAI.
The main findings of this thesis are summarized and discussed in chapter 8, including directions 
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Chronic schistosome infections protect against allergic airway inflammation (AAI) via the induction 
of IL-10-producing splenic regulatory B (Breg) cells. Previous experiments have demonstrated that 
schistosome-induced pulmonary B cells can also reduce AAI, but act independently of IL-10. We have 
now further characterized the phenotype and inhibitory activity of these protective pulmonary B cells. 
We excluded a role for regulatory T (Treg) cell induction as putative AAI-protective mechanisms. 
Schistosome-induced B cells showed increased CD86 expression and reduced cytokine expression 
in response to Toll-like receptor (TLR) ligands compared with control B cells. To investigate 
the consequences for T cell activation we cultured ovalbumin (OVA)-pulsed, schistosome-induced 
B cells with OVA-specific transgenic T cells and observed less Th2 cytokine expression and T cell 
proliferation compared with control conditions. This suppressive effect was preserved even under 
optimal T cell stimulation by anti-CD3/28. Blocking of the inhibitory cytokines IL-10 or TGF-β only 
marginally restored Th2 cytokine induction. These data suggest that schistosome-induced pulmonary 
B cells are impaired in their capacity to produce cytokines to TLR ligands and to induce Th2 cytokine 
responses independent of their antigen-presenting function. These findings underline the presence of 






Chronic infections with the helminth Schistosoma mansoni are associated with immune hypo-
responsiveness and an enhanced regulatory network 1. Regulatory B (Breg) cells, which are 
predominantly characterized by an enhanced production of IL-10 2, are part of this network. Their 
functionality was first demonstrated in mouse models of autoimmune diseases such as experimental 
autoimmune encephalomyelitis (EAE), collagen-induced arthritis (CIA), lupus and chronic colitis 3. 
Interestingly, helminth-induced Breg cells also can inhibit inflammation and were shown to protect 
against EAE, systemic fatal anaphylaxis and ovalbumin (OVA)- or house dust mite allergen (Der p1)-
induced allergic airway inflammation (AAI) 4-6.
Murine Breg cells were mostly detected within splenic B cell subsets 2. Breg cells have also been 
found within the mesenteric lymph node (LN), highly expressing the low-affinity IgE Fc receptor 
CD23 during Heligmosomoides polygyrus infection 6, and within the B-1a B cell compartment of 
the peritoneal cavity 7. Various Breg cell-associated markers and suppressive mechanisms have been 
reported, however most of these studies are based on splenic populations. Apart from their capacity to 
produce IL-10, Breg cells have been described to induce other members of the regulatory network, e.g. 
regulatory T (Treg) cells 4, 5, 8, thereby amplifying the protective effect. B cells expressing the membrane-
bound T cell immunoglobulin and mucin domain-1 (Tim-1) were able to control auto-immune 9 and 
allergic diseases 10. Expression of CD25 by human Breg cells correlated with their IL-10 production 11, 
and in mice CD25+ Breg cells attenuated inflammatory bowel disease (IBD) 12. Furthermore, B cells 
expressing suppressive cytokines other than IL-10 have been described. TGF-β-producing Breg cells 
controlled inflammation in inhalation tolerance 13 and diabetes models 14, and IL-35-producing B cells 
regulated immunity during EAE and Salmonella infection 15, 16. B cells also have the capacity to suppress 
T cell proliferation and cytokine production via cell-cell interactions that involve inhibitory receptors, 
and result in T cell hypo-responsiveness or the induction of apoptosis. Examples of such inhibitory 
receptors are T cell-expressed PD-1, Fas as well as CTLA-4, and their respective ligands PD ligand 1 
(PD-L1), PD-L2, Fas ligand (FasL) and CD80/CD86 on antigen-presenting cells (APCs) including B cells.
Apart from their role as regulators, B cells play an important role in the induction and maintenance 
of Th2 immunity. B cells not only produce IgE and IgG1 antibodies, they can also directly interact with 
Th2 T cells and act as APCs to drive their expansion and cytokine production. Indeed, presentation 
of allergen by pulmonary B cells has been shown to be required for full Th2 cytokine production in 
AAI models using µMT and JH-/- mouse models 17, 18, and immunization experiments with the cysteine 
protease allergen papain suggest that B cells induce T cell/T follicular helper (Tfh) cell IL-4 production 
in the draining LN 19.
We have previously shown that S. mansoni-infected mice are protected against OVA-induced 
AAI, and that both splenic and pulmonary B cells from infected mice were able to transfer protection 
to OVA-sensitized mice 5, 20. Intriguingly, splenic B cells inhibited AAI via IL-10 and the induction of 
Treg cells, while pulmonary B cells essentially acted in an IL-10-independent manner in vivo 5. We 
hypothesized that schistosome infections support the development of distinct Breg cells in the lungs. 
Therefore, we further explored the effector mechanism by which pulmonary B cells can protect against 
AAI. Here, we demonstrate that pulmonary B cells from OVA-allergic mice which were infected with 
schistosomes are phenotypically and functionally distinct from splenic Breg cells. They have a reduced 
cytokine response to Toll-like receptor (TLR) ligands and a reduced Th2 cell priming capacity, which 




schistosome-induced pulmonary b cells do not share phenotypical characteristics of classical breg cells
We first set out to investigate whether a specific pulmonary B cell subset or the expression of specific 
surface markers linked to Breg cell activity was selectively expanded during schistosome infection 
compared with uninfected mice. Pulmonary B cells did not contain typical Breg populations that 
have been described in the spleen, such as CD1dhiCD5+, CD21hiCD23lo MZ or CD1dhiCD21hiCD23hiIgMhi 
transition type 2 MZ B cells (less than 0.5% of all pulmonary CD19+ B cells during infection, data not 
shown). Therefore, we analyzed several other cell-surface markers as putative markers of Breg cell 
phenotype and activity, e.g. the membrane-bound marker LAP, as part of a latent TGF-β complex, 
CD25, Tim-1, CD5 and CD23 6, 9, 10, 13, 14, 21. Pulmonary B cells from chronically S. mansoni-infected, OVA-
allergic (infected/OVA) mice which are known to be protective against AAI 5 had a similar increase 
in LAP-1+ and CD25+ cell frequencies over B cells from uninfected, non-allergic mice (uninfected/
PBS) as B cells from uninfected, OVA-allergic (uninfected/OVA) mice (figure 1a, suppl. figure s1a), 
suggesting that TGF-β- or CD25-expressing B cells are not involved in protection against AAI. Although 
the fold increase in Tim-1+ B cell frequencies was significantly higher (figure 1a, suppl. figure s1a) 
in infected/OVA compared with uninfected/OVA mice, the total percentages of Tim-1+ cells remained 
rather low (less than 7% of all pulmonary CD19+ B cells; suppl. figure s1a). CD5 is one of the markers 
that defines the B-1a subclass of B cells which have been described to have regulatory properties 7. 
The fold increase of CD5+ B cell frequencies was significantly reduced in infected/OVA compared with 
uninfected/OVA mice (figure 1a), indicating that this subclass of B cells is probably not important 
in mediating protection against AAI. The only marker assessed that was clearly enhanced on most 
pulmonary B cells in infected/OVA mice was CD23 (figure 1b, suppl. figure s1b). As the majority 
of pulmonary B cells in naïve mice already express CD23, the fold increase in % CD23+ cells is only 
moderate. However, the per cell expression level of CD23 strongly increases on infected/OVA B cells 
compared with their uninfected/OVA counterparts. The increase in CD23 expression is not surprising 
as enhanced frequencies of CD23-expressing B cells were already demonstrated for schistosome 
infections 22 and most probably reflects the general and modified type 2 inflammation present during 
chronic helminth infection 23. Furthermore, adoptive transfers of sorted CD23low/intermediate or CD23hi B cells 
from infected/OVA mice into OVA-sensitized mice remained inconclusive (data not shown), suggesting 
that the expression level of CD23 on pulmonary B cells does not correlate with suppressive function in 
our system. Collectively, we found that pulmonary B cells of chronically S. mansoni -infected animals 
do not show enhanced expression of phenotypic markers characteristic to classical Breg cell subsets. 
Pulmonary b cell-induced protection against aaI during schistosomiasis is independent of foxP3+ 
treg cells
We previously described that pulmonary B cells transfer protection to OVA-sensitized mice in an IL-
10-independent manner 24. We therefore set out to study the involvement of alternative inhibitory 
mechanisms. One of the major effector functions of murine Breg cells centers around the induction 
and/or recruitment of FoxP3+ Treg cells. In our previous studies, we observed that adoptive transfer of 
pulmonary B cells did not induce increased numbers of FoxP3+ Treg cells in vitro nor in vivo 5. However, 
this does not exclude the possibility that, despite equal numbers, the activity of Treg cells on a per 
cell basis had increased. We therefore transferred pulmonary B cells to FoxP3-DTR transgenic DEREG 
mice, in which Treg cells can be temporarily depleted by DT injections (figure 2a), to investigate 
the contribution of Treg cell activity during pulmonary B cell-induced protection against AAI. BAL 
eosinophil numbers remained equally reduced in both PBS- and DT-treated DEREG mice when receiving 




figure 1. schistosome-induced pulmonary b cells do not share phenotypical characteristics of classical 
regulatory b (breg) cells. Mice were chronically (15 weeks) infected with 36-40 Schistosoma mansoni cercariae. 
Allergic sensitization was induced by two i.p. injections of ovalbumin (OVA)/alum 1 week apart and control mice 
received PBS. Seven days after the last injection, mice were challenged by OVA aerosol exposure on three consecutive 
days. Mice were sacrificed 24 h after the last challenge. The perfused lungs were minced, digested and the single cell 
suspension from 2-3 mice pooled. Next, B cells were purified using anti-CD19 MicroBeads and stained for different 
Breg cell-associated markers. (a) The fold change of percentage surface latency-associated peptide (LAP-), CD25-, T 
cell immunoglobulin and mucin domain-1 (Tim-1)- and CD5-expressing B cells from uninfected- and infected/OVA 
mice over control (uninfected/PBS) are shown, representing a summary of 2-4 independent experiments (n=11-17/
group). (b) Fold change of percentage and geometric mean fluorescence intensity (MFI) of CD23 expression over 
control (uninfected/PBS). Summary of four independent experiments (n=14-17/group). Results are expressed as 
mean ± S.E.M. Significant differences are indicated as follows: **P <0.01, ***P <0.001, ****P <0.0001, as tested by 
two-tailed unpaired Student’s t-test.
not observe an enhanced induction of Treg cells by infected/OVA pulmonary B cells in in vitro co-
cultures with naïve T cells compared with co-cultures with B cells from allergic control mice (data not 
shown). These data indicate that AAI is not restored when Treg cell activity is abolished, and suggests 
that schistosome-induced pulmonary B cells do not drive protection against AAI via enhanced Treg 
cell activity.
schistosome-induced pulmonary b cells express elevated levels of cd86 ex vivo, and secrete less 
Il-10 after in vitro tlr ligation
T cell-derived Th2 cytokines play a dominant role in the induction and maintenance of AAI 25. We 
therefore aimed to investigate the role of pulmonary B cells as APCs and as modulators of effector T cell 
activation. Important signals that can influence T cell activation/induction of apoptosis, proliferation 
and cytokine production are, for example, provided by the co-stimulatory molecule CD86, antigen-
presentation molecule MHCII, inhibitory receptors such as PD-L1, PD-L2, FasL or various cytokines such 
as IL-10 and IL-6. To investigate a putative role for those (co-)stimulatory molecules and/or inhibitory 
receptors on schistosome-induced pulmonary B cells, we first analyzed the expression of the above-
mentioned molecules. Pulmonary B cells from infected/OVA mice showed a significantly increased 
CD86 expression compared with B cells from uninfected/OVA mice. Expression levels of MHCII, 
PD-L1 and PD-L2 were equal between the groups (figure 3a, suppl. figure s2). FasL expression 
was not induced on pulmonary B cells in response to AAI or S. mansoni infection (data not shown). 
Furthermore, we analyzed the capacity of pulmonary B cells to produce cytokines, which may support 
or suppress T cell activation, following stimulation by either SEA or TLR-4 ligand LPS and TLR-9 ligand 
CpG-ODN 1826 as strong B-cell activators. While B cells from infected/OVA mice produced more 
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IL-10 in response to SEA as previously described 5, they interestingly secreted significantly less IL-10 
and IL-6 in response to LPS or CpG-ODN 1826 compared with B cells from uninfected/OVA mice 
(figure 3b). Recently, B cells have been reported to secrete the regulatory cytokine IL-35 in response 
to TLR4 and CD40 ligation 15. Pulmonary B cells in this study were MACS-sorted for CD19, but they 
nevertheless contained CD138-expressing plasma cells (suppl. figures s3a, b), which downregulate 
CD19 expression and have been described as the main IL-35 expressing B cells. We measured a clear 
gene expression of the IL-35 subunits Ebi3 and IL-12p35 by qPCR after stimulation of pulmonary B cells 
with LPS/anti-CD40 or CpG-ODN 1826 (Ct-values: 22-25 for Ebi3 and IL-12p35 after LPS/aCD40 and 
IL-12p35 after CpG-ODN 1826 stimulation; 27-29 for Ebi3 after CpG-ODN 1826 stimulation), stimuli 
that were reported to optimally enhance the expression of the separate IL-35 subunits. However, 
we did not observe an increased expression of either IL-35 subunit by infected/OVA compared with 
uninfected/OVA pulmonary B cells (suppl. figure s3c), suggesting that it is not likely that IL-35 
mediates protection in our model. Taken together, these data show that during chronic schistosomiasis 
pulmonary B cells have an increased CD86 expression, equal expression levels of MHCII, lower IL-10 
and IL-6 production upon TLR ligation and no increase in gene expression of the subunits for IL-35, 
suggesting that pulmonary B cells do not suppress Th2 cytokine production by an increased expression 
of those inhibitory molecules or regulatory cytokines.
figure 2. Pulmonary b cell-induced protection against allergic airway inflammation (aaI) during schistosomiasis 
is independent of foxp3+ regulatory t (treg) cells. Ovalbumin (OVA)-sensitized DEREG (DEpletion of REGulatory 
T cells) mice, which carry a diphtheria toxin (DT) receptor-eGFP transgene under the control of an additional Foxp3 
promoter, were treated with two PBS or DT (1 µg/mouse) i.p. injections in order to deplete the Foxp3+ Treg cells, 1 
day before and 2 days after the adoptive transfer of 5 x 106 CD19+ lung B cells. After 2 days, mice were challenged 
for three consecutive days and sacrificed 24 h after the last challenge. (a) The percentage of Foxp3+ CD25+ Treg 
cells in the lungs are shown, representing a summary of 1-2 independent experiments (n=2-8/group). (b) Fold 
change of bronchoalveolar lavage (BAL) eosinophil numbers over PBS-injected DEREG mice that did not receive B 
cell adoptive transfer. A summary of two independent experiments (n=3-7/group) is shown. Results are expressed 
as mean ± S.E.M. Significant differences are indicated as follows: ****P <0.0001, as tested by two-tailed unpaired 





figure 3. schistosome-induced pulmonary b cells express elevated levels of cd86 ex vivo, and secrete less 
Il-10 after in vitro toll-like receptor (tlr) ligation. Pulmonary B cells were isolated as described in figure 1. For 
both phenotypical characterization and co-culture, pulmonary B cells from 2-3 mice were pooled to obtain sufficient 
cell numbers. (a) Fold changes of geometric mean fluorescence intensity (MFI) expression of indicated antigens on 
B cells from uninfected/ovalbumin (OVA) and infected/OVA mice over control (uninfected/PBS). A summary of 2-4 
independent experiments (n=6-17/group) is shown. (b) Uninfected/OVA and infected/OVA B cells were stimulated 
with supplemented RPMI medium (Med), schistosomal egg antigen (SEA, 20 µg/ml), lipopolysaccharide (LPS, 100 
ng/ml) or CpG-ODN 1826 (5 µg/ml) for 5 days to determine the presence of IL-10 and IL-6 in the supernatant. Data 
represents a summary of 2-4 independent experiments (n=4-12/group). Results are expressed as mean ± S.E.M. 
Significant differences are indicated as follows: *P <0.05, **P <0.01, ****P <0.0001, as tested by two-tailed unpaired 
Student’s t-test.
schistosome-induced pulmonary b cells induce less th2 cytokine secretion in vitro
Because schistosome-induced pulmonary B cells did not show the typical regulatory features of Breg 
cells such as Treg cell induction or increased production of regulatory cytokines, we next investigated 
their potential to reduce AAI through a reduced APC function that would lead to less T cell proliferation 
and/or less T cell cytokines. To this end, T-cell activation was examined under a condition where 
antigen-presentation by B cells was essential to drive T-cell activation. OVA-specific T-cell activation of 
CD4+ T cells from OT-II mice was achieved by culture with OVA peptide-pulsed pulmonary B cells. After 
3 days, OVA-presentation by B cells from uninfected- or infected/OVA mice did not affect intracellular 
expression of T-cell IL-4, IL-13 or IL-17 production, whereas IFN-γ seemed to be slightly up- and 
IL-10 downregulated (figure 4a, suppl. figure s4a). We also cultured OVA-pulsed B cells and OT-II 
T cells in the presence of anti-CD28 to bypass differences in CD80 and CD86, and ensure optimal 
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figure 4. schistosome-induced pulmonary b cells have an impaired capacity to induce th2 cytokine secretion 
in vitro. Pulmonary B cells were isolated as described in figure 1. Pulmonary B cells, pooled from 2-3 mice per group 
were co-cultured at a 1:1 ratio with either naïve, ovalbumin (OVA)-peptide loaded OT-II CD4+ T cells (a) or naïve 
C57BL/6 CD4+ T cells (b-e). (a) B cells were loaded with OVA17 peptide, washed and co-cultured at a 1:1 ratio with OVA-
specific CD4+ OTII T cells in the presence of anti-CD28 (1 µg/ml) for 3 days. Intracellular cytokine staining for the Th2 
cytokines IL-13, IL-4 and IL-10, Th1 cytokine IFN-γ and Th17 cytokine IL-17 cells was performed following phorbol 
12-myristate 13-acetate (PMA)/Ionomycin and Brefeldin A stimulation for the last 4 h. Data are expressed as fold 
change over co-culture with control B cells (uninfected/PBS). A summary of 2-3 independent experiments (n=6-12/
group) is shown. Results are expressed as mean ± S.E.M. (b-e) B cells were co-cultured at a 1:1 ratio with naïve, CFSE-
stained (0.5 uM CFSE, 15 min) C57BL/6 CD4+ T cells in the presence of anti-CD3/anti-CD28 (both (1 µg/ml) for 3 days. 
(b) The proliferation index was calculated within FlowJo. A summary of three independent experiments (n=15-20/
group) is shown. (c) The mean fluorescence intensity (MFI) of the activation marker CD25 on T cells assessed by flow 
cytometry. (d) Fold changes of percentage IL-4, IL-13, IL-10, IL-17 and IFN-γ-producing T cells over control (B cells 
from uninfected/PBS mice). A summary of four independent experiments (n=17/group) is shown. (e) Naïve C57BL/6 
CD4+ T cells (1x105) were cultured at ratios of 1:1, 1:2 and 1:4 (B cell:T cell) with B cells from uninfected/OVA and 
infected/OVA mice. Bar graphs represent fold changes of percentage Th2 cytokines production (with uninfected/OVA 
1:1 ratio set to 1). A summary of two independent experiments (n=6-7/group) is shown. (f, G) IL-5 and IL-13 measured 
by ELISA in supernatants of bronchoalveolar lavage (BAL) fluid (f) and OVA-restimulated mediastinal lymph node 
(medLN) cells (G) from recipient mice after adoptive transfer of either uninfected/OVA or infected/OVA B cells. Results 
are expressed as mean ± S.E.M. Significant differences are indicated as follows: *P <0.05, **P <0.01, ***P <0.001, 
****P <0.0001, as tested by two-tailed unpaired Student’s t-test. #P <0.05, ####P <0.0001, as tested by One-way ANOVA 
and Tukey’s multiple comparisons test. 
co-stimulation. In the presence of anti-CD28, the fold change expression of the Th2 cytokines IL-4 
and IL-13 was significantly lower in co-cultures with infected/OVA B cells compared with co-cultures 
with B cells from uninfected/OVA mice (figure 4a, suppl. figure s4a). The reduced IL-10 production 
found under stimulation conditions of infected/OVA B cell co-cultures was overcome in the presence 
of sufficient co-stimulation and may point to an impaired expression during sub-optimal stimulation.
Additionally, we performed co-culture experiments of pulmonary B cells from uninfected/OVA 
and infected/OVA mice with CD4+ T cells from naive C57BL/6 mice in the presence of anti-CD3/28 to 
bypass the need for B cell antigen presentation and co-stimulation for T cell activation, and cultured 
them for 3 days. We still observed higher Th2 cytokine production in co-cultures with B cells from 
uninfected/OVA mice (figure 4d, suppl. figure s4b), together with slightly more T-cell proliferation 
(figure 4b) and an enhanced T-cell CD25 expression (figure 4c) compared with co-cultures with 
infected/OVA B cells. The ability of B cells from uninfected/OVA mice to induce Th2 cytokines was 
found to be dose-dependent and most effective at a 1:1 ratio (figure 4e), while the percentage of Th2 
cytokine-producing T cells induced by infected/OVA B cells was similarly low at all indicated ratios. To 
evaluate whether B cells could also inhibit Th2 cytokines in vivo, we turned to our previous studies, 
where adoptive transfer of pulmonary B cells from S. mansoni-infected, but not uninfected, mice 
protected recipient mice from AAI 24. We now analyzed the abundance of Th2 cytokines in both the BAL 
fluid and mediastinal LN cell cultures of recipient mice after OVA restimulation. While the transfer 
of uninfected/OVA B cells strongly increased the concentration of Th2 cytokines in the BAL fluid 
compared with control mice (figure 4f), we found both IL-5 and IL-13 to be significantly reduced in 
both tissues after transfer of infected/OVA B cells compared with cells transferred from uninfected mice 
(figure 4f, G). Collectively, we found a lesser induction of Th2 cell proliferation and cytokine production 
by infected/OVA B cells, which is also evident in a setting independent of B cell antigen-presentation 
and with optimal co-stimulation. These findings suggest that schistosome-induced pulmonary B cells 
may not dampen CD4 T cell responses via a reduced APC function, but that this may be the result of 






figure 5. the impaired capacity of schistosome-induced pulmonary b cells to induce th2 cytokines is 
independent of Il-10 and tGf-β. In vitro co-cultures were performed as described in figure 4 in the presence of 
blocking anti-IL-10R, anti-TGF-β or isotype control antibodies. Bar graphs represent fold changes of IL-4 and IL-13 
(with uninfected/ovalbumin (OVA) isotype set to 1). A summary of two independent experiments (n=6-8/group) 
is shown. Results are expressed as mean ± S.E.M. Significant differences are indicated as follows: *P <0.05, ***P 
<0.001, ****P <0.0001, as tested by two-tailed unpaired Student’s t-test, and #P <0.05 as tested by One-way ANOVA 
following Dunnett’s multiple comparisons test.
the impaired capacity of schistosome-induced pulmonary b cells to induce th2 cytokine secretion 
is largely independent of Il-10 and tGf-β
We next aimed to investigate what other suppressive factors were involved in the reduced Th2 cell 
driving capacity of schistosome-induced pulmonary B cells. In that context, the roles of IL-10 and 
TGF-β were investigated by adding anti-IL-10R or anti-TGFβ blocking antibodies to the co-cultures of 
pulmonary B cells and CD4+ T cells. We focused on the production of IL-4 and IL-13 due to the activity 
of these Th2 cytokines in boosting allergic responses in the airways. Blocking IL-10 signaling or 
neutralizing TGF-β only slightly, but significantly, increased the IL-4 production in T cells cultured 
with pulmonary B cells from infected/OVA mice (figure 5). IL-13 production was only increased upon 
blocking IL-10 signaling (figure 5). This may suggest that of the two inhibitory cytokines, the influence 
of IL-10 seemed to be slightly more pronounced. Nevertheless, infected/OVA B cells still induce 
significantly less IL-4 and IL-13 in co-cultures where IL-10 signaling is ablated or TGF-β neutralized, 
suggesting that either one of these cytokines, if at all, only play a minor role.
dIscussIon
Helminths drive strong immunoregulatory processes that limit immunopathology during chronic 
infection, and Breg cells seem to be important players. Notably, S. mansoni-induced splenic and 
pulmonary B cells also attenuate allergic diseases such as AAI upon adoptive transfer. Splenic Breg 
cells mediate their suppressive effect through IL-10- and Treg cell-dependent mechanisms 4, 5, 8. Here, 
we demonstrate that helminth-induced pulmonary B cells are phenotypically and functionally distinct 
from splenic Breg cells that we previously studied 5, by showing a reduced capacity to initiate Th2 
cytokine responses. The question remains whether this is truly the result of an increased inhibitory, or 
simply a reduced Th2 stimulatory, activity.
By definition, Breg cells suppress inflammatory processes and induce tolerance by various 




has a pleiotropic suppressive effect on most hematopoietic cells such as T cells and APCs, it also 
indirectly suppresses immune responses via supporting the generation and maintenance of Treg cell 
subsets 4, 5, 8. We adoptively transferred pulmonary B cells from uninfected/OVA and infected/OVA 
mice into DEREG recipient mice and did not observe a significant change in the protective effect of 
B cells from infected mice in the absence of Treg cells (figure 2). We have not formally addressed 
where these adoptively transferred B cells migrate to in recipient mice. However, we have previously 
examined that i.v. injected splenic B cells migrate to the spleen and lung of allergic mice, and assume 
that the pulmonary B cells studied here also migrate, at least in part, to the lung (unpublished 
findings). Nevertheless, we cannot exclude that systemic signals have also contributed to the observed 
protective effect.
Recently, it has become evident that Breg cells utilize a number of IL-10-independent suppressive 
mechanisms in order to control inflammation 26. For example, B cells can contribute to the maintenance 
of tolerance via the production of TGF-β 13, 14, IL-35 15, 16 or by induction of T cell hypo-responsiveness 14. 
The schistosome-induced pulmonary B cells studied here did not utilize any of the Breg effector 
mechanisms described in the above-mentioned studies. In our study, the majority of the B cells in 
the lungs of infected/OVA mice had elevated levels of CD23 (figure 1b) compared with uninfected/
OVA mice. Interestingly, mesenteric LN CD23hi B cells from H. polygyrus-infected mice were shown to 
suppress Der p1-induced airway inflammation by an unknown mechanism, but independently of IL-10 
6. Although it was unclear whether this suppression was accomplished through CD23, it may point to 
similarities with the pulmonary B cells in the infected/OVA mice described here. As several adoptive 
transfer experiments with sorted pulmonary CD23+ B cells, compared with CD23low/int B cells from 
OVA/infected mice, did not show clear differences in their protection against AAI, the elevated 
expression of CD23 may merely serve as a proxy for a certain inhibitory phenotype without being 
actively involved. Alternatively, CD23 expression may not define a specific Breg population but may 
be more the consequence of the local cytokine milieu 27, as IL-4 and IgE drive CD23 expression 28, 29 on 
B cells during helminth infections 30. Indeed, the CD23 expression seemed to be elevated on almost all 
pulmonary B cells of infected/OVA mice. Interestingly, we found elevated concentrations of total IgG1 
and IgG2a in infected/OVA compared with uninfected/OVA mice (data not shown). Earlier studies have 
suggested an inhibitory role for IgG1 ligating the inhibitory FcγRIIB in OVA-induced AAI 31. However, 
adoptive transfers of pulmonary B cells from uninfected- and infected/OVA mice into OVA-sensitized 
FcγRIIB-/- mice suggested that pulmonary B cell-induced protection against AAI was independent of 
FcγRIIB ligation (data not shown).
Schistosome-induced pulmonary B cells expressed enhanced levels of CD86, whereas MHC Class 
II expression levels remained unchanged and in some experiments were even enhanced. Each of these 
markers has been suggested to affect T cell activation. For example, down-regulation of B cell CD80 
and CD86 expression during Brugia pahangi larval infection restricted T cell proliferation 32. Using B 
cell B7-/- mice, expression of CD86 was shown to be essential for B cell-mediated recovery of EAE by 
induction of Treg cells and IL-10 33. In our study, co-cultures of schistosome-induced pulmonary B 
cells presenting OVA to OVA-specific T cells resulted in reduced Th2 cytokine production compared 
with control conditions. However, since similar results were observed in co-cultures of B cells from 
C57BL/6 mice supplemented with anti-CD3/28 to bypass the role of B cells as APCs, this may suggest 
the involvement of other molecules or mechanisms. 
We additionally examined different inhibitory molecules for their contribution to the protective 
effect observed. Studies in mice with S. mansoni or Litomosoides sigmodontis infections showed that 
PD-1 and interaction with its ligands (PDL-1/2) was important for T(h2)-cell hypo-responsiveness 34, 35, 
and PD-1-PD-L1/2 interactions have also been reported to be involved in regulating autoimmune and 
allergic Th2 responses 36, 37. Other studies however suggested that Th2 hypo-responsiveness during 
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S. mansoni infection was not related to PD-1-PD-L1/2 interaction 38. The latter is in agreement with 
our own data, as we observed that blocking of PD-L1 or PD-L2 expression on infected/OVA B cells 
did not restore Th2 cytokine production or proliferation in co-cultures with T cells (data not shown). 
We also investigated a potential role for the enhanced expression of CD86 on the pulmonary B cells 
from infected/OVA mice. Human CD25hi Breg cells have been reported to increase the expression of 
the inhibitory receptor CTLA-4 on FoxP3+ Treg cells in vitro 11, suggesting that the interaction of B cell 
co-stimulatory molecules CD80/CD86 and CTLA-4 could be important in controlling inflammation. 
However, blocking of CTLA-4 in in vitro co-cultures did not restore Th2 cytokine production in our 
study (data not shown). Collectively, the pulmonary B cells studied are phenotypically and functionally 
different from classical Breg cells, and rather show a reduced Th2-driving capacity. It remains to 
be established whether this is the result of a reduced capacity to drive Th2 stimulation, or rather 
a suppressive signal by which schistosome-induced pulmonary B cells actively reduce Th2 polarization 
and inhibit AAI.
 Alternatively, local Treg cells, induced during helminth infection, may influence B cell function 
leading to reduced B-cell activation, antibody production and the APC function of B cells via e.g. 
TGF-β or IL-35 39-41. Secreted helminth products from Schistosoma may also directly attenuate the T cell 
stimulatory capacity of B cells as described for DCs 42. As pulmonary B cells from infected/OVA mice 
produced less cytokines after stimulation with TLR ligands (suppl. figure s3), the B cells might become 
hypo-responsive themselves in the context of chronic S. mansoni infection, resulting in a reduced 
capacity to stimulate T cells. In addition to their role as APCs and cytokine producers, B cells have 
also been reported to remodel the LN architecture to facilitate DC-dependent Th2 induction and be 
required for the formation of a Tfh cell response in the context of nematode infections 43, 44.
Very little is known with regard to B cell migration to the respiratory system, and the permanence 
of their residence in the tissue, in contrast to other mucosal sites such as the gut or the peritoneal 
cavity. The lung B cell population in chronically S. mansoni-infected mice that are subjected to AAI is 
likely to be heterogeneous, consisting both of resident and infiltrating cells. Further studies are needed 
to examine the origin and migration pattern of the protective pulmonary B cells in S. mansoni infection. 
Recently, various Breg cell populations have been identified in peripheral blood of humans infected 
with schistosomiasis or other helminths 5, 45. Furthermore, in several inflammatory diseases, Breg cells 
were impaired in terms of their number and/or their regulatory function, i.e. in patients with systemic 
lupus erythematosus (SLE), rheumatoid arthritis (RA) or allergic asthma 46-48. Since most human studies 
are restricted to peripheral blood B cells, these results might not fully reflect the processes that occur 
in inflamed organs. Therefore, further studies on B cell biology and its activity in the inflamed organs 
are needed to better understand the importance and relative contribution of the various Breg cell 
subsets in peripheral blood and local tissues. Collectively, we identified that murine infection with 
schistosomes induces potent IL-10-producing suppressive Breg cells in the spleen 5 and impaired Th2-
driving pulmonary B cells in the inflamed tissue (this study) which both contribute to the suppression of 
AAI. Identifying the mechanisms that influence pulmonary B cell function and impair their capacity to 




Six week-old female C57BL/6 OlaHsd mice were purchased from Harlan Sprague Dawley Inc. (USA). 
DEREG (depletion of regulatory T cells) mice 49 were kindly provided by Dr. T. Sparwasser (Twincore/
Centre for Experimental and Clinical Infection Research, Germany) and bred in the animal facilities 




specific-pathogen-free (SPF) conditions in the animal facilities of the LUMC. All animal studies were 
performed in accordance with the guidelines and protocols (DEC-11166, 12182) approved by the Ethics 
Committee for Animal Experimentation of the University of Leiden, The Netherlands.
Parasitic infection and aaI induction
Mice were infected percutaneously with 36-40 S. mansoni cercariae and kept until the chronic phase 
of infection (15 weeks). For AAI induction, mice were sensitized twice by i.p. injections of OVA (10 µg/
mL, Worthington Biochemical Corp, USA) in Imject Alum (2 mg/ml; Pierce, USA) at weeks 13 and 14. 
Seven days after the last injection, mice received OVA aerosol challenges (10 mg/ml in PBS) for three 
consecutive days. Mice were sacrificed 24 h after the last challenge. Bronchoalveolar lavage (BAL) fluids 
were collected and phenotyped by flow cytometry 5, 20.
cell purification 
Perfused lungs were minced to ~1 mm pieces and digested by collagenase III (Worthington) and 
DNase (Sigma-Aldrich, USA) for 1 h. The digested lungs were sequentially dispersed through 70 µm 
sieves. Erythrocytes were removed from the lung single cell suspensions by lysis. Adhesive cells were 
removed from cell suspensions by passage over LS columns (Miltenyi Biotec, Germany). Next, B cells 
were purified using anti-CD19 MicroBeads (Miltenyi Biotec). Untouched splenic CD4+ T cells were 
enriched using negative selection with MicroBeads (Miltenyi Biotec) and were ~95% pure.
adoptive transfer of isolated pulmonary b cells
Recipient mice were sensitized with two injections of OVA/Alum at day 0 and day 7, as described in 
Section 2.2. Ten days after the last injection, the OVA-sensitized animals received an i.v. injection of 5 
x 106 CD19+ lung B cells from uninfected- or infected/OVA mice, or PBS as a control. DEREG mice were 
treated with two diphtheria toxin (DT, 1 µg/ml) i.p. injections or PBS as a control, 1 day before and 2 
days after the adoptive transfer of B cells in order to deplete the FoxP3+ Treg cells. After 2 days, mice 
were challenged for three consecutive days and sacrificed 24 h after the last challenge.
Phenotypic characterization
Ex vivo pulmonary B cells were characterized using CD25-FITC (clone: 3C7; BD Biosciences), Tim-1-PE 
(RMT1-4), B220-V510 (RA3-6B2), PD-L1-Pe-Cy7 (10F.9G2; all Biolegend, USA), B220-APC-eF780 (RA3-
6B2), B220 eF450 (RA3-6B2), LAP-1-PerCP-eFluor710 (TW7-16B4), CD5-APC (53-7.3), CD23-PeCy7 
(B3B4), CD86-PE-Cy5 (GL1), FasL-APC (MFL3), major histocompatibility complex Class II (MHCII)-APC-
eF780 (M5/114.15.2), PD-L2 Biotin (TY25; all eBioscience, USA) combined with streptavidin-Qdot525 
(Life Technologies, USA) and LIVE/DEAD fixable Violet or Aqua stain (eBioscience). For all flow cytometric 
measurements, FcγR-binding inhibitor (2.4G2) was added and fluorescence minus one (FMO) controls 
were used for gate setting for all surface markers and cytokines. All antibody stainings were performed 
as surface stainings for 30 min at 4ºC. 
cytometric bead array
Cytokines were measured in BAL fluid and in cell culture supernatant of mesenteric lymph node (LN) 
cells (0.3x106 cells) restimulated for 3 days with 10 µg/mL of OVA using BD cytometric bead array 
Flex-set kits (BD Biosciences, USA).
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In vitro b cell stimulation
Pulmonary CD19+ B cells and B cell subsets (1x105 cells) were cultured in medium (RPMI 1640 glutamax; 
Invitrogen Life Technologies, USA), containing 5% heat-inactivated FBS (Greiner Bio-One, Austria), 
5 × 10-5 M 2-Mercaptoethanol (Sigma-Aldrich) and antibiotics (100 U/mL of penicillin and 100 µg/mL 
of streptomycin; Invitrogen). Cells were cultured either in the presence of schistosomal egg antigen 
(SEA; 20 µg/ml), lipopolysaccharide (LPS; 100 ng/ml) or CpG-oligodeoxynucleotides (CpG-ODN) 1826 
(5 µg/ml) for 5 days for the detection of IL-10 and IL-6 in culture supernatants by ELISA (BD Biosciences), 
or in the presence of LPS (1 µg/ml) and anti-CD40 (clone 1C10; 10 µg/ml) or CpG-ODN 1826 (1 µg/mL) 
for the detection of IL-35 mRNA expression. 
Immunoglobulin measurements
Total and OVA-specific IgG1, IgG2a and total IgA were measured from the first 1 ml of collected BAL 
fluid by ELISA (BD Biosciences). 
In vitro b cell stimulation and co-culture with cd4+ t cells
Pulmonary CD19+ B (1x106/ml) cells were loaded with 10 µg/ml of OVA17 peptide (OVA323-339: 
ISQAVHAAHAEINEAGR, kindly provided by M.G.M. Camps (Leiden University Medical Center, 
The Netherlands) for 1 h at 37 ° C, washed, and subsequently co-cultured with OT-II CD4+ T cells 
(1x105 cells/well) at a 1:1 ratio in the presence or absence of anti-CD28 (1 µg/ml). Additionally, CD19+ 
B cells were co-cultured with CD4+ T cells at 1:1, 1:2, 1:4 ratios, in the presence of medium or anti-CD3 
(1 µg/ml) plus anti-CD28 (1 µg/ml). To assess proliferation, T cells (10 x 106/ml) were incubated with 
carboxy- fluorescein diacetate, succinimidyl ester (CFSE; 0.5 µM) for 15 min. Under some conditions, 
the following blocking antibodies were added to the cultures: 10 µg/ml of isotype control anti-βGal and 
anti-TGF-β (kindly provided by L. Boon, Bioceros, The Netherlands). T cells were incubated for 30 min 
at 37 °C with 10 µg/ml of anti-IL-10 receptor (kindly provided by L. Boon). After 3 days, CFSE-labelled T 
cell co-cultures were stained with anti-CD3-eFluor450 (17A2), CD25-PE (PC61.5), B220-eFluor780 (RA3-
6B2), 7-AAD, CD4-biotin (GK1.5) (all eBioscience) with streptavidin-Qdot525 to measure proliferation of 
activated T cells. The proliferation index, being the total number of cell divisions divided by the number 
of cells that went into division, was calculated within the FlowJo proliferation platform. For cytokine 
analysis, the cells were restimulated with 100 ng/ml of phorbol 12-myristate 13-acetate (PMA) and 1 
µg/ml of ionomycin for 6 h in the presence of 10 µg/ml of Brefeldin A (all Sigma-Aldrich) for the last 4 
h, followed by fixation using 1.9% paraformaldehyde (PFA; Sigma-Aldrich). Next, the cells were stained 
for viability (LIVE/DEAD Fixable Aqua Dead Cell Stain Kit, ThermoFisher Scientific, USA) IL-4-PE (BVD4-
1D11; BD Biosciences), CD3-eFluor710 (17A2), IFN-γ-FITC (XMG1.2), IL-17-PeCy7 (eBio17B7), IL-10-APC 
(JES5-16E3), IL-13-eFluor450 (eBio13A), and B220-eFluor780 (RA3-6B2; all eBioscience).
Quantitative Pcr (qPcr)
Isolated pulmonary B cells were snap-frozen in liquid nitrogen, and RNA was isolated using the NucleoSpin 
RNA kit (Macherey-Nagel, Germany) according to the manufacturer’s instructions. cDNA was synthetized 
and quantitative real-time PCR performed on a C1000 Thermal Cycler (BioRad, USA) using GoTaq 
qPCR MasterMix (Promega, USA). Transcripts were quantified using the following forward (FP) and 
reverse (RP) primers (Eurogentec, Belgium): β-2-microglobulin FP: 5’-CACTGAATTCACCCCCACTGA -3’, 
β-2-microglobulin RP: 5’-TGTCTCGATCCCAGTAGACGG-3’; Ebi3 FP: 5’-CATTGCCACTTACAGGCTCG-3’, 
Ebi3 RP: 5’-TGATGATTCGCTCAGCCACA-3’; IL-12p35 FP: 5’-GGTGAAGACGGCCAGAGAAA-3’, IL-12p35 
RP: 5’-GTAGCCAGGCAACTCTCGTT-3’. mRNA expression was normalized to the reference gene β-2-
microglobulin, and expressed as the fold change to B cells from uninfected, non-allergic mice by using 





All results were analyzed using GraphPad Prism (version 5.00/6.05 for Windows, GraphPad Software, La 
Jolla USA) and are expressed as mean ± S.E.M. Statistical analysis was performed using the two-tailed 
unpaired or paired Student’s t-test for comparison of two experimental groups, and One-Way ANOVA 
followed by Tukey’s multiple comparisons test for comparisons between more than two groups. 
Differences between groups were considered significant at P <0.05.
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figure s1. Gating strategy and representative flow cytometry plots (relating to figure 1). (a) Percentage of latency-
associated peptide (LAP+), CD25+, T cell immunoglobulin and mucin domain-1 (Tim-1+) and CD23+ pulmonary B cells, 
as well as mean fluorescence intensity (MFI) of CD23. (b) Percentage of CD5+ pulmonary B cells. OVA, ovalbumin; 




figure s2. Gating strategy and representative flow cytometry plots (relating to figure 3a). (a) Percentage of CD86+, 
MHCII+, and (b) PD-L1+ and PD-L2+ pulmonary B cells in addition to the mean fluorescence intensities (MFIs) presented 
in figure 3a. OVA, ovalbumin; FMO, fluorescence minus one control.
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figure s3. Pulmonary B cells were isolated as described in figure 1. Cells from 2-3 mice were pooled to obtain 
sufficient cell numbers. (a) Representative flow cytometry plots showing the expression of the plasma cell marker 
CD138 on pulmonary B cells. (b) Fold change of percentage CD138-expressing B cells from uninfected/ovalbumin 
(OVA) and infected/OVA mice over control (uninfected/PBS). A summary of three independent experiments 
(n=11-14/group) is shown. (c) Fold change of mRNA expression of the IL-35 subunits Ebi3 and IL-12p35 as analyzed 
by quantitative PCR using β-2-microglobulin as a reference gene and the ΔΔ comparative threshold method. Data 
represent one experiment (n=3-6/group). Results are expressed as mean ± S.E.M. Significant differences are indicated 





figure s4. Gating strategy and representative flow cytometry plots (relating to figure 4), showing (a) the expression 
of IL-4 and IL-13 by C57BL/6 T cells after co-culture with pulmonary B cells in the presence of anti-CD3 and anti-
CD28, (b) the proliferation as assessed by CFSE dilution, and (c) the expression of IL-4 and IL-13 by OTII T cells after 
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Infection with the helminth Schistosoma (S.) mansoni drives the development of interleukin (IL)-10-
producing regulatory B (Breg) cells in mice and man, which have the capacity to reduce experimental 
allergic airway inflammation and are thus of high therapeutic interest. However, both the involved 
antigen and cellular mechanisms that drive Breg cell development remain to be elucidated. 
Therefore, we investigated whether S. mansoni soluble egg antigens (SEA) directly interact with B 
cells to enhance their regulatory potential, or act indirectly on B cells via SEA-modulated macrophage 
subsets. Intraperitoneal injections of S. mansoni eggs or SEA significantly upregulated IL-10 and CD86 
expression by marginal zone B cells. Both B cells as well as macrophages of the splenic marginal zone 
efficiently bound SEA in vivo, but macrophages were dispensable for Breg cell induction as shown by 
macrophage depletion with clodronate liposomes. SEA was internalized into acidic cell compartments 
of B cells and induced a 3-fold increase of IL-10, which was dependent on endosomal acidification and 
further enhanced by CD40 ligation. IPSE/alpha-1, one of the major antigens in SEA, was also capable 
of inducing IL-10 in naïve B cells, which was reproduced by tobacco plant-derived recombinant IPSE. 
Other major schistosomal antigens, omega-1 and kappa-5, had no effect. SEA depleted of IPSE/alpha-1 
was still able to induce Breg cells indicating that SEA contains more Breg cell-inducing components. 
Importantly, SEA- and IPSE-induced Breg cells triggered regulatory T cell development in vitro. SEA 
and recombinant IPSE/alpha-1 also induced IL-10 production in human CD1d+ B cells. In conclusion, 
the mechanism of S. mansoni-induced Breg cell development involves a direct targeting of B cells by 
SEA components such as the secretory glycoprotein IPSE/alpha-1. 
author summary
Infection with helminth parasites is known to be inversely associated with hyper-inflammatory 
disorders. While Schistosoma (S.) mansoni has been described to exert its down-modulatory effects 
on inflammation by inducing a network of regulatory immune cells such as regulatory B (Breg), 
the mechanisms of Breg cell induction remain unclear. Here, we use in vivo and in vitro approaches to 
show that antigens from S. mansoni eggs, among which the major glycoprotein IPSE/alpha-1, directly 
interact with splenic marginal zone B cells of mice which triggers them to produce the anti-inflammatory 
cytokine IL-10 and their capacity to induce regulatory T (Treg) cells. We also found that IPSE/alpha-1 
induces IL-10 in human CD1d+ B cells, and that both natural and recombinant IPSE/alpha-1 are equally 
effective in driving murine and human Breg cells. Our study thus provides insight into the mechanisms 
of Breg cell induction by schistosomes, and an important step towards the development of helminth-





Helminths can persist for up to decades in the human host. This is hypothesized to be, at least in part, 
because of their evolutionarily adapted relationship with the host 1. Helminths are well-known for their 
strong capacity to promote the regulatory arm of the hosts immune system, thereby prolonging their 
survival within the host 2. As a bystander effect, helminths can also suppress immune responses to 
other antigens, such as allergens and auto-antigens, and other pathogens. This bystander effect seems 
to be so pronounced that it may prevent the development of inflammatory diseases. Indeed, both 
epidemiological studies and mouse models show a clear protective role of helminths against various 
forms of auto-immunity, allergic airway inflammation, colitis etc. 3,4,5,6,7. The formation of a network 
of regulatory immune cells plays a crucial role for the protective effect. Helminth infection, and in 
particular infection with schistosomes such as Schistosoma (S.) mansoni are well-known to induce 
regulatory B (Breg) cells 8-15, a relatively new member in the network of regulatory immune cells. 
Breg cells have gained considerable attention due to their ability to down-modulate inflammation 
in a variety of conditions ranging from autoimmune disorders such as experimental autoimmune 
encephalomyelitis (EAE), collagen-induced arthritis (CIA), lupus and chronic colitis to anaphylactic and 
allergic airway inflammation 8,10-12,16-23. Regulatory B cells suppress pro-inflammatory immune responses 
via several mechanisms, of which the ones best described are the expression of the regulatory cytokine 
interleukin-10 (IL-10) and induction of regulatory T (Treg) cells 24. 
We previously reported the induction of Breg cells by schistosome infection in both mouse and 
human, and found the most potent IL-10-producing Breg cells within the human CD1d+ B cell subset. 
This corresponds to the CD1d+CD23lowCD21+ marginal zone (MZ) B cell subset in mice, which efficiently 
reduced experimental allergic airway inflammation in our model 12. The cellular mechanisms to achieve 
Breg cell induction as well as the nature of the B cell-activating S. mansoni antigens however remain 
largely unknown. The identification of relevant stimulatory molecules and optimal Breg cell-inducing 
conditions is a critical step in enhancing the activity of Breg cells for use as a new therapeutic tool 
against inflammatory diseases. 
Both an indirect induction of a regulatory phenotype in B cells by activation of accessory cell 
types, as well as a direct binding and interaction between S. mansoni antigens and B cells via pattern 
recognition receptors (PRRs) such as Toll-like receptors (TLRs) expressed on B cells 25 are plausible 
options. In the splenic MZ, located at the border of white and red pulp, MZ B cells are nested between 
SIGN-R1+ MZ macrophages and Siglec-1+ metallophilic macrophages 26. MZ macrophages not only 
fulfill a main function in sensing blood-borne pathogens, but also perform functional interactions 
with MZ B cells. These interactions have important implications for the maintenance of the MZ itself 
and the function of MZ B cells and macrophages 27-29. Hence, it is therefore tempting to speculate that 
MZ macrophages are a prime candidate as Breg cell induction partner. On the other hand, the direct 
ligation of various TLRs on B cells, including TLR2, TLR4, TLR7 and TLR9, has been described to induce 
IL-10 production 30,31. In addition, BCR and CD40 engagement were described to be involved in IL-10-
dependent regulatory B cell function in models of EAE, CIA, and contact hypersensitivity 17-19,32. 
In the current study, we tested the hypothesis that eggs and/or egg-derived excretory-secretory 
molecules from S. mansoni, without the context of natural infection, are sufficient to drive Breg cell 
development by activating splenic MZ B cells. In addition, we investigated whether Breg cells are 
induced indirectly by activation of accessory cell types in the MZ, or by direct binding and interaction 
via PRRs on B cells. We found that egg antigens drive Breg cell development in vivo and in vitro by 
direct interaction with splenic B cells, which after binding and internalization of egg antigens secrete 
elevated levels of IL-10 and are capable of driving Treg cell development. The egg antigen-induced 
Breg cell development was independent of macrophages of the marginal zone but was enhanced by 
CD40 ligation. Most importantly, we identified the egg glycoprotein IPSE/alpha-1 as a single molecule 
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from S. mansoni that is capable to induce Breg cells both in mice and man. This knowledge will assist 
to further define helminth-specific conditions for the generation of Breg cells to be used in therapeutic 
approaches.
results
schistosome egg antigens drive the development of breg cells in vivo
To elucidate the mechanism by which S. mansoni can drive the development of Breg cells, we first 
investigated whether schistosome eggs or their soluble antigens were sufficient to drive Breg cell 
development in vivo, without the context of natural infection. Intraperitoneal treatment of C57BL/6 
mice with two doses of 5000 S. mansoni eggs or 100 µg of soluble egg antigens (SEA) one week 
apart efficiently induced IL-10 protein expression in splenic CD19+ B cells one week after the last 
injection. IL-10 protein secreted during 2 days ex vivo restimulation with SEA was 3 to 4-fold increased 
compared to the amount secreted by restimulated B cells from control-treated animals (figure 1a), 
while IL-6 was unchanged. This indicates a typical cytokine expression pattern characteristic for 
Breg cells. The frequencies of B cells expressing intracellular IL-10 protein were likewise significantly 
2-fold increased (figure 1b and 1c). Also the surface activation marker CD86, often upregulated on 
activated B cells and Breg cells 33-35, was increased on splenic B cells by egg or SEA treatment, while 
CD40 expression was not significantly changed (figure 1d). To verify that the observed effects are 
specific and exclude a general influence of protein solutions on B cell IL-10 production and activation, 
we treated mice with human serum albumin (HSA) as infection-unrelated control protein. We did not 
observe an increased IL-10 secretion (suppl. figure s1a) or CD86 expression (suppl. figure s1b ) 
by B cells compared to the PBS group, and concluded that PBS is a suitable control for subsequent 
experiments. Furthermore, injection of eggs or egg antigens was as efficient in increasing the frequency 
of IL-10-expressing B cells as was chronic infection with S. mansoni (suppl. figure s1c), and egg-
injected mice continued to have an elevated B cell IL-10 production until at least 4 weeks after the last 
egg injection (suppl. figure s1d), indicating that this phenotype is persisting over longer periods. SEA 
was purified from liver eggs and can contain LPS to variable extent. Since the TLR4 ligand LPS is known 
for its capacity to drive B cell IL-10 expression and Breg cell development 33,36,37, it is crucial to exclude 
that the Breg driving capacity by SEA in vivo was due to LPS contamination of the schistosome antigen 
preparations. Therefore, the same experiment was repeated in TLR4-deficient animals and compared 
to wild-type. Upon SEA treatment, IL-10 secretion of B cells as well as intracellular IL-10 and surface 
CD86 expression was overall comparable in both groups (suppl. figure s2), indicating that the Breg-
inducing capacity by SEA was largely not attributable to a putative LPS contamination. To confirm 
the regulatory function, splenic B cells from the various groups were tested for their capacity to drive 
Treg cell development, an acquired phenotype previously described for splenic B cells during natural 
schistosome infections 12. Indeed, splenic B cells from egg- or SEA-injected, but not control-treated, 
mice induced the development of CD25+Foxp3+ Treg cells during 4 day co-culture with CD25-depleted 
CD4 T cells (figure 1e and 1f), which confirms the regulatory capacity of egg antigen-activated B 
cells ex vivo. As expected, IL-10 protein concentration in co-culture supernatants was only increased 
in presence of egg antigen-activated but not control B cells (figure 1G). Collectively, these data show 
that schistosome eggs or their soluble antigens on their own are sufficient to induce IL-10-producing 
Breg cells in vivo, without the context of natural infection, and that these B cells are bona fide Breg cells 
that can drive Treg cell development.
schistosome antigens activate marginal zone b cells in the spleen
Different B cell subsets have been described to give rise to Breg cells, especially in spleen where 




figure 1. schistosome eggs and sea (soluble egg antigen) drive development of breg cells in vivo. C57BL/6 
mice were i.p. injected with two doses of 5000 S. mansoni eggs or 100 µg SEA in PBS, or PBS as control. At day 14, 
CD19+ MACS-isolated splenic B cells were restimulated with SEA (20 µg/ml) for 2 days. (a) Cytokine concentration in 
culture supernatants as determined by ELISA. (b, c) Representative FACS plots (B) and summary (C) for intracellular 
IL-10 expression of B cells after addition of Brefeldin A to the last 4 hours of the culture. (d) Mean fluorescence 
intensity of CD40 and CD86 expression. (e-G) SEA-restimulated B cells were co-cultured for 4 days with CD25-
depleted CD4 T cells. Frequency of CD25+Foxp3+ Treg cells after co-culture in representative FACS plots (e) and 
summary (f) is shown. (G) IL-10 concentration in culture supernatants after co-culture. Summary of 4 experiments 
with N = 12-16 (A-D) or 2 experiments with N = 8-9 (E-G). Significant differences by Mann-Whitney test are indicated 
with * p < 0.05, ** p < 0.01, *** p < 0.001.
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others had previously identified CD23lowCD21+ marginal zone B cells as the major IL-10-producing 
splenic B cell subset during chronic Schistosoma infection and mediating protection in a mouse model 
of airway inflammation 8,12. To test whether soluble egg antigens act on the same splenic subset, 
we sorted splenic CD23lowCD21+ marginal zone B cells from egg-, SEA-treated, or control mice for 
subsequent ex vivo restimulation and cytokine analysis, and compared this with the major splenic B 
cell subset, CD23hiCD21- follicular B cells (figure 2a). Only marginal zone B cells but not follicular B 
cells showed significantly increased IL-10 secretion as was measured in culture supernatants after 2 
day restimulation with SEA (figure 2b). As for total B cells (figure 1a), also for the individual subsets 
IL-6 expression was not increased (figure 2c). Intracellular IL-10 expression and CD86 expression was 
likewise significantly upregulated in marginal zone B cells of egg- or SEA-treated mice compared to 
control-treated mice. SEA seemed to be more potent than egg injection in activating follicular B cells, 
as SEA-injection also significantly increased intracellular IL-10 and CD86 expression in this subset, 
although expression levels remained significantly lower compared to marginal zone B cells (figure 2d 
and 2e). For analysis of B cell activation we generally restimulated cells ex vivo with SEA. This increased 
the baseline expression of CD86 in all groups compared to medium (average MFI of follicular B cells: 
1013-1632±62.2; for marginal zone B cells: 2640-4118±176.9, for all groups and without significant 
differences between groups), but was required for detection of B cell cytokines as a result of the in 
vivo antigen exposure. Without SEA restimulation, we found a trend of increased IL-10 production by B 
cells which only reached significance upon additional restimulation (suppl. figure s1e), indicating that 
renewed exposure to antigen is required to achieve detectable B cell activity and cytokine production. 
This is also supported by experiments in IL-10 GFP reporter mice, in which IL-10 (GFP) accumulates in B 
cells during the entire in vivo treatment period. Here, increased IL-10 (GFP) expression, without ex vivo 
restimulation, was only detectable in B cells of 14 weeks chronically infected mice, but not in B cells of 
mice that received two injections of eggs within a relatively short period of 2 weeks (suppl. figure s1f 
and s1G). Altogether, these data indicate that the result of in vivo development of IL-10 producing 
B cells is in principle detectable without restimulation (suppl. figure s1e and s1G), but the data 
from egg-injected IL-10 reporter mice also suggest that an ex vivo SEA restimulation is required to 
visualize its full IL-10 potential, something which will happen in vivo during a natural infection due 
to the constant production of eggs and the high levels of circulating antigens. Taken together, these 
data support the notion that B cells, and in particular marginal zone B cells, are responsive to in vivo 
schistosome antigen stimulation thus supporting the findings in natural schistosome infections.
macrophage subsets of the marginal zone bind sea but are dispensable for breg cell induction
Molecules secreted by schistosome eggs are highly glycosylated and known to bind to C-type lectin 
receptors 39,40. Since B cells show a very restricted expression of those receptors 41, we hypothesized that 
other C-type lectin receptor-expressing cell types in the splenic marginal zone, such as macrophages 
or dendritic cells, bind SEA and provide additional signals to the marginal zone B cells to support 
Breg cell development. Among the accessory cell types, macrophages of the splenic marginal zone 
were of particular interest because of their known interactions with marginal zone B cells 28,42 and 
schistosome antigens 43,44. However, it was unknown whether marginal zone macrophages can capture 
SEA in vivo and are important for B cell IL-10 expression. To evaluate this, fluorescently labeled SEA 
was injected i.v. and 30 minutes to 24 hours later various splenic cell types were analyzed for bound 
SEA using fluorescence microscopy and flow cytometry. Already after 30 minutes of injection, SEA 
clustered along the marginal zone area of the spleen as detected by fluorescence microscopy of 
splenic tissue sections (figure 3a). SEA localized predominantly within two specialized macrophage 
subsets of the marginal zone: SIGN-R1-expressing MZ macrophages and Siglec-1-expressing 




figure 2. schistosome antigens mainly activate the marginal zone b cell subset of the spleen. C57BL/6 were 
treated as in Figure 1, splenic follicular (FO) B cells (CD19+CD23+CD21low) and marginal zone (MZ) B cells (CD19+CD23-
CD21hi) FACS sorted, and restimulated for 2 days with SEA (20 µg/ml). (a) Gating scheme for both B cell subsets within 
the CD19+ gated B cell population. (b, c) Cytokine concentration in culture supernatants as determined by ELISA. 
(d) Intracellular IL-10 expression of B cell subsets after addition of Brefeldin A to the last 4 hours of the culture. (e) 
Mean fluorescence intensity of CD86 expression of B cell subsets. Summary of 2 experiments with N = 6 (B, C) or 
3-5 experiments with N = 13-21 (D, E). Significant differences by Mann-Whitney test are indicated with * p < 0.05, 
*** p < 0.001. Significant differences between B cell subsets by Wilcoxon paired test are indicated with # p < 0.05, 
## p < 0.01, ### p < 0.001.
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(OVA) as non-schistosomal control protein no fluorescence signal was detected in the spleen (suppl. 
figure s3). Flow cytometry confirmed that 83% of metallophilic macrophages were positive for SEA 
only 30 minutes after injection, and still 53% of cells after 24 hours (figure 3c). In addition, F4/80-
expressing red pulp macrophages and Ly6Chi monocytes efficiently bound SEA (81.7 and 82.6%, 
respectively), while only a small fraction of dendritic cells and neutrophils did bind SEA (figure 3c, suppl. 
figure s4a-s4c for gating scheme of cell types). Metallophilic macrophages not only bound SEA 
abundantly, they also significantly upregulated typical surface activation markers such as CD11c and 
CD86, but not MHCII, at 30 minutes and 2 hours after SEA injection, respectively (figure 3d). Because 
macrophages of the marginal zone were most potent in binding SEA, we next addressed their role for 
SEA-mediated marginal zone Breg cell induction. To this end, macrophages were depleted in vivo by 
i.p. injection of clodronate-containing liposomes 45 prior to injection of schistosome eggs. Eggs were 
injected 3 and 4 weeks after clodronate treatment, at time-points when only macrophages, including 
metallophilic and MZ subsets, were significantly reduced in spleens, but no other cell types (suppl. 
figure s4d and 46). Successful and specific depletion of splenic macrophages was also confirmed by 
fluorescence microscopy of tissue sections (figure 3e) and flow cytometry (suppl. figure s4e) at 7 days 
after the last egg injection, when B cell activity was analyzed. Unexpectedly, IL-10 secretion of splenic 
B cells from macrophage-depleted mice was equal to that from control liposome-treated mice (figure 
3f). Also the upregulation of intracellular IL-10 (figure 3G) and CD86 expression in B cells, as well as 
the induction of Foxp3+CD25+ and IL-10+CD25+ CD4 T cells (suppl. figure s4f and s4G) following SEA 
injection was not affected by the absence of macrophages. In conclusion, splenic macrophages are not 
essential for schistosome antigen-induced Breg cell development, despite the high binding of SEA by 
different macrophage subsets.
mZ b cells bind and take up schistosome antigens
To test whether B cells directly bind and interact with schistosome antigens without the help of 
surrounding accessory cell types, fluorescently labeled SEA was injected i.v. and its co-localization 
with B cells analyzed by fluorescence microscopy of splenic tissue sections. Indeed, egg antigens were 
found to co-localize with some splenic B220+ B cells (figure 4a). Flow cytometry, a more sensitive 
method compared to fluorescence microscopy, showed that only MZ B cells but not follicular B cells 
did bind SEA in vivo, with a maximum of 56.4% of cells being positive at 2 hours after SEA injection. 
SEA was still detectable on 11.5% of marginal zone B cells at 24 hours (figure 4b). Marginal zone B 
cells also showed an increased CD86 surface expression following SEA injection, which was significant 
at 6 hours after SEA injection (figure 4c). Interestingly, marginal zone B cells that bound SEA showed 
a higher CD86 expression compared to cells that were found to be negative for SEA, i.e. approximately 
3-fold (SEA positive) versus only 1.5-fold (SEA negative) compared to B cells from untreated animals 
(figure 4c). This suggests that marginal zone B cells not only efficiently bind egg antigens in vivo, 
but also become (more) activated as a consequence of this interaction. Binding of SEA to B cells was 
confirmed in vitro by culturing splenic B cells with fluorescently labeled SEA for 60 minutes, after 
which up to 16% were positive for SEA as measured by flow cytometry (figure 4d), which is a similar 
percentage as found for total B cells after in vivo application of labeled SEA (figure 4b). By using SEA 
labeled with the pH-sensitive dye pHrodo, it was shown that egg antigens were not only bound to 
the surface but were also internalized by B cells into acidic cellular compartments (figure 4d). As in 
vivo, also in vitro the marginal zone B cell subset bound SEA more efficiently than the follicular B cell 
subset, with in average 15.9% versus 6.9% of cells being positive for SEA (figure 4e). Collectively, these 
data show that B cells, and in particular MZ B cells, are capable of directly interacting with schistosome 




figure 3. macrophage subsets of the mZ bind sea but are dispensable for schistosome antigen-mediated 
breg cell induction. (a, b) Spleens were snap-frozen 30 minutes after i.v. injection of 200 µg fluorescently labeled 
SEA, and binding of SEA analyzed by fluorescence microscopy. Images are representative for 2 experiments with 
N = 5 mice and 3 follicles per section imaged. (a) SEA clustered around the marginal zone of the spleen (indicated 
by white dashed line). (b) SEA localized in the marginal zone to macrophages expressing Siglec-1 (marginal 
metallophilic macrophages) and SIGN-R1 (MZ). (c, d) Mice were i.v. injected with fluorescently labeled SEA and 
splenocytes harvested 30 minutes-24 hours later. (c) Frequency of SEA-positive cells in various splenocyte subsets 
as determined by flow cytometry (gating schemes see suppl. figure s4). MF, macrophages; RP, red pulp; MM, 
marginal metallophilic; DC, dendritic cells. (d) Mean fluorescence intensity of surface markers on MM macrophages 
calculated as fold increase versus the expression at time-point 0 hours. Summary of 2 experiments with N = 2. (e-G) 
Mice were i.p. injected with 200 µl clodronate-containing liposomes or PBS control liposomes. Three weeks later, 
mice were i.p. injected with two doses of 5000 eggs. Seven days after the last egg injection, splenic B cells were 
restimulated for 2 days with SEA. (e) Absence of splenic Siglec-1 and SIGN-R1-expressing macrophage subsets at 
the time-point of spleen collection was confirmed by fluorescence microscopy. B cells were stained with B220. (f) 
Cytokine concentration in culture supernatants as determined by ELISA. (G) Intracellular IL-10 expression of B cells 
after addition of Brefeldin A to the last 4 hours of the culture. One representative (N = 5) out of 2 similar experiments 
is shown. Significant difference by Mann-Whitney test is indicated with * p < 0.05, ** p < 0.01. Significance as 
determined by one-sample t-test of log-transformed data is indicated with # p < 0.05, ## p < 0.01.
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figure 4. schistosome antigens bind to b cells and are internalized into acidic compartments. (a) C57BL/6 mice 
were i.v. injected with 200 µg of fluorescently labeled SEA and spleens snap-frozen 30 minutes later. Fluorescence 
microscopic image shows localization of SEA to B220+ B cells and is representative for 2 experiments with N = 5 mice 
and 3 viewing fields per section imaged. (b, c) Splenic B cells were analyzed by flow cytometry at 30 minutes to 24 
hours after i.v. injection of labeled SEA for (b) frequency of SEA+ cells within total B cells or B cell subsets as gated in 
figure 2a, and for (c) fold increase of CD86 expression on total MZ B cells compared to MZ B cells gated for SEA+ 
and SEA- populations. Summary of 2 experiments with N = 2. (d, e) Splenic B cells from naïve mice were cultured 
in vitro with SEA (20 µg/ml) labeled with a green dye (PF-488) alone, or co-labeled with a pH-sensitive dye (pHrodo 
Red). After 60 minutes, the frequency of SEA+ B cells was determined by flow cytometry. (d) Gated for total CD19+ B 
cells (1 representative out of 2 experiments shown). (e) Gated for follicular (FO) and marginal zone (MZ) B cell subsets 
(summary of 3 experiments). Significant differences indicated with # p < 0.05 and ## p < 0.01 are determined by one-
sample t-test of log-transformed data (C) or between B cell subsets by Wilcoxon paired test.
breg cells can be generated in vitro by direct interaction with schistosome egg antigens
Next, we investigated whether the observed direct interaction of B cells with SEA can drive IL-10 
expression and induction of regulatory B cell function in vitro. To this end, CD19+ splenic B cells 
from naïve mice isolated using MicroBeads were cultured for 3 days with SEA. SEA-stimulated B 
cells secreted significantly more IL-10, but not IL-6, compared to non-stimulated B cells (figure 5a), 




of sorted MZ and follicular B cells showed once more that the MZ B cell subset reacted more potently 
to SEA, e.g. with a significantly higher IL-10 secretion compared to the follicular subset (figure 5b). 
In addition, frequencies of B cells expressing intracellular IL-10 were likewise increased (figure 5c). 
To ensure that the IL-10 phenotype is not reliant on artificially high levels of stimulation with PMA/
ionomycin which is added to facilitate detection of intracellular IL-10, we repeated the assay using cells 
from IL-10-GFP reporter (TIGER) mice with similar results (s5 figure). CD40 and CD86 expression were 
upregulated compared to cultures in medium alone (figure 5d). Importantly, in vitro SEA-activated B 
figure 5. breg cells can be generated in vitro by stimulation with schistosome egg antigens which involves 
lysosomal processing. (a-e) Splenic B cells from naïve mice were cultured for 3 days with 20 µg/ml SEA or medium 
as control. Cytokine concentration in culture supernatants of (a) total B cells (6 experiments) or (b) sorted B cell 
subsets (2 experiments with N = 6). (c) Intracellular IL-10 expression of total B cells after addition of PMA, ionomycin 
and Brefeldin A to the last 4 hours of the culture (4 experiments). (d) Mean fluorescence intensity of the activation 
markers CD40 and CD86 (4 experiments). (e) Splenic B cells were stimulated in vitro as above, and subsequently co-
cultured with CD4+CD25- sorted splenic T cells. After 4 days, the frequency of CD25+Foxp3+ Treg cells within the CD4 
T cell population was determined by flow cytometry. Summary of 4 experiments. (f, G) Splenic B cells from naïve mice 
were cultured in vitro with SEA (20 µg/ml), CpG (5 µg/ml) or Pam3Cys (10 µg/ml) for 2 days. Every day, chloroquine (5 
µM) was added to the culture. Intracellular IL-10 expression after addition of PMA, ionomycin and Brefeldin A during 
the last 4 hours of the culture (f), and cytokine concentrations in culture supernatants (G). Summary of 2 experiments 
with N=3-4. Significant differences are indicated with * p < 0.05, ** p < 0.01 and tested by Mann-Whitney. # p < 0.05 
indicates significant difference between B cell subsets by Wilcoxon paired test.
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cells were also capable of driving Treg cell development during a 4 day co-culture with CD25-depleted 
CD4 T cells (figure 5e), thus providing further evidence for a bona fide regulatory function of the in 
vitro induced Breg cells. Because we had seen internalization of egg antigens into acidic compartments 
(figure 4d), we wondered whether lysosomal processing is necessary for induction of IL-10 expression. 
Addition of chloroquine, an inhibitor of endosomal acidification 47, significantly reduced the IL-10 
secretion and frequency of IL-10+ B cells induced by SEA and CpG (ligand for endosomal TLR9), but 
not by Pam3Cys (ligand for surface TLR2) (figure 5f and 5G). This suggests that internalization and 
endosomal processing of SEA is required for B cell IL-10 induction. The type of receptor involved in direct 
activation of Breg cells by SEA remains unknown. Egg antigens are abundantly glycosylated and known 
to bind to C-type lectin receptors 39,40. Lex-motifs, one of the most abundant glycan structures present 
in SEA, bind to the C-type lectin receptor SIGN-R1. However, when treating SIGN-R1-deficient mice 
with SEA, IL-10 expression was equally well induced compared to wild-type mice (suppl. figure s6a), 
suggesting no involvement of the Lex-motifs. Furthermore, stimulation of various TLRs on B cells, 
including TLR2, TLR4, TLR7 and TLR9, has been described to induce IL-10 production 30,31. Because 
SEA has been reported to contain TLR2 activity 48,49, we compared SEA-induced Breg cell responses 
in wild-type and TLR2-deficient B cells. We did however not observe any difference in IL-10 secretion 
between the two strains (suppl. figure s6b), excluding a role of TLR2-triggering SEA components in 
SEA-induced B cell IL-10 production. This is further supported by the fact that TLR2-mediated B cell 
activation was independent of endosomal processing while SEA-mediated activation was dependent 
on it (figure 5f and 5G). Collectively, these data demonstrate that Breg cells can be generated in vitro 
by culture with schistosome antigens, that endosomal processing is involved in this process, and that 
these Breg cells are functional in the sense that they support Treg cell development.
cd40 ligation enhances the schistosome antigen-induced breg cell development
Previous studies highlighted a role for CD40 ligation during in vitro Breg cell induction 50,51. We therefore 
tested whether CD40 ligation could increase the SEA-mediated effect on Breg cell development. 
Addition of anti-CD40 stimulatory antibody (Ab) to the 3 day SEA culture increased IL-10 secretion 
of splenic B cells by 1.7-fold compared to SEA alone. A similar enhancing effect was observed for 
IL-6 secretion (figure 6a) and CD86 expression (figure 6b). In contrast to anti-CD40 Ab, addition 
of anti-IgM Ab did not significantly enhance the SEA-mediated B cell activation (suppl. figure s7). 
To exclude stimulatory effects from LPS in vitro, B cells from TLR4-deficient mice were stimulated 
with SEA with or without addition of anti-CD40 Ab. The fold increase of IL-10 secretion compared to 
B cells cultured in medium was similar for wild-type and TLR4-deficient cells, thus excluding a major 
effect of the TLR4 ligand LPS (suppl. figure s6c). Finally, co-culture of CD25-depleted CD4 T cells 
with anti-CD40-stimulated B cells increased the frequency of CD25+Foxp3+ Treg cells, which was 
further increased if B cells had been stimulated with SEA plus anti-CD40 Ab (figure 6c). Thus, SEA 
stimulation plus CD40 ligation of B cells further enhanced the capacity to drive the development of 
IL-10-producing Breg cells in vitro. 
Previous reports only addressed the role of CD40 ligation in vitro, but the relevance for in vivo 
Breg cell induction was not investigated. We therefore blocked CD40 ligand in vivo by i.p. injection of 
a hamster anti-mouse CD40 ligand blocking mAb (200 µg; every 4 days starting at day -1 prior to 1st 
SEA injection) during SEA treatment of mice and analyzed the effect on Breg cell activation. In hamster 
IgG-injected control mice, SEA treatment increased the amount of B cell-derived IL-10 secretion by 
3.3-fold compared to PBS treatment. Upon anti-CD40 ligand administration this increase was only 
1.6-fold and thereby significantly lower (figure 6d). Importantly, the SEA-mediated upregulation of 
intracellular IL-10 and CD86 expression by B cells was even fully abolished when CD40 ligand was 
blocked (figure 6e and 6f). Taken together, CD40 ligation enhances the Breg cell-inducing effect of 




figure 6. cd40 ligation enhances sea-induced breg cell development. (a, b) Splenic B cells from naïve mice were 
cultured with 20 µg/ml SEA or medium as control, with or without addition of anti-CD40 co-stimulatory antibody. 
After 3 days of culture, supernatants were analyzed for IL-10 and IL-6 by ELISA (a) and B cell CD86 expression by flow 
cytometry (b). Summary of 6 experiments. (c) Splenic B cells were stimulated for 3 days with anti-CD40 mAb (2 µg/
ml) and SEA (20 µg/ml) or anti-CD40 alone, and subsequently co-cultured with CD4+CD25- sorted splenic T cells. After 
4 days, the frequency of CD25+Foxp3+ Treg cells within the CD4 T cell population was determined by flow cytometry. 
Summary of 4 experiments. (d-f) Mice were i.p. injected with two doses of 100 µg SEA or PBS as control. CD40 ligand 
was blocked in vivo by i.p. injection of 200 µg hamster anti-mouse CD40 ligand or 200 µg hamster IgG as control 
(Ctrl) for 4 times, every 4 days starting at day -1 before SEA/PBS treatment. At day 14 after the first SEA/PBS injection, 
splenic B cells were in vitro restimulated with SEA for 2 days. Summary of 2 experiments (N = 8). (d) Fold increase 
of IL-10 in supernatants from B cells of SEA-injected versus PBS-injected mice. (e) Intracellular IL-10 expression of 
B cells after addition of Brefeldin A to the last 4 hours of the culture. (f) Mean fluorescence intensity of CD86 on B 
cells. Significant differences are indicated with * p < 0.05, ** p < 0.01, *** p < 0.001 as tested by Mann-Whitney test. 
# p < 0.05, ## p < 0.01 and ### p < 0.001 indicates significant difference by one-sample t-test of log-transformed data 
(D) or to respective medium control by Mann-Whitney test.
the secretory schistosome egg antigen IPse/alpha-1 induces breg cell development in  
mice and humans 
SEA is a complex mixture of several different antigens. In the next step, we therefore aimed to identify 
specific antigens in SEA that are relevant for Breg cell induction. We focused on three major antigens that 
provoke an antibody response in nearly all infected patients: omega-1, kappa-5 and IPSE/alpha-1 52,53. 
B cells were able to bind fluorescently labelled natural IPSE/alpha-1 (nIPSE), a secreted egg antigen we 
purified from egg extracts, in a dose-dependent manner during 60 minutes in vitro culture (figure 7a). 
During 3 days culture however, nIPSE induced significantly elevated IL-10 but not IL-6 secretion by B 
cells in a concentration dependent manner (figure 7b and s8a figure). Importantly, recombinant IPSE/
alpha-1 expressed in tobacco plants (pIPSE), which behaves as nIPSE in terms of protein dimerization 
and human basophil activation (suppl. figure s9), had similar effects to the natural molecule on B cell 
IL-10 and IL-6 secretion (figure 7c). Both nIPSE and pIPSE-stimulated B cells were capable of driving 
Treg cell development during B cell-T cell co-culture (figure 7d). Interestingly, SEA depleted of IPSE/
alpha-1 (SEADIPSE) was as efficient as total SEA in inducing IL-10 secretion and CD86 expression by B 
cells, which suggests that also SEA antigens other than IPSE/alpha-1 can activate B cells (figure 7b). 
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figure 7. the secretory sea component IPse/alpha-1 induces breg cell development. (a) Splenic B cells were 
incubated with PF-647-labeled SEA (20 µg/ml), natural IPSE/alpha-1 (nIPSE, 1 – 5 - 10 µg/ml) or left untreated and 
the frequency of SEA- and IPSE-positive cells measured after 60 minutes by flow cytometry. Representative FACS plots 
and summary of 3 experiments is shown (N = 3). (b) Splenic B cells from naïve mice were cultured for 3 days with 10 
µg/ml nIPSE, 20 µg/ml SEA, 20 µg/ml SEAΔIPSE or medium as control, with or without addition of anti-CD40 mAb (2 
µg/ml). Cytokine concentration in supernatants after 3 days as determined by ELISA. Summary of 4 experiments. (c) 
Splenic B cells from naïve mice were cultured for 3 days with 10 µg/ml recombinant, plant-derived IPSE (pIPSE), 20 µg/
ml SEA or medium as control. Cytokine concentration in supernatants after 3 days as determined by ELISA. Summary 
of 4 experiments. (d) Splenic B cells were cultured for 3 days with nIPSE (10 µg/ml), SEA (20 µg/ml) or medium alone 
as control, and subsequently co-cultured with CD4+CD25- sorted splenic T cells from C57BL/6 or DEREG mice. After 
4 days, the frequency of CD25+Foxp3+ Treg cells within the CD4 T cell population was determined by flow cytometry. 
Summary of 3 experiments. Significant differences to medium control are indicated with * p < 0.05, as tested by 
Mann-Whitney test. # p < 0.05 indicates significant difference by one-sample t-test of log-transformed data.  
However, as opposed to IPSE/alpha-1, other major components in SEA, such as omega-1 and kappa-5, 
did not increase IL-10 in any of the tested concentrations (1-20 µg/ml) (suppl. figure s8b), thus 
excluding a role for these antigens in SEA-mediated Breg cell induction. Notably, omega-1 is toxic to 
B cells at concentrations of 5 µg/ml and above, and was therefore only tested at 1 µg/ml. For better 
comparability, we determined the following average relative amounts of IPSE/alpha-1, omega-1 and 




IPSE/alpha-1, 0.6% omega-1 and 1.8% kappa-5. Furthermore, to proof that the Breg cell-inducing 
effect is specific for molecules in SEA, we stimulated B cells in vitro with adult worm antigen (AWA) as 
control of an S. mansoni-derived antigen mixture not containing IPSE. AWA was unable to induce IL-10 
secretion when tested in the same concentration as used for SEA (suppl. figure s8c). For a possible 
future therapeutic application of antigen-activated Breg cells against e.g. allergic diseases, it is crucial 
to confirm the IL-10-inducing effect in human B cells. After 3 days in vitro stimulation with SEA and anti-
CD40, we found a significant increase in the percentage of total human IL-10+ CD19+ B cells compared 
to cells cultured with anti-CD40 alone. Comparing different B cell subsets, which have previously been 
attributed with regulatory properties 54,55, we found the increase in IL-10+ B cells after SEA stimulation 
to be most pronounced among CD1d+ B cells rather than CD24+CD27+ and CD24+CD38+ B cells. Both 
nIPSE and pIPSE significantly increased the fraction of IL-10-expressing cells among CD1d+ B cells, 
whereas neither had an effect on the other two subsets investigated. As CD1d+ B cells only comprise 
a very small fraction of all B cells (CD24+CD27+ B cells >> CD24+CD38+ B cells > CD1d+ B cells), the effect 
of nIPSE and pIPSE does not translate into an increase in the percentage of IL-10+ cell in the total B 
cell pool in contrast to SEA (figure 8). This also suggests that additional molecules in SEA may have 
an IL-10-inducing effect. Collectively, we demonstrated that SEA was bound to and internalized by B 
cells, and that this direct interaction drives the development of Breg cells. Furthermore, we identified 
IPSE/alpha-1 as a single molecule of SEA that induces Breg cells in mice and humans, both as a natural 
and a recombinant molecule.
dIscussIon
In this study, we sought to identify the molecules and mechanisms involved in the induction of IL-10-
producing B cells by the helminth S. mansoni. We found that soluble antigens derived from schistosome 
eggs, amongst which the secretory antigen IPSE/alpha-1, directly interacted with B cells. This led to 
the development of Breg cells characterized by IL-10 secretion and Treg cell-inducing capacity. Next 
to the potentially therapeutic relevance of how to generate regulatory, anti-inflammatory cells, this 
study also provides mechanistic insight into how schistosomes interact with the host immune system, 
expanding the regulatory arm of immunity and thereby prolonging its survival in the host.
While we and others have shown IL-10 expression in splenic Breg cells during natural infection 
with S. mansoni 8,11,12, the contribution of S. mansoni-derived egg antigens was not yet studied. SEA is 
highly immunostimulatory and well-known to promote Th2 as well as Treg cell responses in the host 56. 
Here, we found that S. mansoni egg antigens are also able to induce IL-10-producing B cells in 
vivo, without the context of natural infection. Because SEA is a complex mixture of several different 
antigens, it is not unexpected that different types of immune cells and qualities of immune responses 
are induced. The use of Breg cells as a therapeutic tool against inflammatory diseases is especially 
attractive because Breg cells in turn can induce Treg cell development 57, which would thus amplify 
the beneficial regulatory effect. It was therefore important to investigate whether SEA-induced IL-
10-producing B cells have the capacity to trigger Treg cell development. This was indeed the case as 
we could show by in vitro co-cultures of T cells with egg antigen- or IPSE-activated B cells. Similarly, 
Breg cells isolated from naturally schistosome-infected mice and humans were previously shown to 
drive Treg cell development in vitro 8,12,58, thus indicating a common feature of schistosome-induced 
Breg cells. 
Our finding that egg antigens could induce splenic Breg cell development in vivo raised the question 
whether those antigens can directly interact with B cells in the spleen. In in vivo binding studies using 
fluorescently labeled SEA and fluorescence microscopy, egg antigens were indeed found to directly 
bind to splenic B cells. Although various egg antigens are abundantly glycosylated, the restricted and 
low expression of C-type lectin receptors by B cells 41 argues rather for the involvement of non-C-
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type lectin PRRs expressed by B cells in the direct binding of SEA components. Indeed, preliminary 
experiments with B cells of SIGN-R1-deficient mice, showed an equal IL-10 expression in response to 
SEA compared to wild-type littermates, suggesting no involvement of the Lex-motifs, one of the most 
abundant glycan structures present in SEA and known to bind SIGN-R1. Instead, we found that within 
a mixture of schistosome antigens, at least the egg glycoprotein IPSE/alpha-1 was capable of driving 
Breg cell development in vitro by directly interacting with B cells, equipping them with Treg cell-
inducing capacity. Two independent experimental approaches suggested that egg antigens are taken 
up and processed in acidic lysosomes. Previous reports on in vitro induction of Breg cells by helminth 
antigens did not use highly sort-purified B cells as in our study, but total splenocyte preparations 8,10 
or merely B cell-enriched cultures 13. Hence, it was impossible to exclude indirect, accessory cell type-
mediated B cell stimulation or IL-10 production by other cell types 59,60. Other reports addressed B 
cell activation by IL-10 production, but did not study the regulatory activity of schistosome antigen-
figure 8. human cd1d+ breg cells increase Il-10 expression after sea and IPse/alpha-1 stimulation. B cells 
were isolated from PMBCs of healthy volunteers and stimulated for 3 days with SEA (20 µg/ml), natural IPSE (nIPSE, 
10 µg/ml), plant-derived IPSE (pIPSE, 10 µg/ml), or left untreated. Different Breg cell subsets and intracellular IL-10 
expression were assessed by FACS. Summary of 3 donors. Significant differences to the respective medium control 





exposed B cells compared to unstimulated B cells 14. It must be emphasized that the sole demonstration 
of upregulated IL-10 expression is not sufficient to characterize B cells as Breg cells, as IL-10 can fulfill 
other roles in B cell biology independent from a regulatory function. We thus present the first report on 
direct induction of functional Breg cells with in vitro regulatory activity by helminth antigens.
With respect to the development of therapeutic applications, it would be interesting to see whether 
SEA-induced Breg cells are more qualified than Breg cells induced by other compounds, like TLR7 or 
TLR9 ligands. Opposite to SEA, stimulants like R848 and CpG also induce substantial amounts of B cell 
proliferation and pro-inflammatory cytokines like IL-6 in addition to inducing high levels of IL-10. It 
is currently unknown which side-effects would result in a therapeutic application, but it is tempting 
to speculate that compounds that selectively induce IL-10 are more preferable. We tried to compare 
IL-10-producing B cells induced in vitro by different agents, including SEA, for their capacity to inhibit 
allergic airway inflammation in vivo. We were however not able to confirm a suppressive capacity 
for any of the conditions despite the usage of a published model 31. In the past, we have successfully 
applied adoptive transfers of in vivo, schistosome-induced Breg cells (generated during a natural 
infection) in allergic airway inflammation models 12. Therefore, we assume that underlying differences 
between in vivo and in vitro stimulation of Breg cells may be crucial for the activity in a disease model. 
This may be related to issues like a differential homing or to the strength and kinetics of activation 
and cytokine production which determine the suppressive capacity of Breg cells on bystander immune 
activation in the host. Knowing that schistosome antigens can directly induce Breg cell development, 
we next addressed signals that regulate or enhance antigen-induced B cell IL-10 expression. In previous 
studies, CD40 engagement was described to induce B cell IL-10 expression 18,19,50,51,59. This is in line 
with our results showing that SEA-induced IL-10 expression was significantly increased by addition 
of agonistic CD40 Ab. This points to the potential of a combined therapy for inflammatory diseases 
using helminth antigens together with anti-CD40 Ab treatment. Indeed, a report by the group of Mauri 
et al. provided evidence that experimental therapy with an agonistic Ab against CD40 can ameliorate 
autoimmune disease 61, as did cellular therapy with Breg cells 50, although a combined treatment was 
not yet tested. The groups of Fillatreau and Mauri proposed a two-step model for the acquisition of 
regulatory properties by B cells, with exposure to innate stimuli – such as TLR ligands – as one step 
and CD40 or BCR engagement as second step to establish Breg cell function 36,50. We found a similar 
dependency for in vivo Breg induction by helminth antigen, for which CD40 ligation was crucial. Our 
data also show that, although Breg cell induction in vitro can be achieved alone without additional 
stimuli, engagement of CD40 further enhances this effect. Several cell types including T cells, B cells, 
DCs, basophils, NK cells, mast cells and macrophages express CD40 ligand (CD40L, CD154) 62 and could 
in principle serve as interaction partner ligating CD40 on B cells. It is however tempting to speculate 
that neutrophils play a role as they have been reported to express CD40L and activate MZ B cells for 
immunoglobulin production in a contact-dependent manner 63.
As we found MZ B cells to be the main IL-10-producing B cell subset, it was tempting to speculate that 
accessory cell types of the splenic marginal zone interact with schistosome antigens, and subsequently 
drive the development of MZ Breg cells. Macrophages of the splenic MZ were of particular interest 
because of their known interactions with MZ B cells during steady state 28,42 and their expression of 
SIGN-R1. This C-type lectin receptor was found to bind schistosome antigens in vitro by using SIGN-
R1-overexpressing fibroblasts 43,44. However, it was unknown whether MZ macrophages can capture 
SEA in vivo and are important for B cell IL-10 expression. As hypothesized, we found macrophages 
of the MZ to efficiently bind SEA upon in vivo administration. However, Breg cell induction was not 
affected upon in vivo depletion of macrophages, thus excluding a major role of macrophages in this 
process. Indirectly, also Mangan et al. 10 showed that macrophages were dispensable for Breg cell 
induction during schistosomiasis, as macrophage depletion did not affect the B cell-mediated control 
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of anaphylaxis. The immunological role of SEA-binding MZ macrophage subsets and the identity of 
the binding receptor remain to be determined. 
A limited number of reports is available that used specific helminth antigens to induce B cell IL-10 
expression, namely the filarial antigen ES-62 64 and the oligosaccharide lacto-N-fucopentaose III (LNFP 
III) that contains the LeX trisaccharide antigen present on various schistosome glycoproteins 13. Both 
antigens were either applied in vivo or used in vitro for stimulation of B cell-enriched cultures that still 
contained other cells, which means it remains unclear whether those antigens can directly bind to and 
interact with B cells, without indirect support from other cell types. Our study therefore identified IPSE/
alpha-1 as the first helminth molecule with direct Breg cell-inducing capacity in mice and humans. 
Importantly, this capacity was resembled by recombinant IPSE, which is an important prerequisite for 
a possible therapeutic use. The use of helminth molecules for therapeutic purposes has gained renewed 
interest as controlled human infections with helminths showed disappointing effects in recent phase 
II and phase III trials (reviewed in 65). More studies are required to define the optimal antigen, dose, 
time point and length of treatment as well as the suitability to treat specific inflammatory diseases 66,67. 
Therefore, the identification of helminth-specific Breg-inducing antigens is warranted, even more so as 
the availability of active recombinant forms will ultimately allow its production under GMP conditions. 
IPSE/alpha-1 was originally described as basophil IL-4-inducing principle of Schistosoma eggs 53 
and was in addition shown to induce a mixed Th1/Th2 type of immune response in spleen upon in 
vivo administration 68. In our assays, IPSE/alpha-1 directly interacted with murine B cells via a still 
unknown receptor, which led to activation, induction of B cell IL-10 secretion and Treg cell induction 
in vitro. Although IPSE/alpha-1 is a highly glycosylated protein, we consider a role of IPSE-related 
glycans as unlikely because both, pIPSE and nIPSE were capable to induce B cell IL-10 expression 
despite differences in glycosylation (native IPSE contains Lex motifs 69, while plants per definition cannot 
make Lex motifs 70. In addition, natural omega-1 and IPSE share a similar glycosylation (Lex related) but 
have opposing activities both in B cells (here) and on DCs 71. IPSE/alpha-1 has been shown to not only 
bind to IgE but also to IgG, both to Fc and Fab fragments 53. We therefore hypothesize that IPSE could 
bind to B cells via the B cell receptor or surface-exposed IgG. Particularly important for a possible 
therapeutic use is our finding that both natural and plant-derived IPSE/alpha-1 induced IL-10 expression 
also in human CD1d+ Breg cells. This is even more intriguing as the CD1d+ B cell subset has been 
previously described to be increased in number and activity both in experimental infections in mice 
and in people living in endemic areas 12,58. We propose a mechanism of schistosome-induced Breg cell 
induction in which B cells directly interact with schistosome egg antigens by binding and internalizing 
antigen, lysosomal processing and subsequent up-regulation of CD86 and IL-10 expression. The MZ 
B cell subset appeared to be particularly responsive, and CD40 engagement further enhanced Breg 
cell activity. Furthermore, we have successfully identified the secreted egg antigen IPSE/alpha-1 as 
one of the Breg-inducing antigens. These egg antigen-induced Breg cells were potent in driving Treg 
cell development, allowing for induction of two potent regulatory responses by the same antigen. To 
our knowledge, our study provides the first description of a helminth-specific molecule that interacts 
with and induces Breg cells, and a mechanistic insight into how schistosomes interact with their host, 
influence its regulatory immunity and thereby promoting their prolonged survival in the host.
materIal and methods
animals 
Female C57BL/6OlaHsd mice from Harlan, TLR4-deficient mice (on C57BL/6 genetic background, 
kindly provided by Dr. S. Akira, Osaka, Japan), TLR2-deficient mice (on C57BL/6 genetic background, 
kindly provided by the group of Dr. K. Willems van Dijk), SIGN-R1-deficient mice (on C57BL/6 genetic 




cells) mice (on C57BL/6 genetic background, kindly provided by Dr. T. Sparwasser) and IL-10-GFP 
reporter (TIGER) mice (on C57BL/6 genetic background, kindly provided by Dr. R.A. Flavell) were 
housed under SPF conditions in the animal facilities of the Leiden University Medical Center in Leiden, 
The Netherlands, and used for experiments at 8-14 weeks of age. Percutaneous infection of mice with 
S. mansoni was performed as described elsewhere 12, and mice sacrificed in the chronic phase (14-15 
weeks) post infection.
Preparation and purification of schistosome eggs, egg and worm antigens
Freshly isolated S. mansoni eggs from trypsinized livers of hamsters infected for 50 days were washed 
in RPMI medium with 300 U/ml penicillin, 300 µg/ml streptomycin (both Sigma-Aldrich, Zwijndrecht, 
The Netherlands) and 500 µg/ml amphotericin B (Thermo Fisher Scientific, Breda, The Netherlands) 
and then kept at -80°C. SEA, AWA, omega-1, kappa-5 and IPSE/alpha-1 were prepared and isolated 
as described previously 53,71,72,73. The purity of the antigen preparations was checked by SDS-PAGE 
and silver staining, and protein concentrations determined using the BCA procedure. The antigen 
preparations had an endotoxin content of less than 150 ng/mg protein (SEA) or 3 ng/mg protein 
(purified molecules) as tested by Limulus Amoebocyte Lysate (LAL) test and TLR4-transfected HEK-
reporter cell lines (kindly provided by Prof. Golenbock, University of Massachusetts Medical School, 
Boston, USA).
Production and purification of recombinant IPse from n. benthamiana plants
Recombinant IPSE was produced by transient expression in Nicotiana benthamiana and purified 
according to the methods described in 70. In short, the complete sequence encoding the 134 AA 
mature Schistosoma mansoni IPSE (Smp_112110) was codon optimized and preceded by a signal 
peptide from the Arabidopsis thaliana chitinase gene (cSP) and a N-terminal 6x histidine-FLAG tag 
(H6F) was included. The full sequence was synthetically constructed at GeneArt and cloned into 
a pHYG expression vector. In all experiments the silencing suppressor p19 from tomato bushy stunt 
virus in pBIN61 was co-infiltrated to enhance expression. For gene expression the two youngest fully 
expanded leaves of 5-6 weeks old N. benthamiana plants were infiltrated by injecting Agrobacterium 
tumefaciens containing the IPSE expression plasmid. N. benthamiana plants were maintained in 
a controlled greenhouse compartment (UNIFARM, Wageningen) and infiltrated leaves were harvested 
at 5-6 days post infiltration. Plant-produced recombinant IPSE was obtained by applying leaf apoplast 
fluid containing IPSE to Ni-NTA Sepharose (IBA Life Sciences) in 50 mM phosphate buffered saline (pH 
8) containing 100 mM NaCl. Bound IPSE was eluted with phosphate buffered saline (pH 8) containing 
0.5M imidazole. Total soluble apoplast proteins and purified IPSE were separated under reducing/non-
reducing conditions by SDS-PAGE on a 12% Bis-Tris gel (Invitrogen) and subsequently stained with 
Coomassie brilliant blue staining.
Isolation of splenocytes, b cells and t cells
Single cell suspensions of murine spleens were prepared by dispersion through a 70 µm cell strainer 
(BD Biosciences, Breda, The Netherlands), and erythrocytes depleted by lysis. For analysis of splenic 
myeloid cell populations, spleens were digested for 1 hour at 37°C by incubation with collagenase 
D (2 mg/ml; Roche, Woerden, The Netherlands) and DNase I (2000 U/ml; Sigma-Aldrich) before 
dispersion. B cells were purified from spleens by using anti-CD19 MicroBeads (Miltenyi Biotec, Leiden, 
The Netherlands) following the manufacturer’s protocol. Purity was routinely ~95-98%. After a typical 
CD19 MACS sort, circa 83% of all contaminating cells were CD3+ T cells, 7% CD11b+CD11c+ cells, 2% 
CD11b+ CD11c- cells, and 8% other cells. To determine cytokine secretion of splenic B cell subsets, 
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CD19+ B cells were subsequently sorted by flow cytometry for follicular B cells (CD23+CD21low) and 
marginal zone B cells (CD23-CD21hi) which resulted in purities of > 98%. CD4+ T cells were purified 
from spleens by negative selection and depleted of CD25-expressing cells using anti-CD25 MicroBeads 
(Miltenyi Biotec).
Isolation of human b cells from Pbmcs
Peripheral blood mononuclear cells (PBMCs) were isolated from heparinized blood of healthy volunteers 
by Ficoll gradient centrifugation, and B cells were purified from PBMCs by using anti-CD19 MicroBeads 
(Miltenyi Biotec, Leiden, The Netherlands) following the manufacturer’s protocol. 
In vitro murine and human b cell stimulation
Mouse splenic CD19+ B cells (1.5x106/ml) were cultured in medium (RPMI 1640 glutamax; Thermo 
Fisher Scientific), containing 5% heat-inactivated Fetal Bovine Serum (FBS; Greiner Bio-One, Alphen 
aan den Rijn, The Netherlands), 5 × 10-5 M 2-Mercaptoethanol (Sigma-Aldrich) and antibiotics (100 
U/mL penicillin and 100 µg/mL streptomycin; Sigma-Aldrich). Human B cells (1.5 x 106/ml) were 
cultured in medium (RPMI 1640; Thermo Fisher Scientific), containing 10% heat-inactivated Fetal 
Bovine Serum, pyruvate (1 mM), glutamate (2 mM) and antibiotics (100 U/mL penicillin and 100 µg/mL 
streptomycin; all Sigma-Aldrich). The following stimuli were added as indicated in the figure legends: 
SEA (20 µg/ml), SEA depleted of IPSE (SEADIPSE, 20 µg/ml), natural (1, 5, 10, 20 µg/ml) or plant-
derived IPSE (10 µg/ml), omega-1 (1 µg/ml), kappa-5 (1, 5, 10, 20 µg/ml), AWA (5, 10, 20 µg/ml). 
For some conditions, co-stimulatory rat anti-mouse CD40 antibody (2 µg/ml; clone 1C10; BioLegend, 
Uithoorn, The Netherlands) or goat anti-mouse IgM (0.5, 1, 2 µg/ml; Jackson ImmunoResearch, Suffolk, 
UK) was added to the culture. After 3 days culture at 37°C, supernatants were collected for cytokine 
analysis by ELISA. Cells were restimulated with PMA (100 ng/ml) and ionomycin (1 µg/ml) for 4 hours 
in the presence of Brefeldin A (10 µg/ml; all Sigma-Aldrich) for flow cytometric analysis of intracellular 
IL-10. In experiments addressing involvement of lysosomal acidification, the inhibitor chloroquine (5 
µM; Sigma) was added at the start of a two days culture and refreshed after 24 hours, and the TLR 
ligands CpG ODN 1826 (5 µg/ml; Invivogen) or Pam3Cys (10 µg/ml; Invivogen) used as control stimuli 
next to SEA.
In vivo experiments
For in vivo stimulation of B cells, mice were i.p. injected with two doses of 5000 eggs or 100 µg SEA 
in PBS, determined as optimal doses where B cell IL-10 production plateaued in prior dose-titration 
experiments, and PBS or 100 µg human serum albumin (HSA) in PBS as control 7 days apart. At day 
14 after the first injection, splenic B cells were harvested and cultured in medium at 1.5 x 106 cells/
ml or restimulated for 2 days with SEA (20 µg/ml) to allow detection of cytokines, as established 
for in vivo schistosome-exposed B cells before 12. Supernatants were collected to determine cytokine 
concentration by ELISA. Cells were cultured for additional 4 hours with Brefeldin A (10 µg/ml; Sigma-
Aldrich) to detect intracellular IL-10 by flow cytometry. In some experiments, mice were treated i.p. with 
200 µg of hamster anti-mouse CD40 ligand blocking antibody (clone: MR1) or 200 µg hamster IgG as 
control (Jackson ImmunoResearch) 4 times, every 4 days starting one day before SEA or PBS treatment. 
For in vivo depletion of macrophages, mice were i.p. injected with 200 µl clodronate-containing 
liposomes and control mice with 200 µl of PBS liposomes (ClodronateLiposomes.com, Amsterdam, 
The Netherlands) 45 three weeks prior to egg antigen treatment. Successful and specific depletion of 




co-culture with cd4+cd25- t cells
In vitro or in vivo SEA-stimulated CD19+ B cells were co-cultured with MACS-sorted CD4+CD25- T cells 
at 1:1 ratio (each 1 x 106/ml) to test for in vitro Treg cell induction. After 4 days, Treg cell frequencies 
were determined by flow cytometry by gating for Foxp3+CD25+ cells in the CD3+CD4+ T cell population, 
and culture supernatants collected for subsequent ELISA.
antigen binding assays
SEA, IPSE/alpha-1 and ovalbumin (OVA) were fluorescently labeled with PF-488 or PF-647 using 
the PromoFluor labeling kits (PromoCell, Heidelberg, Germany) according to the manufacturer’s 
protocol. For some experiments, SEA was co-labeled with the pH-sensitive pHrodo Red dye (Thermo 
Fisher Scientific). After protein labeling, non-reacted dye was removed using Zeba desalt spin columns 
(Thermo Fisher Scientific). For analysis of binding in vitro, CD19+ splenic B cells were cultured for 60 
minutes at 37°C with 20 µg/ml fluorescently labeled SEA or 1-10 µg/ml of IPSE antigen, then washed in 
ice-cold PBS before analysis by flow cytometry. For analysis of in vivo binding, mice were i.v. injected 
with 200 µg of fluorescently labeled SEA or OVA as non-schistosomal control protein and spleens snap-
frozen 30 minutes to 24 hours later. Binding of SEA to B cells was analyzed by confocal fluorescence 
microscopy of tissue sections and by flow cytometry.
Induction of Il-4 release from human basophils
Basophils were purified from 250 ml of peripheral blood of healthy human donors to a mean purity 
of 99% by a three-step protocol consisting of a density gradient centrifugation via Ficoll/Percoll 
(100/6, density 1.080 g/l), followed by enrichment of the basophils via counter flow elutriation and 
final purification by magnetic cell sorting using the basophil isolation kit II for negative selection of 
basophils (Miltenyi-Biotech). Purified basophils were cultured in Iscove’s Modified Dulbecco’s Media 
(IMDM; PAA) containing 2 mM glutamine (PAA), 5 µg/ml insulin (Gibco), 50 µg/ml apo-transferrin 
(Sigma-Aldrich), 100 µg/ml Pen/Strep (PAA), 10% heat-inactivated Fetal Calf Serum (FCS-Gold; PAA) 
and 2.5 ng/ml IL-3 (kind gift of Kirin Brewery, Japan). Basophils were pre-incubated for regeneration for 
30 min at 37°C, 6% CO2, and then stimulated at a concentration of 0.025 x 10
6 basophils /ml in 96well 
flat-bottom culture plates in 100 µl at 37°C, 6% CO2. Concentration of stimuli was as indicated. Culture 
supernatants were collected after 18h and stored at -20°C. 
flow cytometry
Flow cytometric analysis of murine B cells was performed by staining with fluorochrome-labeled 
antibodies against CD19, CD21 (both BD Biosciences), CD23, CD40, CD86 or IL-10 (all eBioscience) after 
fixation with 1.9% paraformaldehyde and permeabilization with 0.5% saponin (Sigma-Aldrich). Human 
B cells were stained for CD19, CD38 (both BD Biosciences), CD24, CD27 (both eBioscience), CD1d, IL-10, 
TNF (all Biolegend), and CD39 (Sony Biotechnology, San Jose, USA). Splenic myeloid cell subsets were 
discriminated using fluorochrome-labeled antibodies against CD11b, CD11c (both eBioscience), CD8, 
Ly6C (both Biolegend), F4/80 (AbD Serotec, Puchheim, Germany), Gr-1 (BD Biosciences), and Siglec-1 
(Dr. J. den Haan, VUMC, Amsterdam, The Netherlands). Treg cells were fixed and permeabilized with 
the eBioscience Foxp3 fixation/permeabilization kit and stained using fluorochrome-labeled antibodies 
against CD3, CD4, Foxp3 (all eBioscience) and CD25 (BD Biosciences). All cells were stained with Aqua 
dye (Thermo Fisher Scientific) prior to fixation to discriminate dead cells. For all flow cytometric 
stainings, FcgR-binding inhibitor (2.4G2) was added and FMOs were used for gate setting. Flow 




The concentration of murine IL-6 and IL-10 as well as human IL-4 present in culture supernatants was 
quantified by commercial ELISA kits according to the manufacturer’s instructions (BD Biosciences or 
Eli-Pair, Diaclone). 
confocal microscopy
Spleens were snap-frozen in O.C.T. medium (Tissue-Tek; Sakura, Alphen aan den Rijn, The Netherlands). 
Cryosections (10 µm) were fixed in ice cold acetone for 10 minutes, air-dried, and blocked in 1% BSA 
plus 20% FBS in PBS before staining with Abs at room temperature. Cryosections were incubated with 
rat anti-mouse Siglec-1 (clone SER-4; provided by Dr. J. den Haan, VUMC, Amsterdam, The Netherlands) 
followed by Alexa555-conjugated goat anti-rat IgG (Invitrogen), anti-SIGN-R1 Alexa647 (clone 22D1; 
Dr. J. den Haan) and anti-B220 eFluor450 (eBioscience). Images were acquired using a Zeiss LSM 710 
confocal laser scanning microscope with Zen software (Carl Zeiss Microimaging, Jena, Germany).
statistical analysis
All data are presented as mean ± standard error of the mean (SEM). Statistical analysis was 
performed with GraphPad Prism version 6.00 for Windows (GraphPad Software, La Jolla, CA, USA) 
using nonparametric Mann-Whitney U test to compare different groups and Wilcoxon paired test to 
compare B cell subsets. One-sample t-test of log-transformed data was applied to calculate significant 
changes for data which are expressed as fold increase. All p-values < 0.05 were considered significant.
ethics statement
All animal studies were performed in accordance with the Animal Experiments Ethical Committee of 
the Leiden University Medical Center (DEC-12204). The Dutch Experiments on Animals Act is established 
under European Guidelines (EU directive no. 86/609/EEC regarding the Protection of Animals used for 
Experimental and Other Scientific Purposes). For the isolation of B cells from PBMCs, human subjects 
were recruited within the framework of the study P09.170, which was approved by the Medical Ethical 
Committee of the Leiden University Medical Center. For the isolation of basophils, donors were 
recruited under approval by the Ethics Committee of the University of Luebeck (AZ-12-202A). Studies 
were performed according to the declaration of Helsinki and all participants were adults and have 
given written informed consent. 
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figure s1. additional data on the specificity and persistence of egg antigen-induced b cell activity. (a-b) 
A non-schistosomal control protein does not activate B cells. Wild-type mice were i.p. injected with two doses of 100 
µg SEA in PBS, 100 µg human serum albumin (HSA) in PBS or PBS alone. At day 14, CD19+ sorted splenic B cells were 
restimulated with SEA (20 µg/ml) for 2 days. (a) IL-10 concentration in culture supernatant as determined by ELISA. 
(b) Mean fluorescence intensity of CD86 expression as determined by FACS. One out of 2 similar experiments is 
shown. (c) Intracellular IL-10 expression of splenic B cells isolated from C57BL/6 mice infected chronically (14 weeks) 
with S. mansoni, compared to naïve control mice. (d) IL-10-producing B cells can be detected at least 28d after egg 
injection. Wild-type mice were injected twice with 5000 S. mansoni liver eggs (d-7, d0) by i.p. injection. Splenic B cells 
were isolated on d7, d14 and d28 after the last egg injection and re-stimulated in vitro with SEA (20 µg/ml) for 2 days. 
Supernatants were harvested and the concentration of IL-10 determined by ELISA. One experiment with n=5 mice 
per group. * p < 0.05 as determined by students t-test. (e) Wild-type mice were treated twice with SEA (100 µg) or 
PBS by i.p. injection. On day 14, splenic B cells were isolated and re-stimulated for 2 days with SEA or left untreated 
(medium). IL-10 concentration in culture supernatants as assessed by ELISA. Summary of 5 experiments. (f, G) IL-10 
reporter (TIGER) mice were treated twice with 5000 S. mansoni eggs (f) or infected with S. mansoni until the chronic 
phase of infection (14 weeks) (G). The percentage of IL-10-GFP+ total B cells or follicular (FO) and marginal zone 
(MZ) B cells within the spleen as assessed by FACS. Summary of three experiments with N=15 mice per group (F) or 
one experiment with N=2-4 mice per group (G). Significant differences are indicated with * p < 0.05 and ** p < 0.01 




figure s2. b cell Il-10 induction by egg antigens is independent of tlr4. C57BL/6 wild-type and TLR4-deficient 
mice were i.p. injected with two doses of 100 µg SEA in PBS, or PBS as control. At day 14, CD19+ sorted splenic B cells 
were restimulated with SEA (20 µg/ml) for 2 days. Secreted IL-10, intracellular IL-10 and CD86 expression of B cells are 
shown. Significant differences are indicated with * p < 0.05, ** p < 0.01, *** p < 0.001 as tested by Mann-Whitney test. 
figure s3. macrophage subsets of the mZ do not bind the control protein ovalbumin. Spleens were snap-frozen 
30 minutes after i.v. injection of 200 µg fluorescently labeled SEA or ovalbumin (OVA), and binding analyzed by 
fluorescence microscopy. SEA but not OVA localized in the marginal zone to macrophages expressing Siglec-1 (marginal 




figure s6. b cell Il-10 induction by sea is independent of sIGn-r1, tlr2 and tlr4. (a) C57BL/6 wild-type 
or SIGN-R1-deficient mice were treated with 2 doses of SEA (each 100 µg) for 2 weeks or PBS as control. Secreted 
IL-10 was detected by ELISA after 2 days restimulation of splenic CD19+ B cells with SEA (20 µg/ml). Summary of 
N=2-6 mice per group. (b, c) Splenic B cells from naïve wild-type, TLR2-deficient (b) and TLR2-deficient (c) mice 
were cultured for 3 days with 20 µg/ml SEA or medium as control, with or without addition of anti-CD40 (0.5 µg/ml). 
IL-10 concentration in culture supernatants is expressed as fold increase versus the medium or anti-CD40 control in 
a summary of 3 experiments. Significance was tested by one-sample t-test of log-transformed data and is indicated 
by # p < 0.05, ## p < 0.01.
figure s5. the Il-10 phenotype is not reliant on artificially high stimulation with Pma/ionomycin. Splenic B 
cells from IL-10-GFP (TIGER) mice were cultured for 2 days with 20 µg/ml SEA or medium as control. Intracellular IL-10 
expression of total B cells as assessed by GFP signal in the presence or absence of PMA and ionomycin during the last 
4 hours of the culture. Data are from 1 experiment with N=5 per group.
figure s4. depletion control for splenic cell subsets and treg cell activity after clodronate treatment. (a-c) 
Gating scheme and representative FACS plots of splenocyte subsets which were subsequently analyzed for in vivo-
captured fluorescently labeled egg antigens (shown in figure 3). Splenocytes were pre-gated for living singlets. (a) 
Red pulp macrophages were gated as F4/80+CD11bint, marginal metallophilic (MM) macrophages are Siglec-1-positive 
and highly autofluorescent. (b) Dendritic cells were gated CD11chiCD11bint/+ and further divided into CD8+CD11bint 
and CD8-CD11b+ subsets. (c) Monocytes were gated as CD11b+Ly6ChiGr-1int, neutrophils as CD11b+Ly6CintGr-1hi. (d) 
Frequency of splenic cell types before (0 days) and at 1-28 days after i.p. injection of clodronate-containing liposomes. 
Only macrophage frequencies were significantly reduced at day 21 and 28. (e) Frequency of splenic cell types at 
the time-point of B cell analysis in egg-treated mice (day 7 after the second egg injection, i.e. day 35 after clodronate 
treatment). (f,G) Macrophage depletion prior to SEA treatment does not change the frequency of Treg cells. Mice 
were treated with chlodronate and injected with SEA i.p. The percentage of Foxp3+ CD25+ Treg cells in splenocytes (f) 
and IL-10+ CD25+ T cells (G) as assessed by FACS. Summary of 2 experiments with N=4-6 mice per group (D), N=6-12 
(E), or data from one experiment with N=5 mice per group (F, G). Significant differences to the respective control (D, 






figure s8. IPse/alpha-1 activates breg cells dose-dependently while the major egg antigens omega-1 and 
kappa-5 as well as worm antigen are ineffective. Splenic B cells from naïve mice were cultured for 3 days with 
different concentrations (indicated by numbers in the x-axis label) of natural (n) IPSE/alpha-1, omega-1 or kappa-5, 
or medium as negative and 20 µg/ml SEA as positive control. (a) IL-10 and IL-6 concentration in culture supernatants 
after nIPSE stimulation as measured by ELISA.  Average of duplicates from one experiment shown. (b) IL-10 
concentration in supernatants of kappa-5 or omega-1 stimulated B cells. Average of duplicates from one experiment 
shown. (c) Splenic B cells were stimulated in vitro with SEA (20 µg/ml), anti-CD40 (2 µg/ml) or adult worm antigen 
AWA (5 – 10 – 20 µg/ml) for 3 days. IL-10 in culture supernatant as determined by ELISA. Average of duplicate values 
from one experiment shown.
figure s7. anti-Igm ab does not further increase sea-induced Il-10 expression of b cells. Splenic B cells from 
naïve mice were cultured with 20 µg/ml SEA or medium as control, with or without addition of anti-IgM Ab in 
different concentrations. After 3 days of culture, supernatants were analyzed for IL-10 and IL-6 by ELISA. Summary of 
3 experiments. Significant differences are indicated with ** p < 0.01 and *** p < 0.001 as tested by Mann-Whitney test.
figure s9. Plant-based production of IPse. (a) SDS-PAGE and Coomassie blue staining of apoplast fluids (AF) 
from empty vector (EV), N-terminally tagged H6F-IPSE infiltrated N. benthamiana plants and subsequent small-scale 
purification of IPSE using Ni-NTA resin and the Äkta Prime purification system. Purified IPSE was analysed under 
reducing and non-reducing conditions (± DTT). (b) IL-4 release from isolated human basophils during 18h stimulation 
with pIPSE and nIPSE (0.16-2500 ng/ml), as determined by ELISA. Data are presented as percentage of maximum IL-4 
release. Summary of N=4-6 donors. 
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Chronic Schistosoma mansoni infections induce a network of regulatory immune cells, including 
interleukin (IL)-10-producing regulatory B (Breg) cells. The signals that drive Breg cell development and 
activation are however not well characterized, and multiple signals likely synergize to induce optimal 
Breg cell induction in vivo. We here compared the transcriptome of splenic marginal zone (MZ) B 
cells, which preferentially acquire a Breg cell phenotype, and follicular (FO) B cells of chronically S. 
mansoni-infected mice using RNA sequencing technology, in order to gain a global picture of signals 
and pathways involved in S. mansoni-induced Breg cell development in vivo. We report that MZ and 
FO B cells display distinct transcriptional profiles, and that both B cell subsets moreover undergo 
transcriptional changes in response to infection which are partially cell-type specific. Comparing the MZ 
and FO B cell transcriptome suggests the cytokines IL-1β, IL-6 and type I interferons (IFN-I) as well as 
pattern recognition receptors (PRRs) including toll-like receptors (TLRs) and C-type lectin receptors 
(CLRs) as preferentially important for MZ B cells during chronic schistosome infections. This analysis 
thus suggests that inflammatory signals, including pro-inflammatory cytokines and the ligation of PRRs 





B cells with regulatory properties, called regulatory B (Breg) cells, are a subset of B cells with 
immunomodulatory capacity. Breg cells suppress immunity in a range of different contexts, including 
autoimmunity 1, allergy 2 and cancer 3. Breg cells are most often characterized by their production 
of the regulatory cytokine interleukin (IL-)10, although various other mechanisms of suppression 
have been described 4-6. Breg cells are moreover a heterogeneous group of cells, and apart from 
their suppressive function as defining characteristic, various different subsets have been described 
based on origin and phenotype 6, 7. Amongst others, marginal zone (MZ) B cells of the spleen and their 
precursors are well known to acquire regulatory functions 8-10. Breg cells have been described in a range 
of infectious diseases 11, including experimental 12-15 and human 12, 16 helminth infections.  
Breg cells expand and acquire increased suppressive activity in the context of infection and 
autoimmunity 1, 6, 17. The signals for Breg cell development and activation that have been most widely 
studied are ligation of the B cell receptor (BCR) 18-20, CD40 10, 18, 21, 22 and toll-like receptors (TLRs), 
especially TLR4 23-25, TLR7 26 and TLR9 8, 23. Additionally, a range of cytokines, including IL-1β and IL-6 27, 
IL-15 28, IL-21 29, IL-35 30, 31, the tumour-necrosis factor (TNF) family members B-cell-activating factor 
(BAFF) 32 and a proliferation-inducing ligand (APRIL) 33, as well as type I interferons (IFN-I) 34, 35 have 
been described to support Breg cell activation. The variety of signals described in Breg cell induction 
suggests different sources of activating signals. An inflammatory environment seems central and is 
a shared feature of infection and autoimmunity. The role of BCR- and TLR-derived signals shows that 
in infection, pathogen-derived molecules are candidates for Breg cell-activating signals. Interestingly, 
it has recently been shown that pathogen-derived signals that induce Breg cells can also stem from 
the microbiota, as microbiota-derived signals induced splenic and mesenteric lymph node Breg cells in 
an IL-1β- and IL-6-dependent manner in arthritis 27, and multiple studies have shown that alterations of 
the gut microbiota affect the Breg cell compartment 27, 36, 37.
We and others have previously demonstrated that chronic infection with the helminth Schistosoma 
(S.) mansoni induces IL-10-producing Breg cells in both humans and mice. Most of these cells are 
found within the human CD1d+ B cell subset and the murine CD1d+CD21+CD23lo MZ B cell subset 12, 
14. The number of identified, S. mansoni-specific signals that induce Breg cells is however very limited. 
Breg cells can be induced by schistosomal egg antigens 38, 39, but this is notably less potent than 
the induction of Breg cells during chronic infection. The S. mansoni egg glycoprotein IPSE/alpha-1 is 
the only single helminth-derived molecule that has been shown to directly interact with splenic B cells 
and induce IL-10 production, but this has so far only been demonstrated in vitro 39. Chronic S. mansoni 
infection induces a multitude of different immune responses in the host, and it is thus likely that 
multiple signals synergize in vivo to induce optimal Breg cell induction. Herein, we therefore studied 
the transcriptome of splenic MZ B cells isolated from chronically S. mansoni-infected mice.
The transcriptome of certain murine Breg cell subsets has been studied previously. Through such 
studies, CD9 has been identified as a marker of murine IL-10-competent, CD19+ CD1dhi CD5+ Breg cells 
induced by in vitro polyclonal stimulation 40. In addition, by filtering a microarray library for secreted 
factors produced by splenic B cells activated with LPS and anti-CD40 agonistic antibodies in vitro, IL-35 
was identified as suppressive cytokine produced by these Breg cells 30. Interestingly, IL-35 production 
was confined to CD138hi CD22- regulatory plasma cells described in the context of Salmonella infection 30. 
A further transcriptomics analysis of a subset of these natural regulatory plasma cells characterized 
as LAG-3+ CD138+ has revealed a distinct expression profile for several transcriptional regulators, 
including Klf4, Fos, Junb, Irf8 and Foxm1 41. For Breg cells in the context of acute helminth infections, 
microarray analysis identified TLR7 as overexpressed in S. mansoni-induced CD19+ CD1dhi Breg cells 
compared to CD19+ CD1dlo B cells. In vitro TLR7 stimulation of splenic B cells from naïve mice promoted 
Breg cell activation and IL-10 production 26, but it remains unclear from this study whether TLR7 ligands 
are present and whether TLR7 ligation is central to Breg cell expansion during S. mansoni infection.
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In this study, we aimed to identify the similarities and differences between MZ and classical 
follicular (FO) B cells in their response to chronic S. mansoni infection, in order to better understand 
signals, receptors and pathways that lead to the preferential development of MZ B cells into Breg cells. 
We have compared the transcriptome of MZ B cells and FO B cells from chronically S. mansoni-infected 
and -uninfected control mice. 
results
chronic s. mansoni infection induces breg cells within the splenic mZ b cell pool
In order to study the transcriptome of splenic MZ and FO B cells, we first isolated total splenic CD19+ 
B cells and confirmed the capacity of these cells to produce IL-10 by in vitro restimulation with S. 
mansoni soluble egg antigen (SEA). As expected, splenic B cells isolated from chronically S. mansoni-
infected mice secreted significantly more IL-10 protein, but only low levels of IL-6 protein, compared 
to uninfected controls (figure 1a). The frequency of B cells with intracellular IL-10 expression was 
also significantly increased (figure 1b). Total non-restimulated splenic CD19+ B cells were sorted into 
CD21+ CD23lo MZ B cells and the major splenic B cell subset, CD21lo CD23hi FO B cells, for subsequent 
RNA isolation and RNAseq analysis (figure 1c). 
To investigate transcriptional changes that are associated with the response of splenic B cells to 
S. mansoni, we compared the gene expression profile in MZ B cells and FO B cells from chronically S. 
mansoni-infected and uninfected control mice in a principal component analysis (PCA; figure 1d). 
Biological replicates of all four experimental groups clustered well. MZ and FO B cells were segregated 
across the first principal component (PC1), representing the cell type difference and accounting for 
66.8% of the total data variability. The second principal component (PC2) represented the treatment 
effect, accounting for 12% of the total data variability. Notably, while PC1 separates MZ and FO B cells 
to a similar degree irrespective of treatment, PC2 separates FO B cells from S. mansoni-infected (FO.
Inf) mice and from control (FO.PBS) mice stronger than MZ B cells from S. mansoni-infected (MZ.Inf) 
mice and from control (MZ.PBS) mice. PC3, which does not clearly separate by cell type or treatment 
condition, only accounts for 6.2% of total variability.
Both MZ and FO B cells from control and S. mansoni-infected mice constitutively expressed the B 
cell markers Cd19, Cd22, Cd79a/Cd79b and Ptprc (B220) along with other B cell-associated markers 
including Tnfrsf13b (TACI) and Tnfrsf13c (BAFF-R). MZ B cells expressed lower levels of Sdc1 (coding for 
CD138) than FO B cells (figure 1e), and Lag3 was not detectable in the dataset, indicating that the B cells 
assessed here are phenotypically different from the natural regulatory plasma cells recently described 41. 
T cell genes including Tcra, Tcrb, Cd3e, Cd4, Cd8a and Cd28 were also not detected in the dataset, 
showing that the isolated B cell populations were not contaminated with T cells. MZ B cells strongly 
overexpressed Cd1d1 and CD1d2 (together CD1d), Cd9, and to a lesser extent also Cd5, Cd24a, Cd27 
and Cd38, all markers characteristic of a Breg cell phenotype (figure 1e). The strong overexpression of 
Cd9 in MZ B cells is in line with previous reports on this marker as identifier of murine IL-10 competent, 
CD19+ CD1dhi CD5+ Breg cells 40. With respect to cytokines, MZ B cells strongly overexpressed Il10, 
confirming that this splenic B cell subset is IL-10-competent. MZ B cells also mildly overexpressed 
Ebi3, in addition to expressing Il12a, which together form the regulatory cytokine IL-35 described to be 
produced by certain Breg cell subsets 30 (figure 1e). In chronically S.mansoni-infected animals, both B 
cell subsets moreover strongly overexpressed Ighe and Ighg1 compared to steady-state (figure 1e). B 
cells from all experimental groups constitutively expressed the B cell lineage transcription factor (TF) 
Pax5, while FO B cells overexpressed Bcl6 exclusively expressed in germinal centers and MZ B cells 
overexpressed Prdm1 (Blimp-1) which drives B cell differentiation into plasma cells. The TFs IRF4, NFAT 
and STAT1/STAT3 have previously been suggested to be important for B cell IL-10 expression 20, 34, 35, 42, 




figure 1. chronic s. mansoni infection induces breg cells within the splenic mZ b cell pool.  Splenic B cells from 
chronically (14 weeks) S. mansoni-infected mice and uninfected control mice were isolated by CD19 MACS isolation. 
(a-c) Cells were restimulated with SEA (20µg/ml) for 2 days, n=5-6/group. Statistical significant differences were 
determined by unpaired t-test and are indicated by * p < 0.05, ** p < 0.01. (a) Cytokine concentrations in culture 
supernatant determined by ELISA. (b) Intracellular IL-10 expression after addition of Brefeldin A during the last 4 
hours of culture, determined by FACS. (c) Representative FACS plot depicting the gating strategy to identify MZ 
B cells (CD21+CD23lo) and FO B cells (CD21loCD23hi) applied during sorting. (d-e) Sorted MZ and FO B cells were 
subjected to RNA isolation and RNAseq analysis. (d) Principal component analysis (PCA) including all 16 samples. 
(e) Heatmaps depicting the level of expression in reads per kilobase of transcript per million mapped reads (RPKM) 
for each experimental group, and the expression fold change (FC) between pair-wise comparisons.
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infection (figure 1e). B cells from all experimental groups moreover constitutively expressed Cd40, 
whereas Cd274 (PD-L1), Cd80 and Cd86 were slightly overexpressed in MZ B cells (figure 1e). 
mZ and fo b cells display distinct transcriptional profiles and undergo transcriptional changes 
that are partially cell-type-specific in response to chronic s. mansoni infection
To investigate the genes and signalling pathways associated with B cell responses to S. mansoni, 
we performed a differential expression analysis either comparing S. mansoni infection and control 
condition for both B cell subsets (denoted as MZ.Inf_PBS and FO.Inf_PBS, respectively), or comparing 
MZ and FO B cells in uninfected and S. mansoni-infected mice (denoted PBS.MZ_FO and Inf.MZ_FO, 
respectively). Chronic infection with S. mansoni resulted in transcriptional changes in both MZ and 
FO B cells, albeit to a different degree. MZ B cells displayed less differentially expressed genes (DEGs) 
than FO B cells in response to infection (figure 2a, upper panel). The transcriptional profile strongly 
differed between MZ and FO B cells, both after chronic S. mansoni infection and in control mice 
(figure 2a, lower panel). A list of all DEGs per condition is provided as suppl. table s1. 
A total of 438 DEGs were shared between MZ and FO B cells in response to infection, of which 19 
DEGs were differentially expressed in opposing direction. A total of 252 DEGs (37%) in MZ B cells and 
1982 DEGs (82%) in FO B cells were uniquely regulated for the respective B cell subset in response to 
infection (figure 2b, upper panel). The transcriptional profile of MZ and FO B cells clearly differs, both 
after chronic S. mansoni infection and in control mice, with the majority of DEGs (4492 DEGs; 79% and 
75%, respectively) being shared in both conditions (figure 2b, lower panel). 
canonical Pathways differentially activated in mZ and fo b cells of chronically s. mansoni-
infected animals
To evaluate the response of MZ and FO B cells to S. mansoni infection more broadly, we used 
the Canonical Pathway function of Ingenuity Pathway Analysis (IPA) 43 to search for common and 
discordant signalling pathways in MZ and FO B cells. To identify pathways that are more related to MZ 
or FO cells, respectively, we made use of the activation z-score calculated by IPA, which is a statistical 
measure to infer the likely activation state of the pathway, with z-scores of > 2 or < -2 suggesting 
significant activation or inhibition, respectively. Both MZ and FO B cells proliferate in infected mice, as 
apparent from cell cycle-related pathways being significantly activated in both cell types in response 
to infection (figure 3). Interestingly, immune-related functions are found in the list of pathways 
significantly downregulated after infection for both cell types, which may suggest that these pathways 
are negatively regulated following previous activation. The list of pathways found to be significantly 
inhibited in the comparison MZ.Inf_PBS but not in FO.Inf_PBS (figure 3, left panel) contained ‘Toll-like 
Receptor Signaling’, ‘STAT3 Pathway’, ‘B Cell Activating Factor Signaling’ (B-cell activating factor = 
BAFF) and ‘April Mediated Signaling’, which is in line with previous reports suggesting TLR-, STAT3-, 
BAFF- and APRIL-signalling to be associated with Breg cells 23, 32, 35, 44. The pathways ‘p38 MAPK Signaling’, 
which is downstream of receptors for inflammatory cytokines, FasL, TGF-β, G-protein coupled receptors 
as well as DNA damage signals 45, and ‘Acute Phase Response Signaling’, which is a rapid inflammatory 
response pathway triggered by pro-inflammatory cytokines 46, likely reflect the response of MZ B cells 
to the inflammatory environment in chronic S. mansoni infection. Pathways found to be significantly 
inhibited in the comparison FO.Inf_PBS but not in MZ.Inf_PBS (figure 3, right panel) contained ‘IL-6 
Signaling’, ‘IL-8 Signlling’ and ‘HMGB1 Signaling’. In human infection and cancer, B cells have been 
suggested to express the IL-6 receptor 47, 48, whereas little is known of B cell responses to IL-8. HMGB1 
is secreted by immune cells, and mediates inflammatory responses via interaction with TLR4 49, 50. 
We did not only identify Canonical Pathways for the pairwise comparisons of cellular responses 




infection. A list of significantly activated or inhibited pathways for these comparisons is provided as 
suppl. figure s1.
Predicted upstream regulators with differential activation status in mZ and fo b cells of 
chronically s. mansoni-infected animals 
The Upstream Regulator analysis of IPA 43 examines the presence of known targets and their direction 
of change in the dataset compared to what is expected based on the literature in order to predict 
likely relevant upstream signals that explain the observed gene expression changes in the dataset. 
These Upstream Regulators do not have to be part of the dataset itself. As many Upstream Regulators 
passed the regular z-score threshold, we applied a more stringent cut-off of z-scores > 4 or < -4 to 
identify highly activated or inhibited Upstream Regulators (suppl. figure s2). These lists still contained 
many hits of a range of different molecule types, which is why we focussed on cytokines and cell 
surface receptors as most informative molecule types with respect to identifying extracellular signals 
important for Breg cell activation in chronic S. mansoni infection. The list of significant (z-score > 2 
or < -2) cytokines predicted as Upstream Regulators that are unique to the response of MZ B cells to 
infection includes IL-1β as IL-6 as strongly activated and highly significant hits (figure 4a, left panel). 
In contrast, the list of Upstream Regulators that are unique to the response of FO B cells to infection 
figure 2. mZ and fo b cells display distinct transcriptional profiles and undergo transcriptional changes 
that are partially cell-type-specific in response to chronic s. mansoni infection. (a) Volcano plots comparing 
differential gene expression for the response of MZ and FO B cells to infection, and we as for cell type difference 
in control and infected condition. The number of differential up- and downregulated genes for each comparison 
is depicted in the plot. avgLog2FC = average log2 fold change; minusLog10AdjPVal = -log10 adjusted p-value. (b) 
Venn diagrams depicting the overlap of differentially expressed genes (DEGs) for the response of MZ versus FO B 
cells to infection, and for the cell type difference after infection versus at steady-state. The number of DEGs that are 




includes amongst others the Th2 cytokines IL-4 and TSLP as activated Upstream Regulators (figure 4a, 
right panel). In comparison of MZ and FO B cells at steady-state and after infection, it becomes 
apparent that the list of Upstream Regulators predicted to be more activated in MZ B cells contains 
several interferons, including members of the IFN-I family and IFNγ as type II interferon (figure 4b). 
Notably, Upstream Regulators are signals solely predicted by IPA to cause the observed transcriptional 
pattern, irrespective of whether e.g. corresponding receptors are expressed. We therefore evaluated 
the expression of receptors for predicted Upstream Regulators in our dataset. The IL-6R subunit Il6ra 
and the IL-1R accessory protein Il1rap were both expressed in both B cell subsets, with Il1rap being 
slightly overexpressed in MZ B cells and Il6ra being slightly overexpressed in FO B cells. Moreover, 
the IFNAR subunits Ifnar1 and Ifnar2 are both clearly expressed in MZ and FO B cells irrespective of 
infection status (figure 4c). Collectively, these data might indicate that, whereas FO B cells respond to 
the Th2 environment to undergo a germinal center reaction and differentiate into long-lived plasma 
and memory B cells, MZ B cells might be more responsive to pro-inflammatory, non-Th2-related 
cytokines such as IL-1β, IL-6 and IFN-I. 
With respect to surface receptors, only few Upstream Regulators were predicted as significantly 
activated or inhibited for the response of MZ and FO B cells to infection, respectively (figure 4d). 
The comparison of both cells types at steady-state and after infection yielded TNFRSF17 and TLR4 
as significantly more activated in MZ than FO B cells at steady-state, and TLR9 as well as TLR7 as 
significantly more activated in MZ compared to FO B cells after infection (figure 4e). These data 
suggest that TNFRSF17 (BCMA), which binds APRIL with high affinity and BAFF with low affinity, as 
well as the toll-like receptors TLR4, TLR7 and TLR9 are more important for the activation of MZ than 
FO B cells. This goes hand in hand with the fact that these receptors are known to be important 
for the induction of Breg cells 8, 23, 24, 26, 32. In our dataset, Tlr4 and Tlr9 were constitutively expressed 
across all conditions with little changes between cell types or in response to infection, whereas Tlr7 
figure 3. canonical Pathways differentially activated in mZ and fo b cells of chronically s. mansoni infected 
animals. IPA software was used to identify Canonical Pathways significantly activated (z-score > 2; -log(p-value) > 
1.3) or significantly inhibited (z-score < -2; log(p-value) > 1.3) for the response of MZ B cells to infection and of FO 
B cells to infection. Canonical Pathways that are not shared between the two pair-wise comparisons are indicated in 
bold font. Canonical Pathways significant for the comparison of MZ and FO B cells at steady-state and after infection 




was overexpressed in MZ B cells. Interestingly, Tlr3 was found to be strongly overexpressed on MZ B 
cells (figure 4f), and TLR3 was also predicted by IPA as Upstream Regulator for MZ B cells, although 
not passing the p-value significance threshold (data not shown). In summary, TLR ligation might 
thus, in addition to signals provided by cytokines, be important for the response of MZ B cells to 
S.mansoni infection.
figure 4. Predicted upstream regulators with differential activation status in mZ and fo b cells of chronically 
s. mansoni-infected animals. IPA software was used to identify predicted Upstream Regulators significantly 
activated (z-score > 2; p-value < 0.05) or significantly inhibited (z-score < -2; p-value < 0.05). An overview over all 
identified Upstream Regulators is given in suppl. figure s2. Upstream regulators were filtered either for ‘cytokines’ 
manually including cytokines listed under molecule type ‘group’ (a, b), or for ‘transmembrane receptor’ and ‘G-
protein coupled receptor’ to select for cell surface receptors (d, e). (a, d) Upstream Regulators for the response of MZ 
and FO B cells to infection. (b, e) Upstream Regulators for the cell type difference at steady-state and after infection. 
Upstream Regulators that are not shared between pair-wise comparisons for cellular response to infection and cell 
type difference are indicated in bold font. (c, f) Heatmaps depicting the level of expression in reads per kilobase 




a cluster identifies genes with opposing transcriptional changes in mZ and fo b cells 
We also compared the DEG lists for the response of MZ and FO B cells to infection, and the cell type 
difference in control condition and after infection, in plots comparing DEG fold changes between 
conditions. Interestingly, both plots for cell type difference and for response to infection displayed 
a distinct cluster of 64 and 71 genes, respectively (lists provided as suppl. table s4). Almost all genes 
(n=63) were contained in both clusters (suppl. figure s3). These genes are upregulated in MZ B cells, 
but downregulated in FO B cells, in response to infection (figure 5a), or upregulated in MZ B cells 
from infected animals, but downregulated in steady-state MZ B cells, compared to the respective FO 
B cell condition (figure 5b). The cluster contained the genes C1qa, C1qb, C1qc and C6 coding for 
the complement factors C1 and C6. The cluster also contained Clec4a3, Clec4n and Mrc1, the latter ones 
coding for the C-type lectin receptors (CLRs) dectin-2 and mannose receptor (MR; CD206), respectively 
(figure 5c). Thus, the cluster identified additional signals that might preferentially activate MZ B cells 
in the context of S. mansoni infection.
dIscussIon
Breg cells are a relatively new member in the network of immune regulatory cells that have only been 
extensively studied in the recent decades, and many open questions around their origin, induction as 
well as phenotypical and functional characteristics remain. In this study, we focused on the identification 
of signals that may drive the preferential development of splenic MZ B cells over FO B cells into IL-10-
producers in chronic S.mansoni infection in order to identify leads for further investigation.
We and others have previously reported that chronic S. mansoni infection induces IL-10+ B cells 
within the murine and human CD1d+ B cell subset 12, 14, which corresponds to the CD21+ CD23lo MZ 
B cell subset. In our dataset, MZ B cells as expected overexpressed several markers characteristic for 
splenic MZ Breg cell subsets, but are phenotypically distinct from regulatory plasma cells. Breg cells are 
most widely recognized for their production of IL-10 5, 6. We found Il10 to be strongly overexpressed 
in MZ B cells compared to FO B cells, both at steady-state and after infection, identifying MZ B cells 
as IL-10-competent. The expression of Il10 did not further increase after infection in either of the B 
cell subsets, indicating that optimal IL-10 expression requires an additional ex vivo restimulation with 
a mitogen, as described previously 51.
From the analysis of DEGs it became apparent that MZ and FO B cells display clearly distinct 
transcriptional profiles, not only after infection but also at steady-state. This difference likely reflects 
the distinct roles of MZ B cells as innate-like cells that mediate responses to antigens in blood-borne 
pathogens, and of FO B cells undergoing germinal center reactions to differentiate into long-lived 
plasma cells producing class-switched antibodies 52. Both B cell subsets underwent transcriptional 
changes in response to chronic S. mansoni infection, whereby FO B cells displayed about 3.5-times 
more DEGs than MZ B cells. Again, these differences might be related to the unique function of both 
cell types rather than a differential activation status of MZ and FO B cells after infection, which is 
supported by the fact that Canonical Pathways identified by IPA to be highly activated in both cell 
types in response to infection include proliferation-related pathways. The analysis within IPA also 
suggested several pathways which have previously been associated with Breg cell induction 23, 32, 44 
as more relevant for MZ B cells in response to infection, including TLR-, STAT3- BAFF- and APRIL-
signalling. This indicates that these pathways are also induced in the context of S. mansoni infection. 
The Upstream Regulator analysis performed in IPA identified several regulators as predicted to be 
more activated in MZ B cells of chronically S.mansoni infected mice than in FO B cells. With respect 
to cytokines, IPA identified IL-1β and IL-6 as potential Upstream Regulators, and their receptors are 
part of the transcriptome dataset and expressed in MZ and FO B cells. Rosser et al. showed that both 




the IL-1- or the IL-6-receptor (IL-1R, IL-6R) develop more severe experimental arthritis. The production 
of IL-1β and IL-6 by macrophages and DCs was moreover found to be dependent on an intact gut 
microbiome 27. With respect to S. mansoni, it is tempting to speculate that an infection and especially 
eggs penetrating the intestinal wall may cause translocation of bacteria across the intestinal wall and 
systemic exposure to microbial products, potential providing signals for Breg cell induction. In humans, 
it has already been shown that schistosomiasis can cause high endotoxemia 53.
Apart from IL-1β and IL-6, IPA also identified several members of the IFN-I cytokine family as well 
as IFNγ as Upstream Regulators predicted to be more activated in MZ B cells compared to FO B cells. 
Menon et al. showed that IFNα as a IFN-I family member induces Breg cells in humans 35. B cells are 
widely recognized to express the IFNα/β receptor (IFNAR) and to respond to IFN-I 54-56, and both IFNAR 
subunits Ifnar1 and Ifnar2 are expressed in MZ and FO B cells irrespective of infection status. Moreover, 
recent reports have highlighted that helminths including S. mansoni or their products can induce IFN-I 
production in mouse models. Gastrointestinal helminths of rodents have been shown to induce IFN-I 
figure 5. a cluster identifies genes with opposing transcriptional changes in mZ and fo b cells. (a, b) Plots 
depict the fold change (FC) of pair-wise comparisons for the cellular response to infection (a) and for cell type 
differences (b). (c) A heatmap depicting the level of expression in reads per kilobase of transcript per million mapped 
reads (RPKM) for each experimental group, and the expression fold change (FC) between pairwise comparisons for 
selected genes included in the identified clusters.
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in gut and lung in an microbiota-dependent manner 57, and in skin DCs 58, respectively. S. mansoni eggs 
and egg antigens induce an IFN-I signature both in splenic DCs in vivo 59 and in bone marrow DCs in 
vitro 60. Collectively, this analysis suggests the cytokines IL-1β, IL-6 and members of the IFN-I family as 
Upstream Regulators more important for MZ than FO B cells in S. mansoni infection, and the literature 
provides interesting initial observations that they might be involved in Breg cell induction, making 
them promising targets for further investigation. 
With respect to cell surface receptors, IPA identified TLR7 and TLR9 as Upstream Regulators predicted 
to be significantly more activated in MZ B cells than FO B cells after infection. Both TLR7 and TLR9 are 
endosomal TLRs that recognize nucleic acids. TLR7 has been described to be overexpressed in CD19+ 
CD1dhi B cells compared to CD19+ CD1dlo B cells, and to increase the capacity of CD19+ CD1dhi B cells to 
produce IL-10 26. TLR9 expressed on B cells has been reported to recognize DNA-containing complexes 
on apoptotic cells, resulting in IL-10 production and protection from experimental autoimmune 
encephalitis (EAE) 8, whereas another study suggests B cell TLR9 is not required for the recovery from 
EAE 23. The notion that TLR9 induces Breg cells is supported by numerous studies using synthetic TLR9 
ligands to induce murine and human Breg cells in vitro 61, 62, but the role of TLR9 for Breg cell induction 
has so far not been studied in the context of S. mansoni. As chronic S. mansoni infection and especially 
egg migration causes tissue damage, granuloma formation and potentially also systemic exposure 
to microbial pathogen-associated molecular patterns (PAMPs), it is however likely that endogenous 
ligands released following apoptosis and/or microbial ligands for nucleic acid-binding TLRs including 
TLR9 get exposed. In addition to Tlr7 and Tlr9, the third endosomal TLR recognizing nucleic acids, Tlr3, 
is strongly overexpressed in MZ B cells. The Upstream Regulator analysis does however not suggest 
a differential signalling through TLR3 in MZ and FO B cells in chronic S. mansoni infection to be 
responsible for the differential expression patterns found in these cell types. Collectively, these data 
suggest that Tlr3 is predominantly expressed on MZ B cells compared to FO B cells, but that TLR7 and 
TLR9 rather than TLR3 might play a role in the differential response of both cell types to chronic S. 
mansoni infection.
A cluster of genes with opposing expression pattern in MZ and FO B cells identified complement 
factors and CLRs as upregulated in MZ B cells, but downregulated in FO B cells, after S. mansoni 
infection. B cells express various complement receptors including complement receptor 2 
(CR2 = CD21), but little is known about the expression of complement factors by B cells 63, 64. CD21 
on B cells recognizes complement factor C3d-opsonized microbial products, resulting in enhanced 
BCR signalling 65. To our knowledge, the expression of complement factors by B cells has not been 
described before, and our findings should be supplemented by gene and protein expression data 
before potentially investigating the role of complement expression by B cells further. 
Apart from TLRs, CLRs are a second class of pattern recognition receptors (PRRs). Others have 
previously reported that B cells express CLRs including dectin-1 and MR 66, and we have found CLRs 
including dectin-2 and MR to be preferentially expressed by MZ B cells after infection. Notably, S. 
mansoni molecules have been described to ligate CLRs. Omega-1 induces DC Th2 polarization via MR 67, 
but failed to induce Breg cell development in vitro in naïve splenic B cells 39, likely arguing against 
a potent role for MR in Breg development. SEA induces prostaglandin E2 synthesis by DCs through 
dectin-1 and dectin-2, also promoting DC Th2 polarization 68. Apart from one study suggesting that 
signalling via dectin-1 induced IgG1 class switching by LPS-activated B cells 69, the role of these dectins 
in B cell and specifically Breg cell activation has not been addressed. 
Collectively, comparing the transcriptome of MZ and FO B cells identified cytokines including IL-1β, 
IL-6 and IFN-I, as well as PRRs including the TLR7 and TLR9, Dectin-1 and MR as predicted upstream 
regulators that might cause a differential activation of these B cell subsets in S. mansoni infection. 




surface receptors involved in the induction of Breg cells, at least in the context of autoimmunity 10, 18-22. 
The analysis performed herein however suggests that these receptors are not differentially activated in 
MZ and FO B cells of chronically S. mansoni infected animals.
Transcriptomics allow to study the entirety of genes transcribed at a certain time point and 
potentially allows insight into the breadth of cellular process at interplay. Such a dataset allows to 
address very different points of interest, including but not limited to predicted upstream signals and 
pathways that may lead to the observed transcriptional pattern. Others, such as e.g. the identification of 
cell-type-specific TFs or metabolism-related regulators and pathways were not the focus of this study, 
albeit the fact that they may be of interest in the context of Breg cells. Transcriptomics as performed 
in this study also bear limitations. Gene expression does not necessarily reflect the translation into 
functional protein, and key findings therefore will need to be supplemented e.g. by data on protein 
expression. It also has to be taken into consideration that this analysis is a snapshot of the splenic MZ 
and FO B cell transcriptome after 14 weeks of S. mansoni infection. At this time point, the peak of Th2 
response to egg deposition has passed, and regulatory responses are on the rise. Moreover, the pool 
of MZ B cells and FO B cells isolated for analysis and carefully sorted into subsets on the basis of 
expression of selected markers might still comprise a heterogeneous population of cells at different 
stages of maturation and differentiation. In order to fully understand changes of MZ and FO B cells 
as the infection progresses from the acute, Th2-dominated to a more chronic state, the transcriptome 
of cells isolated form different time points of infection should be compared. Making use of single cell 
RNAseq technologies would also allow to better assess cellular differences.
In this study, we assessed the transcriptome of B cells during chronic S. mansoni infection and 
gained insight into the global pattern of differential signals and pathways important for MZ and 
FO B cells, respectively. We identified several inflammatory signals that seem to preferentially drive 
the activation of MZ B cells over FO B cells, but we cannot dissect from these data whether these 
signals are S. mansoni-specific or the result of the general inflammatory environment caused by 
chronic infection. A strategy to further address this topic could be to compare this transcriptome of 
MZ and FO B cells from chronically infected mice to the one of mice injected with S. mansoni eggs in 
the absence of full infection, a model we have previously shown to also induce IL-10+ splenic MZ B 
cells 39. This model induces less inflammation as a result of tissue damage and pathology, and could 
therefore potentially allow to distinguish schistosome-specific and general inflammatory signals. 
Collectively, this study identified several interesting leads with respect to signals that might 
differentially activate MZ and FO B cells in S. mansoni infection, but follow-up studies will be needed 
to verify the findings and test functional consequences of individual pathways and regulators for Breg 
cell induction.  
materIal and methods
animals
Female C57BL/6 mice (Harlan) were housed under SPF conditions in the animal facility of the Leiden 
University Medical Center (Leiden, The Netherlands). All animals were used for experiments at 6-12 
weeks of age. All animal studies were performed in accordance with the Animal Experiments Ethical 
Committee of the Leiden University Medical Center. 
s. mansoni infection & isolation of splenic b cell subsets
Mice were infected percutaneously with 36 cercariae and readouts were performed during the chronic 
phase of infection (14  weeks p.i.). Spleens were homogenized by passage through a 70µM cell strainer 
(BD Biosciences) and erythrocytes depleted from the single cell suspension by osmotic lysis. B cells were 
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purified from splenocytes by anti-CD19 MicroBeads (Miltenyi Biotech) following the manufacturer’s 
instructions. Subsequently, B cells were labelled with fluorescent antibodies against CD21 (clone 7G6) 
and CD23 (clone B3B4) and sorted into MZ B cells (CD21+ CD23lo) and FO B cells (CD21lo CD23hi).  Sorted 
cells were washed twice with PBS and snap-frozen and transferred to -80°C until further use. 
rna isolation
RNA was isolated from snap-frozen cell pellets by use of NucleoSpin RNA isolation kit (Machery-Nagel). 
A small aliquot of RNA was used to quantify RNA content using a Qubit Fluorometer (Invitrogen) and 
to confirm sample quality by Bioanalyzer total RNA pico kit (RIN 7.4-9.2). Library preparation and 
sequencing were contracted out to ServiceXS BV (now GenomeScan BV; Leiden, The Netherlands). 
The NEBNext Ultra Directional RNA Library Prep Kit for Illumina was used to process the samples. 
mRNA was isolated from total RNA using oligo-dT magnetic beads and used for library preparation. 
rna sequencing, read mapping and differential expression analysis
For each of the 4 experimental groups (MZ_PBS, FO_PBS, MZ_Inf, FO_Inf), 4 biological replicates were 
generated, resulting in a total of 16 samples. Paired-end stranded RNA sequencing was performed 
on a Illumina HiSeq 2500, and generated approximately 17 million (range: 15.7-40.8 million) paired-
end fragments per sample. Consistent across all samples, approximately 75% of the fragments could 
be aligned to annotated transcripts (UCSC annotation, dated 2014-11-25) over Mus musculus mm10 
reference genome using GSNAP aligner (version dated 2014-12-23). The Trimmed Means of M values 
(TMM) method was used to produce normalization factors correcting raw counts for different library 
sizes. The initial count table (ca. 25.000 genes) was filtered to only include genes which had at least 2 
aligned fragments per million of aligned fragments (CPM) in at least 4 out of the 16 samples, resulting 
in a final count table of ca. 12.000 genes included in further analysis. For each gene, its reads per 
kilobase of transcript per million mapped reads (RPKM) values have been obtained by normalizing 
CPM values to the transcript lengths approximated by sums of lengths of all exons of the gene. Analysis 
of differential gene expression was performed with the edgeR package in the R environment. A design 
matrix for a model with no baseline and 4 groups has been constructed. Next, a genewise negative 
binomial generalized linear model, with the design matrix and gene-specific dispersions, was fitted 
followed by a likelihood ratio tests for 4 contrasts (MZ.Inf_PBS contrasting MZ.Inf vs. MZ.PBS, and 
similarly: FO.Inf_PBS, Inf.MZ_FO and PBS.MZ_FO). Finally, in order to correct for multiple testing, we 
used the False Discovery Rate control method of Benjamini–Hochberg at a p < 0.05 threshold.
IPa canonical Pathway and upstream regulator analysis
Canonical Pathway and Upstream Regulator analysis were performed using Ingenuity Pathway Analysis 
(IPA; Qiagen Inc.; 43). The input were all up- and down-regulated genes using a cut-off for the adjusted 
p-value of < 0.05. A core analysis was performed for each of the pair-wise comparisons followed 
by a comparison analysis. For the analysis of Canonical Pathways, the list of available pathways was 
filtered prior to analysis to contain only the category ‘signalling pathways’ and exclude ‘metabolic 
pathways’. Canonical Pathways were considered significant if log(p-value) > 0.5 and z-score > 2 or <-2. 
Upstream Regulators were considered significant if p-value < 0.01 and z-score > 2 or < -2 or highly 
significant if z-score > 4 or <-4.
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suppl. table s1 shows a list of all DEGs for each of the four analysed contrasts. 
suppl. table s2 contains results of the Canonical Pathway analysis performed in IPA. 
suppl. table s3 contains results of the Upstream Regulator analysis performed in IPA. 
suppl. table s4 shows a list of DEGs within the identified cluster. 





figure s1. canonical Pathways significantly activated or inhibited for the difference of mZ and fo b cells at 
steady-state and after infection. Also see Figure 3.
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figure s2. upstream regulators significantly activated or inhibited for all pair-wise comparisons and 
containing all molecule types. Also see Figure 4.
figure s3. clusters of genes with opposing fold change for both cell type difference and response to infection 
comparisons. Also see Figure 5.
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The helminth Schistosoma mansoni induces a network of regulatory immune cells, including interleukin 
(IL)-10-producing regulatory B (Breg) cells. However, the signals required for the development and 
activation of Breg cells are not well characterized. Recent reports suggest that helminths induce type 
I interferons (IFN-I), and that IFN-I drives the development of Breg cells in humans. We therefore 
assessed the role of IFN-I in the induction of Breg cells by S. mansoni. Chronic S. mansoni infection 
induced a systemic IFN-I signature. Recombinant IFNα enhanced IL-10 production by Breg cells 
stimulated with S. mansoni soluble egg antigen (SEA) in vitro, while not activating Breg cells by itself. 
IFN-I signalling also supported ex vivo IL-10 production by SEA-primed Breg cells, but was dispensable 
for activation of S. mansoni egg-induced Breg cells in vivo. These data show that while IFN-I can serve 





The helminth Schistosoma mansoni induces a network of regulatory immune cells during the chronic 
phase of infection 1. The induction of B cells with regulatory properties, so called regulatory B (Breg) 
cells, by S. mansoni has been studied extensively 2-5. Breg cells as part of the regulatory network play 
an important role in limiting immunopathology and attenuate responses to bystander antigens such 
as allergens 6. Breg cell induction as observed during chronic infection can be replicated by soluble egg 
antigens (SEA) 7, 8 and even the single, egg-derived molecule IPSE/alpha-1 8 in the absence of infection. 
While it is currently unclear which receptors and pathways S. mansoni-derived molecules engage, 
factors consistently reported to be important for Breg cell development and activation are stimulation 
through the  B cell receptor (BCR 9-12), CD40 9, 13-16 and the toll-like receptors (TLR) TLR2/4 17-19, TLR7 20 
and TLR9 17. Moreover, different cytokines including IL-21 21, IL-35 22, 23, BAFF 24, 25, APRIL 26 and type I 
interferons (IFN-I) 27 have been described to support Breg cell development.
IFN-I are a large family of cytokines, containing 14 IFNα subtypes and a single IFNβ, central in 
the immune response to viral infections 28. Induced, amongst others, by ligation of pattern recognition 
receptors (PRRs) of immune and non-immune cells, IFN-I act in an auto- and paracrine manner to 
induce an antiviral state, but can also interfere with innate and adaptive immune responses 29, 30. IFN-I 
can enhance antigen presentation and chemokine production in innate cells, promote effector T cell 
responses and induce B cell antibody production in viral infection (reviewed in 30). The role of IFN-I in 
bacterial, fungal and intracellular parasitic (mainly Leishmania, Plasmodium and Trypanosoma spp.) 
infections is complex, with possible beneficial and detrimental outcomes for the host (reviewed in 28). 
Only recently, reports have highlighted the potential of helminths or their products to induce IFN-I 
in mouse models. Infection with the gastrointestinal helminth Heligmosomoides polygyrus has been 
shown to induce IFN-I signalling in gut and lung in a microbiota-dependent manner, protecting mice 
from RSV infection 31. S. mansoni eggs and SEA have been shown to induce an IFN-I signature both 
in splenic DCs and in in vitro differentiated bone marrow DCs (BMDCs) 32, 33, and Nippostrongylus 
brasiliensis induces IFN-I in skin DCs 34. A more generalized expression of IFN-stimulated genes (ISGs) 
in response to S. mansoni products has so far only been shown by Webb et al. for whole lung tissue 
following i.p. sensitization and i.v. challenge with S. mansoni eggs 33.
B cells express the IFNα/β receptor (IFNAR) and respond to IFN-I 35-37. B cell responses to IFN-I are 
most extensively studied in autoimmunity. In systemic lupus erythematosus (SLE), IFN-I are considered 
to promote the activation of autoreactive B cells, maturation into plasmablasts and autoantibody 
production, contributing to disease pathology 38. Menon et al. add important knowledge to the picture 
by showing that plasmacytoid DCs (pDCs) drive the formation of IL-10-producing Breg cells by IFNα 
production and CD40 ligation in healthy individuals, but fail to do so in SLE patients. While Breg cell-
derived IL-10 normally provides an important feedback loop that limits IFNα production, SLE patients 
have hyper-activated pDCs that fail to induce Breg cells, possibly due to Breg cells being less responsive 
to supra-optimal concentrations of IFNα 39. In patients with certain types of multiple sclerosis (MS) IFNβ 
therapy is a commonly applied treatment option. It has been reported that IFNβ therapy not only 
increased IL-10 production by monocytes and T cells 40, 41, but also B cells and plasmablasts 42.
Whereas Breg cells can be induced by S.mansoni-derived antigens in vitro, this is less potent than 
the induction of Breg cells during chronic infection, and the induction of Breg cells by IPSE/alpha-1 
has only been demonstrated in vitro 8. Helminth infections trigger a multitude of different immune 
responses in the host in vivo, and it is likely that additional signals, in addition to helminth molecules, 
are required for optimal Breg cell induction. Here, we sought to address whether IFN-I are central 
to the induction of Breg cells by S. mansoni. We show that S. mansoni infection induced a systemic 
IFN-I signature in vivo. Recombinant IFNα enhanced B cell IL-10 production in response to SEA and 
SEA+aCD40 in vitro, while blocking antibodies against IFNAR alpha chain (IFNAR1) reduced the ex vivo 
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IL-10 production by in vivo-primed B cells. However, B cell induction in response to egg administration 
in vivo was not affected in IFNAR-/- mice. Collectively, these data show that IFN-I provide additive 
signals for Breg cell induction by S. mansoni in vitro, but are not crucial for S. mansoni -induced Breg 
cells in vivo.
results
s. mansoni induces a systemic Ifn-I signature in vivo
We first sought to assess whether chronic S. mansoni infection induces a systemic IFN-I signature. 
High-dose infection with 180 S. mansoni cercariae significantly increased the serum concentration 
of IFNα3 in the majority of animals (figure 1), while lower doses of 20-40 cercariae did not (data not 
shown). Systemic levels of IL-5 and IL-12/23p40 were similarly increased, while IFNβ, IL-10, and IL-17 
were only elevated in a minority of animals (figure 1). The production of IFN-I subtypes is often difficult 
to assess, as they are frequently produced at low levels and transiently, or consumed by neighbouring 
cells following production, which might explain the high dose of infection necessary to reliably detect 
IFN-I in the serum. Irrespective, the significant increase in serum IFN-I following high-dose infection 
supports the notion that S. mansoni induces a systemic IFN-I signature.
recombinant Ifnα enhances sea/acd40-induced b cell Il-10 production in vitro
We have previously demonstrated that SEA induces B cell IL-10 production and that CD40 ligation 
enhances SEA-induced Breg cell development 8, while others have reported a synergistic effect 
of IFNα and CD40 ligation on the development of IL-10-producing human B cells 39. We therefore 
tested the effect of simultaneous stimulation of splenic B cells with SEA, agonistic anti-CD40 
antibody (aCD40) and recombinant IFNα in vitro. After 3 days of culture, the concentration of IL-10 
in culture supernatants of SEA-stimulated B cells increased with increasing doses of IFNα, whereas 
IFNα alone had no effect (figure 2a). The strongest induction of B cell IL-10 production could be 
observed when cells were co-stimulated with SEA and aCD40, compared to SEA alone (figure 2a). 
IFNα at concentrations of 103-104 U/mL (equivalent to circa 15-150ng/mL) significantly enhanced 
IL-10 production in response to SEA and SEA+aCD40, whereas IL-10 production seemed to plateau 
at 105 U/mL IFNα (figure 2a). IL-10 production after co-stimulation with IFNα increased up to 4-fold 
compared to the control condition without addition of IFNα. IFNα also enhanced IL-6 production, 
a pro-inflammatory cytokine known to be produced by B cells, in response to SEA and aCD40, albeit 
to a lesser extent (figure 2a). This indicated a pattern of cytokine expression characteristic for Breg 
cells. Conversely, the percentage of IL-10-producing B cells after 3 days of stimulation with SEA or 
SEA+aCD40 in the presence of IFNα did not increase (figure 2b). This suggests that the peak of 
the stimulatory activity of IFNα occurs earlier, possibly because of a decline in the IFNα concentration 
in culture supernatant due to consumption, and had already passed when the intracellular staining was 
performed after 3 days of culture. As a control, we also stimulated B cells with CpG ODN1826 (class 
B) and IFNα. Already a low concentration of 103 U/mL IFNα strongly amplified the CpG ODN1826-
induced cytokine production (suppl. figure 1a) and the percentage of 10-producing B cells 
(suppl. figure 1b). These data show that IFNα provides additional signals for 
the induction of B cell IL-10 production in cells activated with known Breg cell-inducing stimuli SEA or 
CpG ODN1826.
Ifnar1 signalling provides co-signals for Il-10 production by in vivo primed b cells
To assess whether IFN-I signalling provides important signals for IL-10 production by in vivo primed 




figure 1. s. mansoni induces a systemic type I Ifn signature. Mice were infected with 180 S. mansoni cercariae 
and serum samples taken at d49 of infection for assessment of cytokine levels by ELISA/CBA. Pooled data from 
2 experiments, n=20/group. Significant differences were determined by unpaired t-test. * p < 0.05, ** p < 0.01, 
*** p < 0.001.
vivo with SEA in the presence or absence of blocking antibodies against IFNAR1. We also used blocking 
antibodies against CD40 ligand (CD40L) upon ex vivo restimulation to assess the importance of CD40 
co-ligation on B cells for IL-10 induction. While blocking CD40L alone, or in combination with blocking 
IFNAR1, had either no or no additional effect, blocking IFNAR1 signalling significantly reduced 
the concentration of IL-10 in 2-day culture supernatants (figure 3a). The production of IL-6 was not 
affected by either of the blocking agents (figure 3a), while the percentage of IL-10 producing B cells 
in culture was mildly but significantly reduced by both blocking agents (figure 3b). We concluded that 
signalling via IFNAR1, but not the ligation of CD40, is essential for SEA-induced B cell IL-10 production 
in this setting. 
figure 2. recombinant Ifnα enhances sea/acd40-induced b cell Il-10 production. B cells were isolated from 
the spleen of naïve mice and stimulated in vitro with SEA (20µg/mL), aCD40 (0.5 µg/mL) and IFNα (103-105U/mL) 
as indicated. After 3 days of culture, supernatants were analyzed for IL-10 and IL-6 concentration by ELISA (a), and 
the percentage of IL-10+ B cells assessed by flow cytometry (b). Summary of 3 (A) or 2 (B) experiments, each data point 
is the mean of two technical replicates. Data are presented as mean ± SEM. Significant differences were determined 
by one-way ANOVA followed by Dunnett’s multiple comparisons test. * p < 0.05, ** p < 0.01, *** p < 0.001.
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Ifnar1 signalling is dispensable for breg cell induction in vivo
To assess whether IFN-I signalling provides important signals for Breg cell development and IL-10 
production in response to S. mansoni egg products not only in vitro but also in vivo, we induced Breg 
cell development by two doses of i.p. administered S. mansoni eggs (5000) in WT control or IFNAR1-/- 
mice, a model we previously showed to be very suitable to demonstrate schistosome-induced splenic 
Breg cell development 8. The absence of IFNAR1 did not affect the concentration of IL-10 in B cells and 
total splenocyte culture supernatants in response to restimulation with SEA and aCD40 (figure 4a). 
In addition, the percentage of IL-10+ B cells seemed increased rather than decreased in IFNAR1-/- mice 
(figure 4b). Additionally, no changes in IL-10 production could be observed when blocking IFNAR1 
signalling by means of in vivo administration of anti-mouse IFNAR1 blocking antibody (suppl. figure 2). 
Thus IFNAR1 signalling seems to be dispensable for the induction of Breg cells to S. mansoni egg 
challenge in vivo.
dIscussIon
In this study, we sought to address whether IFN-I might provide the ‘missing link’, synergizing with 
S. mansoni-derived signals for the induction of Breg cell IL-10 production. We show that, although 
S. mansoni infection induces a systemic IFN-I signature, and IFN-I signalling enhances in vitro IL-10 
production by Breg cells exposed to S. mansoni antigens, IFN-I responsiveness is ultimately dispensable 
for Breg cell induction by S. mansoni eggs in vivo. 
We and others have previously shown that chronic S. mansoni infection induces Breg cells 3, 4, 43, 44, 
and that this Breg cell-inducing effect can be replicated by isolated eggs, SEA and even the single, egg-
derived molecule IPSE/alpha-1 in the absence of adult worms and a natural infection 7, 8. Components 
of SEA directly bind to splenic B cells 8, but the receptors ligated and signalling pathways activated 
by these antigens remain to be identified. Moreover, SEA immunization is less potent than chronic 
infection at Breg cell induction in vivo, and the induction of Breg cells by IPSE/alpha-1 has only been 
demonstrated in vitro 8. Helminth infections trigger a multitude of different immune responses in 
the host in vivo, and it is likely that additional signals, in addition to helminth molecules, are required 
for optimal Breg cell induction.
Our data showing an increased concentration of IFN-I in serum of mice actively infected with 
S. mansoni are in line with previous reports on the capacity of S. mansoni eggs or egg antigens, 
figure 3. ex vivo block of Ifnar1 reduces b cell Il-10 production. Splenocytes from SEA-injected mice (100µg 
SEA i.p. on d0 & d7; section d14) were re-stimulated ex vivo with SEA (20ug/mL) for 2 days in the presence or absence 
of anti-CD40L (aCD40L; 10µg/mL) and anti-IFNAR1 (aIFNAR1; 10µg/mL) blocking antibodies as indicated. After 2 days 
of culture, supernatants were analyzed for IL-10 and IL-6 concentration by ELISA (a), and the percentage of IL-10+ B 
cells assessed by flow cytometry (b). Summary of 2 experiments, n=10/group. Data are presented as mean ± SEM. 
Significant differences were determined by RM-One Way ANOVA & Dunnett’s post-test comparing all groups to 




figure 4. Ifnar1 signalling is dispensable for breg cell induction in vivo. Splenocytes and MACS-isolated CD19+ 
B cells from S. mansoni egg-injected mice (5000 S. mansoni eggs i.p. on d0 & d7; section d14) were re-stimulated 
ex vivo with SEA (20µg/mL) and aCD40 (2µg/mL) for 2 days. After 2 days of culture, supernatants of isolated B cell 
and total spenocyte cultures were analyzed for IL-10 concentration by ELISA (a), and the percentage of IL-10+ B 
cells within splenocyte cultures assessed by flow cytometry (b). Summary of 2 experiments, n=8-10/group. Data are 
presented as mean ± SEM. Significant differences were determined by one-way ANOVA followed by Tukey’s multiple 
comparisons test. ** p < 0.01, *** p < 0.001.
H. polygrus infection and N. brasiliensis antigens to induce IFN-I 31-34. pDCs are considered an 
important source of IFN-I 45. IFN-I were however produced by conventional DCs (cDCs) rather than 
pDCs after SEA-stimulation of BMDCs in vitro 33. We have not addressed the cellular source of IFN-I 
in our study, therefore both pDCs and cDCs remain possible sources. Notably, little is reported to 
date regarding IFN-I production by human DCs in response to helminths, but work of our own group 
suggests that S. mansoni egg antigens do not induce IFN-I in human monocyte-derived DCs (Everts, 
personal communication). 
We here show that recombinant IFNα, while having no measurable effect on its own, significantly 
and dose-dependently increased IL-10 production by B cells in response to in vitro stimulation with 
SEA alone or SEA+aCD40. IFNα also had a synergistic effect on SEA+aCD40-induced IL-6 production, 
albeit to lesser extent. Conversely, the percentage of IL-10+ B cells was unchanged or slightly reduced 
after 3 days of culture in the presence of increasing amounts of IFNα, suggesting that IFN-I may 
change the dynamics and timing of IL-10 production. Menon et al. observed an optimal IL-10 
induction in naïve TLR9-stimulated B cells at 50x105 U/mL IFNα and a less effective stimulation at 
higher concentrations 39, whereas we find an additive effect even at 1x106 U/mL on both SEA- and 
TLR9-stimulated B cells on IL-10 concentration in culture supernatants. The fact that IFNα has no 
effect at all on IL-10 or IL-6 expression by itself underpins that IFN-I signalling modulates responses 
in pre-activated B cells rather than providing an activation signal to B cells by itself, which has been 
similarly reported by others 27, 42. In this context, it is plausible that stimulation with S. mansoni-derived 
antigens in vitro provides this pre-activation signal, rather than SEA- and IFN-I-specific signalling 
pathways synergizing to promote B cell IL-10 production. This is in line with previous reports describing 
IFN-I signalling to regulate B cell responses to other pre-activating stimuli such as BCR or TLR7 
ligation 35, 36. In this context, Braun et al. show that murine, mature splenic B cells get partially activated 
by treatment with IFNα/β, characterized by the upregulation of activation markers and increased 
survival in the absence of proliferation or terminal differentiation, and display enhanced response to 
BCR ligation 35. Poovassery and colleagues report that both BCR and IFNAR signalling restore TLR7-
induced B cell hyporesposiveness 36. That the percentage IL-10+ B cells tends to decrease at the end of 
culture might suggest that the peak of IFNα stimulatory activity has occurred earlier and that after 3 
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days of culture the IFN-I concentration in culture supernatant has already declined, making an earlier 
time point for the assessment of IL-10+ B cells preferable.
Arguably, in vitro stimulation of isolated B cells with recombinant IFNα does not mimic the natural 
situation very well. We therefore also assessed the role of IFN-I signalling on Breg cell recall responses 
ex vivo. Blocking IFNAR1 upon ex vivo restimulation of in vivo SEA-induced Breg cells significantly 
reduced IL-10, but not IL-6 production. Adding blocking antibodies against CD40L to the cultures, 
and thereby preventing the ligation of CD40 expressed on B cells by accessory cells present in whole 
splenocyte cultures, had only negligible effects. This might indicate that, while CD40 ligation has 
previously been shown to enhance B cell IL-10 expression 8, 9, 15, it does not provide additional signals for 
B cell IL-10 production in this restimulation setting. This might point at a difference in the contribution 
of CD40 signalling to Breg cell induction upon concurrent priming of B cells with an antigen and 
agonistic aCD40 8 and upon ex vivo restimulation as performed in this study. Finally, we found B cell 
IL-10 production to be unaltered in IFNAR1-/- mice upon egg i.p. administration, suggesting that IFN-I 
signalling is dispensable in this setting. This strongly suggests that in vivo, where multiple pathways 
are activated simultaneously and potentially act synergistically, IFN-I signalling does not play a major 
additive role for the development and activation of Breg cells in response to S. mansoni. 
The physiological role of IFN-I in helminth infections has not been extensively studied to date. 
Enteric H. polygyrus-induced IFN-I protects from RSV co-infection 31. SEA-stimulated BMDCs induce 
IFN-I 32, and SEA-stimulated cDCs as well as skin DCs exposed to N. brasiliensis were shown to be 
dependent on IFN-I signalling for their effective induction of Th2 response 33, 34. Therefore, more 
research is needed to fully understand the role of IFN-I in helminth and, more specifically, in S. mansoni 
infections.
Collectively, the data presented here show that, while IFN-I can enhance IL-10 production by S. 
mansoni-activated Breg cells both in vitro and ex vivo, IFN-I signalling is dispensable for the formation 
and activation of S. mansoni-induced Breg cells in vivo. A better understanding of the signals for 
optimal Breg cell development and activation is required to develop novel therapies around Breg cells. 
materIal and methods
animals
Female C57BL/6 mice (Harlan) were housed under SPF conditions in the animal facility of the Leiden 
University Medical Center (Leiden, The Netherlands). Ifnar1-/- mice on an C56BL/6 background were 
housed at the University of Manchester. All animals were used for experiments at 6-12 weeks of age. All 
animal studies were performed in accordance with either the Animal Experiments Ethical Committee of 
the Leiden University Medical Centre or under a license granted by the home office (UK) in accordance with 
local guidelines. 
s. mansoni infection & preparation of sea
Routinely, mice were infected percutaneously with approximately 40 cercariae, and all readouts were 
performed during the chronic phase of infection (14-16 weeks p.i.). For the high dose infection model, 
mice were infected with approximately 180 cercariae and serum collected on day 49 after infection. 
S. mansoni eggs were isolated from trypsinized livers or guts of hamsters after 50 days of infection, 
washed in RPMI medium supplemented with penicillin (300U/mL), streptomycin (300µg/mL) and 
amphotericin B (300µg/mL) and stored at -80°C until use. SEA was prepared as previously described 46. 
Protein concentration was determined by BCA. SEA preparations were routinely tested for endotoxin 




splenocyte and b cell isolation 
Spleens were homogenized by passage through a 70µM cell strainer (BD Biosciences) and erythrocytes 
depleted from the single cell suspension by lysis. B cells were purified from splenocytes by anti-CD19 
MicroBeads (Miltenyi Biotech) following the manufacturer’s instructions. 
In vitro stimulation
Splenic CD19+ B cells (1.5x106/mL) were cultured in medium (RPMI 1640 GlutaMAX; Thermo 
Fisher Scientific) supplemented with 5% heat-inactivated fetal calf serum (FCS; Greiner Bio-One) 
2-mercaptoethanol (5x10-5 M), penicillin (100U/mL) and streptomycin (100µg/mL; all Sigma-Aldrich). 
Cells were stimulated with the following stimuli as indicated in the figures: SEA (20µg/mL), aCD40 
(clone 1C10; 0.5µg/mL; Biolegend), recombinant IFNα (Biolegend), CpG ODN 1826 (class B; 0.2-1µM; 
Invivogen), aCD40L blocking antibody (clone MR1; 10µg/mL; kind gift from L. Boon, Bioceros), aIFNAR1 
blocking antibody (clone MAR1-5A3; 10µg/mL; eBioscience). 
flow cytometry
Cells were stained with antibodies against B220 (clone RA3-6B2), CD21 (clone 7G6), CD23 (clone 
B3B4) and IL-10 (clone JESS-16E3). Dead cells were stained with live/dead fixable aqua dead cell stain 
kit (ThermoScientific). FcγR-binding inhibitor (2.4G2, kind gift of L. Boon, Bioceros) was added to all 
stainings. Flow cytometry was performed on a FACS Canto II using FACSDiva software (BD Biosciences) 
followed by data analysis using FlowJo.  
elIsa and cba
The concentration of IL-6 and IL-10 in cell-free culture supernatants was assessed by OptEIA ELISA 
kits (BD Biosciences) according to the manufacturer’s instructions. The concentration of cytokines in 
serum of chronically infected mice was assessed by BD cytometric bead array (CBA) Flex-set kits (BD 
Biosciences), except for IFNα3 and IFNβ which were measured by ELISA (PBL).
statistical analysis
Statistical analysis was performed using GraphPad Prism (version 7.02). All data are presented as mean 
± standard error of the mean (SEM). P-values < 0.05 were considered statistically significant.
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figure s2. Ifnar1 signaling is dispensable for breg cell induction in vivo. Mice were treated as depicted in a. On 
day 14, spleens were harvested and total splenocyte cell suspensions and isolated CD19+ B cells restimulated with SEA 
(20ug/ml) and aCD40 (2ug/ml) for 2 days. Supernatants were analyzed for IL-10 and IL-6 concentration by ELISA (b), 
and the percentage of IL-10+ B cells assessed by flow cytometry (c). Data from one experiment, n=5/group. Data are 
presented as mean ± SEM. Significant differences were determined by one-way ANOVA followed by Tukey’s multiple 
comparisons test. * p < 0.05, ** p < 0.01, *** p < 0.001.
figure s1. recombinant Ifnα enhances cpG-induced b cell Il-10 and Il-6 production. B cells were isolated 
from the spleen of naïve mice and stimulated in vitro with CpG ODN1826 (class B; 0.2-1µM) and IFNα (103-104 U/
mL) as indicated. After 3 days of culture, supernatants were analyzed for IL-10 and IL-6 concentration by ELISA (a), 
and % IL-10 B cells assessed by flow cytometry (b). Summary of 2-3 experiments, each data point is the mean of two 
technical replicates. Data are presented as mean ± SEM. Significant differences were determined by one-way ANOVA 
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Allergic airway diseases are a major global health burden, and novel treatment options are urgently 
needed. Numerous epidemiological and experimental studies suggest that certain helminths 
and bacteria protect against respiratory allergies. These microorganisms are strong regulators of 
the immune system, and a variety of potential regulatory mechanisms by which they protect against 
allergic airway inflammation have been proposed. Whereas early studies addressed the beneficial effect 
of natural infections, the focus now shifts toward identifying the dominant protective molecules and 
exploring their efficacy in models of allergic airway diseases. In this article we will review the evidence 
for microbe-mediated protection of allergic airway diseases, the potential modes of action involved, 
and discuss advances as well as limitations in the translation of this knowledge into novel treatment 





Asthma is an atopic, chronic inflammatory disorder that is estimated to affect 315 million people 
worldwide 1. First episodes of atopic disease usually occur during childhood following sensitization 
to inhaled allergens. Infants that suffer from atopic dermatitis (AD) and/or allergic rhinitis (AR) often 
develop allergic asthma (AA) later in life. Different risk factors for the development of asthma have 
been identified in children including infection with respiratory viruses (respiratory-syncytial virus, 
rhinovirus) and impaired lung development in children born prematurely 2. 
AA, the most common form of asthma, is characterized by bronchial hyperresponsiveness and 
airway obstruction, resulting in episodes of wheezing and breathlessness. These symptoms are fueled 
by chronic inflammatory responses against allergens, in which T helper (Th) 2 cells, eosinophils and 
elevated immunoglobulin (Ig) E levels play a central role 3. Dendritic cells (DCs) are important in 
the initiation phase when they take up allergens, migrate to the draining lymph nodes and induce 
the differentiation of allergen-specific Th2 cells (figure 1). Renewed exposure to the allergens induces 
a cascade of Th2-cytokine production (interleukin (IL)-4, IL-5, IL-13), which promotes class-switching of 
B cells to IgE production, the development of eosinophilic airway inflammation, goblet cell hyperplasia 
and airway hyperresponsiveness. Notably, the recently discovered innate lymphoid cells type 2 (ILC2s), 
activated by innate cytokines from damaged epithelial cells, have been described as a significant early 
source of Th2-cytokines after local allergen exposure 4. 
The prevalence of childhood asthma has increased dramatically in westernized countries in 
the second half of the 20th century. Recent studies suggest that the incidence of asthma has now 
reached a plateau in high prevalence countries 5, the global burden of asthma however continues 
to rise as incidence rates in Africa, South America, and parts of Asia still rapidly increase 6. Asthma is 
a multivariable disease in which genetic predispositions are certainly important risk factors. However, 
the rapid increase in incidence rates over the last few decades points toward a strong contribution 
of environmental factors to disease development. One explanation is provided by the ‘hygiene 
hypothesis’ suggesting that a decrease in childhood exposure to infectious agents as a result of 
increasing sanitation standards, improved health care, and life style changes attributes to the increase 
in incidence of allergies and asthma 7. 
Microbial organisms such as commensal bacteria and helminths are part of human evolutionary 
history. These microorganisms have developed various strategies to modulate the host immune 
system, often by amplifying the natural immune regulatory network of the host and simultaneously 
reducing immunopathology. Many of these organisms establish chronic infections, which may also 
reflect the assumption that the host immune system tolerates these non-lethal organisms rather than 
inducing potent inflammatory responses at the cost of severe tissue damage and immunopathology 8. 
As such, the immune system categorizes the degree of danger associated with invading pathogens and 
only reacts strongly to the most threatening organisms such as certain viruses, bacteria and protozoan 
parasites. In contrast, mainly repair and tissue integrity responses are activated following exposure to 
less dangerous microorganisms. More recently, the concept has been advocated that certain helminths 
and bacteria, which are tolerated by the host, may actually imply benefits. Bacteria of the intestinal 
microbiome for example ferment food, produce essential vitamins and prevent colonization by other, 
more harmful bacteria 9. Furthermore, these helminths and microbiota prevent exaggerated immune 
responses to ubiquitous antigens, as they are strong inducers of the regulatory arm of the immune 
system. In line with that, the ‘hygiene hypothesis‘ implies that a reduced infectious pressure leads to an 
immune imbalance, which promotes allergic disorders in genetically susceptible people 10. In addition, 
potential benefits of certain microorganisms for the human body are being lost as the diversity of 
the microbiome decreases 9.
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Despite the increase in asthma prevalence worldwide in the last decades not many novel therapeutic 
options have been developed. Current therapies for asthma patients still consist of inhaled steroids 
and bronchodilators. These medications only alleviate symptoms, which will reoccur after medication 
has stopped. The treatment of severe asthma proves to be difficult and available therapeutic options 
are limited to systemic steroids and anti-IgE treatment. Thus, new therapeutic approaches which alter 
the immune response and promote long-lasting tolerance against allergens are needed. Exploiting 
the modulatory capacities of evolutionarily-conserved ‘old friends’ 11, like bacteria and helminths, is 
a promising strategy to design novel treatments for airway allergies such as asthma. 
In this review, we will highlight the current evidence for the protective effect of helminths and 
certain bacteria in allergic disorders from both epidemiological studies and animal models. We will 
address both life infections and antigens derived from these organisms, and summarize the proposed 
mechanisms of protection. Finally, we will discuss the recent advances in the field and give 
recommendations for future microbial-based treatments against allergic diseases.
figure 1. bacteria and helminths induce t regulatory and b regulatory cell responses that dampen allergic 
airway inflammation. Left panel: Allergic airway inflammation is most often characterized by a predominant 
Th2 response. This is initiated by mature dendritic cells that after allergen recognition and presentation, skew T 
cells towards a Th2 phenotype. Th2 cells initiate effector responses by in particular recruitment and activation of 
eosinophils and by class switching B-cells to produce IgE antibodies. 
Right panel: Bacteria and helminths can intervene in this response at various levels. An example is given in which they 





evidence for inhibition of allergic airway inflammation (aaI) by microorganisms 
The association between microbial infections and the reduced incidence of allergic disorders has been 
addressed in numerous epidemiological studies. Meta-analyses consistently show that several helminth 
species, e.g., Acaris, Trichuris, hookworm and Schistsoma can protect against allergic sensitization 12-14. 
Hookworm infection is most clearly associated with a reduced risk of developing asthma 14, while other 
species give either no significant protective effect or have not been extensively studied. Nevertheless, 
individual studies have suggested that infection with Schistosoma mansoni reduces the severity of 
asthma 15 and allergic skin reactions 16;17. In addition, a range of other factors have been suggested 
to determine the protective effect of helminth infection on atopic disease, such as time, intensity 
and chronicity of infection and host genetics 18. Of note, worm infections have also been linked to 
protection against other inflammatory non-communicable diseases, such as inflammatory bowel 
disease (IBD), multiple sclerosis (MS) and type-1 diabetes 19. 
Infection with or exposure to certain bacteria can also interfere with the development of allergies 
and airway disease. For example, there is mounting evidence that environmental factors such 
as living on a farm protect from developing asthma 20-22 and this protective effect is attributed to 
the environmental exposure to different bacterial and fungal microorganisms 23. In contrast to previous 
belief, the lung is not sterile but colonized by certain bacterial species, and it was suggested that 
the composition of the lung microbiome was different in patients with asthma compared to healthy 
individuals 24;25. Changes in the bacterial composition may have consequences for disease severity as 
patients with steroid resistance displayed a different composition of the lung microbiome compared to 
patients responsive to steroids 26. Whether these changes are an effect of pathophysiological processes 
in the airways of patients with asthma or a predisposing factor for the development of asthma is not 
clear. Nevertheless, it is clear that colonization of the airways with certain bacteria increased the risk 
of developing allergic airway disease in children 27;28. In contrast, exposure and infection with a range 
of other microorganisms may protect from the development of asthma. In epidemiological studies 
the prevalence of asthma was negatively associated with Herpes simplex virus I, Hepatitis A, and 
Toxoplasma gondii infection 29. Not only exposure to external bacteria but also the composition of 
the microbiome can affect the development of asthma. The total diversity of the gut microbiota during 
the first month of life has been associated with the development of AA in infancy and childhood 30 
and a higher prevalence of asthma has been found in children treated with antibiotics 31;32. These 
associations must however be reviewed carefully as the causal relationship can be overestimated 
as reverse causation and confounding factors may have impacted the analysis 33. Further examples 
are provided by infections with the gut bacterium Helicobacter pylori (H. pylori), which is reversely 
linked with asthma prevalence, particularly in children 34-37. Interestingly, infection with H. pylori is also 
negatively associated with the development of other non-communicable disease such as IBD and MS 38. 
The association between the decreasing prevalence of infection with H. pylori 39 and the increase in 
non-communicable diseases such as asthma has been linked to the so called `disappearing microbiota 
hypothesis` 9. Experimental studies in models of allergic airway disease have confirmed this relation and 
furthermore unraveled the underlying mechanisms of this protective effect 40-42. 
Protective, microbial-induced mechanisms against respiratory allergies 
A number of different mechanisms by which helminths, certain bacteria and their molecules protect 
against AAI have been described. The variety of proposed mechanisms most likely reflects the variety 
of different molecules and models studied. Although part of these mechanisms may have overlapping 
features, it is plausible that helminths and bacteria have evolved distinct ways of altering the immune 
responses of the host to promote their survival and use different molecules to do so. 
In general, helminths are recognized as potent regulators of the host immune system. They 
strongly induce Th2 cells, IgE class-switching and eosinophil-rich tissue infiltrations, but at the same 
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time promote regulatory cells, like regulatory T (Treg) and B (Breg) cells, tolerogenic/immature DCs 
and alternatively activated macrophages (AAMs). The regulatory cytokines IL-10 and transforming 
growth factor (TGF)-β play a key role in their capacity to regulate the host immune system. Bacteria of 
the microbiome are associated with various types of pro-inflammatory immune responses. However, as 
certain bacteria try to maintain their niche, they produce factors which are able to inhibit inflammation. 
H. pylori infection in the stomach for example can induce a strong Th1 response, but also secretes 
molecules that induce tolerogenic DCs and inhibit T cell proliferation as reviewed by Müller 43. 
These factors may simultaneously affect immune responses to bystander antigens such as allergens. 
Collectively, both helminths and bacteria as well as their products have various regulatory effects on 
the host immune system. A large number of protective mechanisms have been described by which 
microbes and/or their products can inhibit experimental airway allergies (see table 1 and figure 2 
for an overview of the discussed literature) The following main mechanisms appear to be important in 
microbial-induced protection against allergies and airway disease:
1) T cell polarization
AA is a predominantly Th2-mediated disease. Initial observations of protective effects from microbial 
compounds were thought to be mediated by influencing the Th1/Th2 balance. Indeed, many 
microorganisms and some microbial molecules that protect against AA induce Th1 cells and/or the Th1 
cytokine IFN-γ, and/or reduce Th2 cytokines 44-48. Interestingly, a similar shift from allergen-specific Th2 
to Th1 cytokines was demonstrated in vitro in peripheral blood mononuclear cells from patients allergic 
to timothy grass pollen in response to cystatin from the filarial helminth Acanthocheilonema viteae 49. 
Other helminth-derived material dampens allergen-specific Th2 immunity while simultaneously 
inducing a strong helminth antigen-specific Th2 response 50. CpG oligodeoxynucleotides (CpG ODNs) 51 
and H. pylori neutrophil-activating protein (HP-NAP) 52 were shown to inhibit AAI and to skewe human 
allergen specific Th2 cells to Th1 cells in vitro 53;54.
2) Induction of Treg/Breg cells
Anti-microbial pro-inflammatory responses are often accompanied by compensatory regulatory 
responses to prevent excessive damage as a result of inflammatory responses. Different regulatory 
cells are involved in protection against AAI induced by helminth parasites and bacteria. Treg cells are 
currently the most well-studied regulatory cell type and include the thymus derived, peripheral derived, 
and in vitro induced regulatory T cells (tTreg, pTreg, and iTreg respectively) 55;56. They suppress other 
effector T cells via the regulatory cytokines IL-10 and TGF-β, as well as through cytokine-independent 
or cell-cell contact-mediated mechanisms. A role for Treg cells induced by natural helminth 57-64 or 
microbial infection 40;41;46;65;66 in the suppression of AAI has been demonstrated by different groups 
(figure 1). In addition to live infection, a number of helminth- 67-69 and bacteria-derived molecules also 
mediate protection in association with the induction of Treg cells 42;70-74. Infection with many helminths 
and certain microbiota is associated with the induction of IL-10 and TGF-β 66;75, and the protective 
effects of these microorganisms or their molecules on AA are often, but not always, dependent on these 
cytokines. One study with schistosome eggs for example described a Treg cell-mediated protection 
against AAI which appeared to be independent of these cytokines 76.
Another suppressive cell type, which has been increasingly studied is the Breg cell. Various 
model systems suggest that Breg cells can mediate protection against AA. Both IL-10-dependent and 
-independent effects have been described depending on the tissue source of these Breg cells: e.g., 
spleen IL-10-dependent; 77 versus gut/lungs IL-10-independent; 78;79. Moreover, Breg cells enforce their 
protective effects not only by inhibiting effector T cell responses, but also by inducing Treg cells and 




a number of bacteria have shown to be strong inducers of Breg cells 78;79;81-84. For some of these species, 
it has been demonstrated in experimental models that their protective effect against allergic airway 
disease critically depends on Breg cells (figure 1) 78;79;81 
Parasites or bacteria and their products may not only work via the direct induction of regulatory 
cells but may also influence the availability of other molecules that exert this effect. For example, certain 
strains of the human gut bacterium Clostridia can protect mice from developing colitis and allergic 
diarrhoea by the production of short chain fatty acids (SCFAs) 85. These SCFAs stimulate epithelial cells 
to produce TGF-β, which is likely to contribute to the induction of IL-10-producing Treg cells. Especially 
the SCFA butyrate was able to induce Treg cells 86. Interestingly, the gut microbiome and the production 
of SCFAs is dependent on diet. A high-fiber diet induces more SCFAs compared to one low-in-fiber via 
alterations of the microbiota with a direct inhibitory effect on the development of AAI 87.
In summary, many studies report a microbial-mediated induction of Treg/Breg cells, and show that 
either blocking their effector functions inhibits the protective effect or that the adoptive transfer of 
table 1. an overview of mechanisms by which bacteria and helminths and their products may modulate 
allergic inflammatory responses. Various cell types seem to be modulated by microorganisms or their compounds 
during their inhibition of an allergic response. Both results obtained in animal models and from in vitro experiments 
on human cells are summarized in this table.
affected cell mechanism microorganism
composition  
or molecule reference
T cell Skewing  to Th1 rather than 
Th2 cells
Ascaris suum PAS-1 [44]
Acanthocheilonema viteae Cystatin [49]
ES-62 [47]
Caenorhabditis elegans Crude extract [45]
Nippostrongylus brasiliensis ES [50]
Helicobacter pylori HP-NAP [52;53]






N/A CpG ODNs [51;54]
Induction Treg cells Anisakis simplex MIF-like protein [69]
Ascaris suum PAS-1 [68]
Heligmosomoides polygyrus Live infection [59;60;63]
Litomosoides sigmodontis Live infection [58]
Nippostrongylus brasiliensis Live infection [64]
Schistosoma mansoni Live infection [61]
Sm22.6/Sm29/PIII [67]
eggs [76]
Trichinella spiralis Live infection [57;62]
Alcaligenes faecalis β-glucan curdlan [70]
Clostridium leptum Live infection [66]
Helicobacter pylori Live infection [40;41]
 VacA and GGT [42]
Lactobacillus rhamnosus GG 
or Bifidobacterium lactis
Live infection [65]






affected cell mechanism microorganism
composition  
or molecule reference
Mycobacterium bovis BCG Freeze-dried 
preparation
[71;72]
Multiple bacteria BV, a lysate [73]
Streptococcus pneumonia Type-3 polysacharide 
and pneumolysoid 
[74]
Induction γδTCR+ T cells Ascaris suum PAS-1 [68]
Escherichia coli Live infection [106]
B cell Induction Breg cells Heligmosomoides 
polygyrus
Live infection [79]
Schistosoma mansoni Live infection [78;81]
Induction IgE cross-
reactivity
Schistosoma haematobium Live infection [105]
DC or 
macrophage
Alteration activation status Acanthocheilonema viteae Cystatin [95]
Clonorchis sinensis Total protein [90]
commensals in general Live infection [100]
Bacillus cereus Synthetic lipopeptide [96]
Induction DC IL-18 
secretion
Helicobacter pylori Live infection [41]
Mast cell Blockage mast cell 
degranulation
Acanthocheilonema viteae ES-62 [104]
Epithelial cell Activation epithelial cells Pseudomonas aeruginosa 
transfected with type 1 
fimbiae
Inactivated [107]







Clostridium leptum Live infection [66]
Lactobacillus paracasei NCC Live infection [75]
Reduction chemotaxis 
eosinophils
Heligmosomoides polygyrus Live infection [63]
Nippostrongylus brasiliensis Live infection [64]
Strongyloides stercoralis, Live infection [97]
Escherichia coli LPS [99]
Reduction chemotaxis iNKT commensals in general Live infection [101]
Reduction development 
basophil precursors
commensals in general Live infection [102]
Alteration microbiota by 
diet induced SFAs
Effect on multiple bacteria Live infection [87]
these regulatory cells is sufficient to exert protection. Despite the clear notion that Treg or Breg cells 
are important mediators of suppressive effects in AAI, the precise mechanisms by which these cells 
function is not yet well-described. Treg and Breg cells inhibit other effector T cells and APCs but may 




figure 2. mechanisms by which bacteria and helminths may modulate allergic inflammatory responses. 
The proposed mechanisms in which bacteria and helminths can reduce allergic airway inflammation are various in 
their origin and involve multiple immune cell types. In some studies that are discussed in this review, a combination 
of multiple mechanisms is proposed.
3) Modulation of DC/macrophage function
While both DCs and macrophages have been primarily implicated in the priming of pro-inflammatory 
Th1 responses, they are also important contributors to the initiation of regulatory (and Th2) immune 
responses. Antigen processing in the absence of danger signals retains DCs in an immature state 
and preferentially induces Treg cells. Several microorganisms have evolved this feature to their 
benefit. A molecule from Schistosoma directly acts on DCs via the toll-like receptor 2 to promote 
the polarization of Treg cells 89, while other helminth molecules downregulate co-stimulatory molecules 
thereby possibly influencing subsequent T cell polarization 90. AAMs, induced by IL-4 and IL-13, are 
elicited during polarized type 2 immune responses. They are important innate effectors in anti-parasite 
immunity and wound healing, especially during helminth infections 91. Interestingly, AAMs have also 
been described to possess immunosuppressive activities in models of schistosomiasis and filariasis 
92;93. Lung-stage helminth infections strongly induce alternative activation of alveolar macrophages 94. 
A protein from filarial helminths has been reported to protect against experimental AAI in a macrophage- 
and IL-10-dependent manner 95, further pointing toward the importance of innate immune cells with 
regulatory properties in protection against allergic inflammation (figure 1). H. pylori infection strongly 
reduces allergic airway disease in experimental models 40, and this protective effect was associated with 
the production of the cytokine IL-18 by tolerogenic DCs which skew the T cell phenotype toward Treg 
cells rather than Th17 cells 41. This effect could be further pinned down to two specific virulence factors 
of H. pylori, the vacuolating cytotoxin (VacA) and the γ-glytamyl transpeptidase (GGT) 42. A bacterial 
synthetic lipopeptide was also able to inhibit the disease by keeping the DCs in a tolerant state 96.
4) Other mechanisms
Inhibition of cell migration to the lungs is another immunosuppressive effect of microbial exposure. 
AAI is characterized by the influx of eosinophils, which is mediated by specific chemokines such as 
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eotaxin (figure 1). Different studies have described that helminth infection reduces the levels of eotaxin 
in the bronchoalveolar lavage fluid 63;64;97 and the expression of its receptor CCR3 on eosinophils 98. 
Prenatal microbial exposure can modulate AAI in the offspring by inhibition of eosinophil infiltration 99. 
Interestingly, mice receiving antibiotics or totally lack gut commensal bacteria show a stronger 
AAI compared to mice with normal gut flora. This phenomenon has been associated with e.g. 
a dysregulation in DC recruitment and maturation 100 and an accumulation of invariant natural killer 
T (iNKT) cells in the lung 101. Furthermore these mice have an increased frequency of circulating 
basophils, which was explained by the finding that the basophil precursors of these mice have a higher 
expression of the IL-3 receptor which regulates their development 102. Interestingly, the blockage of 
IL-33 release and subsequent suppression of ILC2 induction by secreted helminth molecules 103 has 
recently been described in mediating protection against AAI, adding ILCs to the list of effector cells 
modulated by helminth molecules. Other mechanisms of protection include the blockage of FcεRI-
induced degranulation of human mast cells by the helminth-derived glycoprotein ES-62 104 as well 
as the induction of carbohydrate cross-reactive, allergen-specific IgE during helminth infections with 
a reduced capacity to induce basophil degranulation 105. Furthermore, the induction of γδTCR+ T cells 
by both helminth and bacteria has been reported 68;106. A bacterial compound able to inhibit AAI has 
also been shown to e.g. induce proliferation and wound repair of bronchial epithelial cells 107.
clinical trials utilizing helminths and microbiota for treatment of respiratory allergies
Modulation of the host immune response against helminths or certain bacteria allows the establishment 
of chronic infection and a mutual beneficial co-existence in the host. As a bystander effect, 
immunoregulation often results in suppression of immunity to other antigens such as allergens. 
Although it is conceivable that part of the activity from life microbes on the immune system can be 
condensed to the activity of single or multiple molecules, it is elaborate to identify them and it will 
be a long process before they can be applied in the clinic. Therefore, several researchers have taken 
the approach of applying clinically controlled full infections in clinical trials, bypassing the process of 
identifying the responsible molecules.
These controlled infections have been applied now in a number of inflammatory diseases with 
mixed results. At present, the eggs of the pig whipworm Trichuris suis are approved for therapy of IBD, 
the first helminth-based therapy being used 108-110. Randomized, controlled trials have shown promising 
results in terms of safety and efficacy in MS patients 111. However, no beneficial effect of T. suis eggs was 
observed in patients with AR after 3 weekly doses of 2500 T. suis eggs over a 6 month period 112;113. It 
remains to be established whether a longer treatment, more or higher dosages, different worms and/
or treatment of a younger study population would be more effective. Probiotics and various inactivated 
bacterial strains have also been widely examined for their health-promoting activities and treatment 
of various inflammatory disorders. However, probiotics are also not routinely used as a treatment in 
allergic patients. A meta-analysis of application of probiotics to pregnant women or babies concluded 
that probiotics do not prevent the development of asthma 114, although it is suggested that probiotics 
might be effective in preventing AD 115. For example, AD could be reduced by oral application of 
a lysate of heath-killed Escherichia coli and Enterococcus faecalis in a subgroup of children with at 
least one parent with AD 116. Broncho-Vaxom (BV), an extract which contains a mixture of multiple 
bacteria is already used to treat patients from recurrent respiratory tract infections, but it is not yet 
applied against asthma 73. Other bacterial preparations showed some effectiveness in clinical trials. 
For example, newly diagnosed adult patients with moderate persistent asthma experienced some 
improvement of lung function and asthma symptoms when treated with inactivated Mycobacterium 
phlei 117. In conclusion, several trials have applied helminths, bacteria or complete extracts/lysates in 




diseases. There is little evidence so far for a therapeutic effect of controlled microbial infections on 
respiratory allergies. Although this is a relative young field and conceptually very exciting, it needs to 
be further explored and developed in the near future with help from small-medium enterprises (SMEs) 
and pharmaceutical companies.
helminth- and microbial-derived molecules for the treatment of respiratory allergies 
Although some of the clinical trials showed promising results, treatment options based on natural 
infections bear risks and the first trials for respiratory allergies showed that further testing and 
optimization is needed before implementation in the clinic is possible. Therefore several groups have 
instead focused their efforts on studying the effects of (single) helminth- or bacteria-derived molecules 
as opposed to natural infections. However, as this is a more elaborate path to follow, this field is still in 
its infancy and the current data available are mainly from animal models. 
Molecules derived from helminths that show protective effects in models of AA include whole 
antigen generated from adult worms 45;90;118 or other live cycle stages such as eggs 119, excretory-
secretory products (ES) 50;120;121 and isolated 44;47;68;104;122 as well as recombinantly expressed 49;67;69;95 single 
antigens. Different strategies are also examined with regard to the protective effects of bacterial 
derived products. Common components of bacteria such as the cell wall LPS 99;123;124, curdlan 70 and 
CpG sequences in the DNA 51 have been reported to be protective. Importantly, in many of the applied 
experimental models exposure to LPS actually induces rather than inhibits AAI. These findings 
demonstrate that exposure to bacteria is not universally protective but may rather depend on certain 
bacterial traits. Some groups use live-attenuated or inactivated bacteria 48;107;117;125, a lysate 73 or frieze-
dried bacteria 71;72. In some cases more specific single molecules were tested 42;52, however this field is 
not yet strongly evolved. The type of preparation of the compound may be of great importance, as it 
was shown that inhibition of AAI was only effective when using frieze-dried but not heat-killed or alive 
Mycobacterium bovis BCG 71.
from the bench to the clinic
Nearly all of the experimental studies have been conducted in models of AAI based on the model 
allergen ovalbumin that is isolated from chicken egg white. While this model is well established and 
allows the use of genetically modified mice to study antigen-specificity, there is a great need to apply 
models based on natural allergens (house dust mite, grass, tree pollen) as it allows to more easily 
relate findings from the model to the field and the clinic. Furthermore, these models use a natural 
route of sensitization. First studies show protective effects of both helminth- 49;126 and bacteria-derived 
products 73;75 in models based on natural allergens. It is of interest that some cases of asthma in humans 
are induced by fungal antigens, and some studies have also suggested a protective role of helminth 
and bacterial compounds in fungus-induced AAI in mice 103;127. 
Another aspect of interest when studying the protective effect of microorganisms and their 
molecules is the timing and duration of administration. Allergen-sensitization often occurs early in 
life, followed by life-long suffering from asthmatic disease. Any preventative treatment approach 
would therefore be most beneficially applied during infancy. Of interest, it has been suggested in 
various studies that treatment of neonatal mice with bacteria or their compounds is more effective 
in inducing tolerance compared to adult mice 40;41;65. The treatment of newborns might however be 
difficult to achieve in practice. Interestingly, a number of papers we have discussed have applied 
treatment to the pregnant and later lactating mothers, showing protection against features of AAI in 
the offspring 75;99;128. The rationale for the success of these early treatment approaches might come 
from epigenetic changes in immune-associated genes. In regard to this, it was shown that epigenetic 
changes had occurred in mice following contact with environmental bacteria, leading to a reduced 
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susceptibility to allergies 128. Altogether, it is clear that microbial molecules should be best applied as 
early as possible to prevent the development of allergic diseases, it nevertheless is of great importance 
to investigate microbial molecules for their potential to dampen already established disease. 
Although there are some promising results that indicate treatment of ongoing asthmatic disease 
is possible 45;69, the majority of the data suggests that this is much more difficult to achieve than 
the prevention of disease onset. But as patients are repeatedly exposed to allergens, testing potential 
therapeutic molecules in a setting of repeated challenge is thus important. While some molecules fail to 
protect upon re-challenge 73 others maintain their protective effect 71;74, making them more suitable as 
a putative treatment for established disease. Working toward the implementation of a novel treatment 
for asthmatic patients, not only the timing but also the route of administration needs to be considered. 
In allergen immunotherapy, alternative routes of local (e.g. sublingual, intranasal) and systemic (e.g. 
oral) allergen administration to mucosal surfaces show promising results in terms of immunogenicity 
and safety in clinical trials 129 compared to the standard method of subcutaneous injections. In mouse 
models the same, but also different and less obvious routes of molecule application are applied 
(intraperitoneal, often in combination with an adjuvant; intravenous; intranasal/aerosol; intratracheal), 
when testing the therapeutic potential of microbial-derived molecules. In view of human application, 
we believe that administration routes that are most likely to induce tolerance should be favored also in 
the animal models to allow extrapolation of the results to humans.
From a clinical point of view, there are several issues that need to be addressed when working 
toward the implementation of helminth- and microbial-derived molecules in the clinics. As summarized 
elsewhere 130;131, potential side effects need to be considered. These include anaphylaxis and atopic 
reactions to helminth parasite-derived molecules, as well as the risk of general immune suppression in 
the patient. Trials of the recombinant Na-ASP-2 hookworm vaccine for example have shown important 
differences in the immune response between individuals not exposed to hookworm and individuals from 
endemic areas that have previously been infected 132;133. In order to avoid general immune suppression, 
it is favorable to be able to induce antigen-specific tolerance, or local tolerance restricted to the site 
of allergen-induced inflammation (e.g. the lungs). Furthermore, it should be ensured that tolerance 
induced by microbial-derived molecules does not inhibit immune responses to natural infections with 
potential pathogenic microorganism. Interestingly, in mice the application of freeze-dried BCG to 
inhibit AAI did not interfere with the diagnosis of live infection with the bacteria 71. Finally, the risk of 
cross-reactivity between antigens of microorganisms and allergens needs to be taken into account. 
It is becoming clear that asthma is a term that describes a collection of symptoms. Personalized 
medicine tries to tailor treatment regimens specifically to a patient condition or characteristic by 
investigating individual-based treatments, as some patients might benefit from therapies that 
only show efficacy in a subgroup of the asthmatics. In greatest need for novel treatment options 
are probably patients that suffer from severe asthma, which are often resistant to treatment with 
steroids and cannot be subjected to specific immunotherapy. For these patients, it would be of 
special importance to develop a treatment that cures ongoing disease, which is harder to achieve 
than preventative approaches as discussed above. This may prove to be difficult as advanced local 
tissue degeneration has occurred which will probably not be restored even when inflammation has 
been dampened. However, it is important to realize that the larger group of asthma patients with 
milder forms of disease, which are now well controlled by steroids, form a realistic target group to 
apply a ‘treatment to cure’ therapy with microbial molecules. Altogether, we believe that, rather 
than applying natural infections, the isolation of modulatory, protective components from bacteria 





eXPert commentary and fIve year vIew
Despite the increasing worldwide prevalence of asthma little has changed in the last years in 
the treatment or prevention of this disease. The main therapy is still based on inhaled steroids and 
bronchodilators. Despite the development of monoclonal antibodies targeting IgE or Th2 cytokines 
(IL-5, IL-13, IL-4 receptor alpha chain) no ground-breaking advancement has been made in prevention 
or treatment of asthma. Epidemiological and experimental research has increased our understanding 
of mechanisms how microorganisms can evade the immune system and suppress the development 
of allergy and airway disease. Several mechanistic pathways how these microorganisms actively 
suppress immune reactions have indeed been discovered. In our opinion, these novel insights are 
promising and open up a novel avenue for the development of innovative therapeutics. As live 
infection with bacteria and parasites is not always perceived as a desirable strategy, focus has been 
shifted to isolating molecules from microorganisms. Several molecules have been identified and are 
currently being evaluated in experimental models. We expect that in the following years the number 
of identified suppressive molecules will further increase and that these molecules will be evaluated 
in preclinical models. The predictive values of these models in regard to the effectiveness in human 
disease may be limited. Nevertheless, these model data will provide interesting and valuable insights 
about the underlying mechanisms involved in the suppressive capacity of these molecules, timing of 
treatment and route of administration. One major issue is if these molecules can be used solely for 
prevention or also for treatment of people with already developed allergic disease. This will certainly 
also critically determine the therapeutic windows in which treatment is feasible. Next, crucial steps 
need to be made toward the clinic in which active involvement of SMEs and pharmaceuticals will help 
to initiate clinical trials in patients with allergic disease such as AA. These trials should then reveal if 
a molecular approach can advance our therapeutic options in allergic disease and asthma and if we can 
effectively modulate immune responses to allergens long-term.
Key Issues
 · Atopic diseases (e.g. allergic rhinitis, allergic asthma) are a major global health burden today. 
Medication options are limited and only alleviate the symptoms, therefore novel treatment options 
need to be developed urgently. 
 · Helminths/microbiota modulate the host immune system, suppressing the immune response 
to themselves and bystander antigens such as allergens. The ‘hygiene hypothesis’ suggests 
that the drastic increase in incidence rates for atopic diseases can be ascribed to a reduction in 
infectious pressure and the resulting imbalance of the immune system. 
 · A body of epidemiological evidence underpins that helminths (e.g. hookworms, schistosomes) and 
certain bacteria (e.g. H. pylori) protect against allergic asthma in humans. 
 · In vivo studies suggested mechanisms by which microorganisms or their products protect against 
allergic airway disease, including shifting of the Th1/Th2 immune balance, induction of Treg/Breg 
cells, modulation of DC/macrophage function and impairment of chemotaxis and effector cell (e.g. 
mast cell, basophil) function. 
 · Helminth- and microbial-derived molecules have been identified which efficiently protect against 
experimental allergic airway inflammation, and which include whole antigen preparations, 
excretory-secretory products and single molecules (single/recombinant) of helminths as well as 
live-attenuated and freeze-dried bacteria, bacterial lysates and single bacterial molecules.
 · At the moment microbial-derived treatments are not routinely applied in the clinics to treat allergic 
airway disease. Working toward a novel treatment option for atopic patients based on microbial-
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derived molecules, a range of factors such as safety, mode of action (general vs. antigen-specific 
tolerance), timing and route of administration need to be taken into account. 
 · We expect that more immune suppressive molecules will be described and that these molecules 
will further progress into clinical trials.
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Chronic helminth infection with Schistosoma mansoni protects against allergic airway inflammation 
(AAI) in mice and is associated with reduced Th2 responses to inhaled allergens in humans, despite 
the presence of schistosome-specific Th2 immunity. Schistosome eggs strongly induce type 2 immunity 
and allow to study the dynamics of Th2 versus regulatory responses in the absence of worms. Omega-1 
(ω-1) is a glycoprotein secreted by S. mansoni eggs, and represents one of the major type-2 immunity-
inducing components within soluble egg antigen (SEA). Treatment with isolated S. mansoni eggs by 
i.p. injection prior to induction of AAI to ovalbumin (OVA)/alum led to significantly reduced AAI as 
assessed by less BAL and lung eosinophilia, less cellular influx into lung tissue, less OVA-specific Th2 
cytokines in lungs and lung-draining mediastinal lymph nodes, and less circulating allergen-specific 
IgG1 and IgE antibodies. While OVA-specific Th2 responses were inhibited, treatment induced a strong 
systemic Th2 response to the eggs. The protective effect of S. mansoni eggs was unaltered in µMT 
mice lacking mature (B2) B cells, and unaffected by Treg cell depletion using anti-CD25 blocking 
antibodies during egg treatment and allergic sensitization. Notably, prophylactic egg treatment 
resulted in a reduced influx of pro-inflammatory, monocyte-derived dendritic cells into lung tissue of 
allergic mice following challenge. Treatment with recombinant, Nicotinia benthamiana-expressed ω-1 
replicated the protective effect observed by eggs. Altogether, S. mansoni eggs can protect against 
the development of AAI, despite strong egg-specific Th2 responses, and protection can be achieved by 





The prevalence of allergies and asthma has dramatically increased in developed countries over the last 
decades, and the incidence rates continue to increase especially in low and middle-income countries 1. 
It has been suggested that environmental factors, such as an increased exposure to air pollutants and 
tobacco smoke 2, but also an overly sanitary life-style with decreased exposure to parasites may play an 
important role in the increased prevalence of asthma. 
The protective effect of parasitic infections against allergic asthma has been introduced as one of 
many elements in the so-called ‘old friends hypothesis’ 3-6. The relationship between helminths and 
asthma is complex, with factors such as worm species, timing, intensity and chronicity of infection as 
well as host genetics at interplay 7, and a causal link in humans has yet to be demonstrated. Acute or 
light helminth infections seem to promote allergic sensitization and allergic symptoms, while chronic 
helminth infections are more often associated with protection 7, 8. This may also explain why deworming 
at population level has been shown to result in enhanced skin-prick test positivity or rates of eczema 
in some cases, while having no effect in others 8. A large body of epidemiological and experimental 
studies has shown that, despite heterogeneity in the results, especially hookworm infections have been 
consistently found to reduce allergic sensitization 9, 10. Schistosoma spp. has also been reported to be 
protective against allergic sensitization in humans 9, 11. 
Schistosoma spp. infections consist of an acute phase dominated by a strong Th2 response to 
the eggs, and a chronic phase with a diminished Th2 response and increased activity of regulatory 
immune cells 12. To distinguish between egg-induced and worm-induced protection from allergic 
airway inflammation (AAI), experimental infections with mixed sex or male Schistosoma worms were 
performed 13-19. However, these reports revealed conflicting results as some indicated a reduction in AAI 
in the presence of egg-producing infections 14, 16, 18, 19, whereas others showed a reduction in the absence 
of eggs 13, 17. In addition, some studies show protection from AAI during the acute (5-11 weeks) 17, 19, and 
others during the chronic (12-16 weeks) 14, 18 phase of infection, which elicit characteristically different 
immune responses.
Omega-1 (ω-1) is a glycoprotein secreted by S. mansoni eggs, and represents one of the major 
type-2 immunity-inducing components within soluble egg antigen (SEA). The glycoprotein is a T2 
RNase and has been well-described to condition DCs for Th2 priming in a protein- and glycosylation-
dependent manner 20, 21. Ω-1 gets bound and internalized via its glycans by a member of the C-type 
lectin receptor (CLR) family, called mannose receptor (MR), and subsequently interferes with protein 
synthesis by RNA degradation 20. Moreover, ω-1 has been described to be a hepatotoxin 22, 23, to 
induce inflammasome activation and interleukin (IL)-1β secretion in macrophages 24, and to induce 
Foxp3+ regulatory T (Treg) cells in non-obese diabetic (NOD) mice via retinoic acid and transforming 
growth factor (TGF)-β production by DCs 25. Interestingly, treatment of obese mice with ω-1 improves 
their metabolic homeostasis by promoting IL-33 release in white adipose tissue and subsequent 
accumulation of ILC2s 26.
From an immunological perspective, the conundrum that Th2-inducing helminth infections can 
dampen symptoms linked to allergic Th2 responses, as observed in humans and mouse models 7, 8, 
is still subject to discussion. Often, the immunomodulatory activity of helminths is associated with 
the induction of a regulatory network. In mouse models, the rodent nematodes Heligmosomoides 
polygyrus and Nippostrongylus brasiliensis revealed important insights into the role of Treg 27 and 
regulatory B (Breg) 28 cells as well as the regulatory cytokine IL-10 29, 30 in protection against AAI. Treg 
and Breg cells as well as IL-10 have also been described to mediate protection induced by S. mansoni 
infections 14, 16-19. However, data showing that the acute phase S. mansoni infections and/or the presence 




To further explore the dynamics and interplay between Th2 responses and regulatory responses 
in the protective effect of S. mansoni infections against AAI, we used isolated eggs instead of 
a full natural infection. We show that eggs are equally protective as a natural S. mansoni infection 
in a prophylactic setting, despite the induction of a strong egg-specific Th2 response. Egg treatment 
did not lead to Treg cell expansion or enhanced activity markers on Treg cells following allergen 
challenge. The observed protection was subsequently found to be independent of both Treg cells and 
B cells. Instead, S. mansoni egg-induced protection was associated with a reduced pulmonary influx of 
pro-inflammatory monocyte-derived dendritic cells (moDCs). Importantly, we could demonstrate that 
the protective effect of eggs can be replicated by recombinant, N. benthamiana-expressed ω-1. This 
study shows that, although inducing egg-specific Th2 responses, S. mansoni eggs can protect from 
AAI, closely resembling the human situation. This study moreover provides the first description of 
protective effects of ω-1 in the context of AAI.
results
s. mansoni eggs protect against ova/alum-induced aaI 
We and others have previously reported that chronic, but not acute, mixed infection with S. mansoni, 
which most closely resembles the natural situation in humans, protects mice from AAI 14, 16, 18, 19. 
A plausible explanation for the differential effect of acute and chronic infection might be the changing 
balance between Th2 and regulatory responses. To further explore the dynamics and interplay between 
Th2 and regulatory responses in helminth infections, we first tested whether S. mansoni liver-derived 
eggs can confer protection from AAI in the absence of worms. These eggs were isolated from livers 
of infected hamsters and frozen prior to use. We have confirmed that the excretory-secretory product 
(eggES) of these freeze-thawed eggs is similar to that of freshly isolated, mature liver eggs (suppl. 
figure 1 a). Mice were treated twice with 5x103 eggs by i.p. injection prior to allergic sensitization with 
OVA emulsified in alum adjuvant (figure 1 a). This treatment resulted in a profound suppression of 
overall cellularity and eosinophilia both in the bronchoalveolar lavage (BAL) fluid (figure 1 b) and in 
lung tissue (suppl. figure 1 b), accompanied by a reduction in various other leukocyte populations 
(figure 1 c). The reduction in AAI in treated mice was also reflected by the reduction of cellular infiltration 
around the airways (figure 1 d) as assessed by histology. Assessment of serum immunoglobulins 
revealed that egg treatment ablates the OVA-specific IgG1 and IgE response (figure 1 e). We also 
assessed local cytokine production in BAL fluid, as well as local recall responses to the allergen by 
restimulation of mediastinal lymph nodes (medLNs) with OVA. In both BAL fluid and OVA-restimulated 
medLN cell cultures, the production of allergic Th2 cytokines IL-5 and IL-13 was greatly increased 
in allergic mice, but blocked upon egg treatment (figure 1 f, G). IL-10, whilst not detectable in 
BAL fluid, followed the same pattern as IL-5 and IL-13 in OVA-restimulated medLN cell cultures 
(figure 1 G). Additionally, IFN-γ could hardly be detected in both BAL fluid and OVA-restimulated 
medLN cell cultures (figure 1 f, G). Collectively, these data show that S. mansoni egg administration 
prior to allergic sensitization inhibits the development of OVA-induced AAI.
Protection occurs despite the induction of an egg-specific th2 response
Human and animal hosts are known to mount a strong type 2 immune responses to egg deposition 
in live infections. To determine whether egg treatment induced a systemic, antigen-specific cytokine 
response in our model, we restimulated spleen cell cultures with soluble egg antigens (SEA). SEA 
restimulation profoundly increased the production of IL-5, IL-10 and IL-13, but not IFN-γ, in mice that 
had received isolated eggs compared to naïve or allergic, untreated mice (figure 2 a). In the medLNs, 
similar cytokine profiles were observed following SEA restimulation (suppl. figure 2). Furthermore, 




figure 2. Protection occurs despite the induction of an egg-specific type 2 induction. (a, b) Cytokine 
concentration in spleen cell supernatants after 4d re-stimulation with SEA (10µg/mL; a) or OVA (10µg/mL; b). 
Representative of 2 experiments, n=3-4. (c) SEA-specific IgG1 and SEA-specific IgE antibodies in serum measured by 
ELISA. Representative of 3 experiments, n=4-5. Significant differences were determined by one-way ANOVA following 
Dunnett’s multiple comparisons test and are indicated with * p < 0.05, *** p < 0.001. 
figure 1. s. mansoni eggs protect against ova/alum-induced aaI. (a) Schematic representation of 
the experimental model. (b) Total number of cells, percentage of eosinophils and total number of eosinophils in 
BAL fluid as assessed by FACS. Summary of multiple experiments. (c) Total number of neutrophils (Neu), dendritic 
cells (DC), T cells and B cells in BAL fluid as assessed by FACS. Representative of multiple experiments, n=4-5. (d) 
Representative images of haematoxylin and eosin (H&E) histology staining from PFA-fixed sections (scale bar = 
100µm). Scores for severity of cellular infiltration around the airways on a scale of 0-4 were assessed by two blinded 
observers. The average of both scores is displayed. Significant difference was determined by unpaired t-test, * p < 
0.05. (e) OVA-specific IgG1 and OVA-specific IgE antibodies in serum measured by ELISA. Representative of multiple 
experiments, n=4-5. (f) Cytokine concentration in BAL fluid measured by CBA. Representative of multiple experiments, 
n=4-5. (G) Cytokine concentration in medLN cell supernatants after 4d re-stimulation with OVA (10µg/mL) measured 
by CBA. Representative of multiple experiments, n=4-5. Significant differences were determined by two-way ANOVA 
following Tukey’s multiple comparison test (B) or one-way ANOVA following Dunnett’s multiple comparisons test 
(C-F) and are indicated with * p < 0.05, ** p < 0.01, *** p < 0.001. 
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(figure 2 b). Strikingly, these data show a systemic inhibition of OVA-specific type 2 immunity in 
addition to the local inhibition observed in figure 1. Additionally, high levels of IgG1 were observed, 
the SEA-specific IgE response was however found to be weak (figure 2 c). These data show that egg 
treatment induces a fully developed Th2 response to egg antigens in the absence of an allergic Th2 
response to OVA.
egg-induced protection against aaI is independent of treg cells
S. mansoni infection 16, 19 and antigens 31, 32 have been described to induce Treg cells in mice and humans. 
Therefore, we addressed whether egg treatment enhanced the number or activation state of Treg cells 
following allergen challenge in our model. The frequency and number of Treg cells was significantly 
increased in the BAL fluid of allergic mice, but remained at baseline in mice treated with eggs 
(figure 3 a). While the frequency of Treg cells remained unchanged in the medLNs, total numbers 
increased in allergic mice irrespective of egg treatment (figure 3 b). Additionally, extracellular 
regulatory markers CTLA-4 and GITR showed enhanced expression on Treg cells in the BAL 
(figure 3 c) and medLNs of allergic animals (figure 3 d), but were not further increased by egg treatment. 
To further dissect the role of Treg cells in egg-mediated suppression, we depleted Treg cells by means of 
monoclonal, anti-CD25 depleting antibodies (clone PC61) during egg treatment and allergic sensitization 
(figure 3 e). Successful depletion of Treg cells was confirmed by flow cytometry (suppl. figure 3 a). 
Mice depleted of CD25-expressing Treg cells still displayed significantly reduced BAL cellularity 
and number of BAL eosinophils, comparable to control mice treated with antibodies against anti-
β-galactosidase (anti-βGAL) (figure 3 f), as well as reduced numbers of neutrophils (figure 3 G). In 
contrast, in egg-treated mice Treg cell depletion did seem to affect the number of DCs, T cells and 
B cells in the BAL fluid at least to some extent, as their numbers were increased and not significantly 
different anymore between allergic controls and egg-treated mice (figure 3 G). We observed 
a similar trend in the secretion of type 2 cytokines IL-5 and IL-13 in BAL fluid following Treg cell 
depletion, which were restored compared to those in allergic control mice (figure 3h). These data may 
suggest a selective effect on the lung T cell compartment following anti-CD25 treatment, resulting in 
enhanced T cell activation. Although there is a general trend towards increased airway inflammation 
following anti-CD25 treatment in both allergic control and egg-treated mice, this effect seems to be 
more pronounced in the egg-treated group with respect to the lung T cell compartment. Anti-CD25 
treatment did however not restore eosinophilic inflammation in egg-treated mice. Collectively, these 
data suggest that depletion of Treg cells does not have a major influence on inhibition of AAI by egg 
treatment and thus cannot explain egg-induced protection against AAI.
mature b cells are not crucial for egg-induced protection against aaI
In addition to Treg cells, we also sought to investigate the role of B cells in egg-induced protection 
against AAI. B cells possess various functions ranging from antibody production, formation of memory 
and antigen presentation to the production of pro- and anti-inflammatory cytokines. The production 
of regulatory cytokines such as IL-10 and the production of inhibitory immunoglobulins are widely 
recognized regulatory functions exerted by B cells 33. Here, we used µMT mice, which lack mature 
(B2) B cells 34, to test whether B cells are required for the protective effect on OVA/alum-induced AAI 
observed after egg treatment. Both WT and µMT mice responded equally well to induction of AAI as 
shown by total BAL cellularity and the presence of eosinophils in BAL fluid (figure 4 a). Egg treatment 
significantly inhibited eosinophilia both in WT and µMT mice (figure 4 a), and a similar pattern could 
be observed for BAL neutrophils, DCs and T cells (figure 4 b). Additionally, while the abundance of 
B cells sharply increased in WT mice and decreased with egg treatment, the number of B cells was 




figure 3. regulatory t cells are not involved in egg-induced protection against aaI. (a, b) Percentage and total 
number of Foxp3+ CD25+ Treg cells in BAL fluid (a) and medLNs (b) assessed by FACS. Representative of multiple 
experiments, n=4-5. (c, d) Geometric mean expression of CTLA-4 and GITR on Foxp3+ CD25+ Treg cells in BAL fluid 
(c) and medLNs (d) assessed by FACS. Representative of multiple experiments, n=4-5. (e) Schematic representation of 
experimental model. (f) Total number of cells, percentage of eosinophils and total number of eosinophils in BAL fluid 
as assessed by FACS. Representative of 2 experiments, n=4-6. (G) Total number of neutrophils, dendritic cells (DCs), T 
cells and B cells in BAL fluid as assessed by FACS. Representative of 2 experiments, n=4-6. (h) Cytokine concentration 
in BAL fluid measured by CBA. Representative of 2 experiments, n=4-6. Significant differences were determined by 
one-way ANOVA following Dunnett’s multiple comparisons test as indicated with * p < 0.05, ** p < 0.01, *** p < 0.001, 
or by unpaired t-test as indicated by # p < 0.05. 
IL-5 and IL-13 concentrations upon egg treatment similarly to WT animals, albeit not significant 
(suppl. figure 4). The expression of Th2 cytokines in supernatants of in vitro OVA-restimulated 
medLN cell cultures from WT mice was highly elevated in AAI mice and significantly reduced after egg 
treatment (figure 5 c). Allergic µMT mice produced significantly less IL-5, IL-10 and IL-13 compared to 
their WT counterparts (figure 4 c), like recently also shown in a house dust mite model of asthma 35. As 
expected, OVA-specific IgG1 and IgE antibodies in µMT mice remained at baseline values observed in 
naïve WT animals (figure 4 d), excluding a major role of inhibitory antibodies in protection. These data 
show that B2 B cells, while contributing to Th2 cytokine production and the production of antigen-
specific antibody responses, are not required for egg-mediated protection from AAI. 
egg treatment is associated with decreased recruitment of modcs into the lung compartment
Different studies have shown that helminths not only affect T and B cells, but can also mediate 
important effects by acting on DCs 36, 37. Pulmonary DCs play a central role in the immune response 
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figure 4. mature b cells are not involved in egg-induced protection against aaI. (a) Total number of cells, 
percentage of eosinophils and total number of eosinophils in BAL fluid as assessed by FACS. (b) Total number of 
neutrophils, dendritic cells (DCs), T cells and B cells in BAL fluid as assessed by FACS. (c) Cytokine concentration 
in medLN cell culture supernatants after 4d re-stimulation with OVA (10µg/mL) measured by ELISA. (d) OVA-
specific IgG1 and OVA-specific IgE antibodies in serum measured by ELISA. All data are a summary of 2 
experiments, n=5-12. Significant differences were determined by one-way ANOVA following Dunnett’s multiple 
comparisons test as indicated with * p < 0.05, ** p < 0.01, *** p < 0.001, or by unpaired t-test as indicated by 
# p < 0.05, ## p < 0.01. 
to allergens 38. Under steady state conditions, CD103+ and CD11b+ conventional DC (cDC1 and cDC2, 
respectively) populations can be distinguished, whereas allergic inflammation triggers a strong influx 
of inflammatory moDCs 39. Both CD11b+ cDC2 and moDCs can drive allergic Th2 responses in a model 
of HDM allergy, whereby moDCs were only sufficient in a high-dose HDM model of AAI 40. moDCs 
produce various chemokines and present allergen locally in the lung especially in a model of high-dose 
allergen exposure 40. Next, we investigated whether prophylactic egg treatment alters the presence and 
function of different DC subsets in the lung of OVA/alum-allergic mice. The number of CD11c+ MHCII+ 
DCs strongly increased in allergic compared to control mice (figure 5 a). Interestingly, egg treatment 
significantly impaired the number of lung DCs following challenge, whereas the total number of cells 
in the lung remained unaffected (figure 5 a). The reduction in the number of DCs seems to be solely 
attributable to an abrogated expansion of the moDC compartment, as both the numbers of CD11b+ 
cDC2 and CD103+ cDC1s proved to be unaffected by egg treatment (figure 5 b). Monocytes, which can 
differentiate into moDCs under inflammatory conditions, migrate in a CCR2/CCL2-dependant manner, 
whereas CD11b+ cDC2 and CD103+ cDC1s do not 40. We found the concentration of CCL2 in BAL fluid 
to be strikingly increased in allergic mice, and significantly reduced upon egg treatment (figure 5 c), 





the suppressive effect of s. mansoni eggs on aaI can be reproduced by one of the major egg 
antigens, the glycoprotein ω-1
S. mansoni eggs contain hundreds of proteins and glycoproteins, of which a subset constitutes eggES 
that can potentially modulate host immunity 41. We therefore aimed to identify single molecules within 
eggES that could mediate AAI suppression. The glycoprotein ω-1 is abundant in eggES and most well-
known as major Th2-inducing component of S. mansoni eggs 20, 21, but has also been reported to have 
a range of other effects including the induction of Foxp3+ Treg cells in NOD mice 25. Moreover, ω-1 is 
known to act on myeloid cells, binding and being internalized by MR, which makes ω-1 an interesting 
candidate molecule in the light of changes within the lung myeloid compartment observed following 
egg treatment. As the natural molecule is difficult to isolate in large quantities, we treated mice with 
recombinant ω-1 (2x 50µg/mouse) expressed in plants, which has a similar Th2-inducing activity 
as the native protein 42. Treatment was performed prior to allergic sensitization, following the same 
protocol as for the egg treatment model (figure 6a). We found ω-1 treatment to significantly impair 
overall cellularity and eosinophilia in OVA/alum-induced AAI (figure 6b). Albeit not significant except 
for B cells, the influx of various other cell population also seemed affected (figure 6c). ω-1-treated 
mice showed less cellular infiltration around the airways (figure 6d). Treatment with ω-1 furthermore 
significantly reduced the production of OVA-specific IgG1, and showed a tendency towards also 
reducing OVA-specific IgE (figure 6e), while clearly inducing IgG1 and IgE production in response to 
ω-1 (figure 6f). Similar to eggs, ω-1 treatment also significantly reduced the concentration of IL-5 and 
IL-13 in BAL fluid (figure 6G) and the OVA-specific production of IL-5, IL-10 and IL-13 in in vitro re-
stimulated medLN cultures compared to allergic, untreated mice (figure 6h). In contrast, re-stimulation 
of medLN cells with ω-1 induced the production of IL-5, IL-10, IL-13 and IFNγ, albeit at a much lower 
concentration that OVA re-stimulation (figure 6I). As we have observed for treatment with eggs, ω-1 
also did not alter the abundance of Foxp3+CD25+ Treg cells or their CTLA-4 expression in lung-draining 
medLNs (figure 6J). While we have not performed Treg depletion experiments in ω-1-treated mice, 
like we did for the egg-treated mice, these data suggest that Treg cells might also not play a major 
role in ω-1-mediated suppression of AAI. Like observed for egg treatment, ω-1 treatment reduced 
the number of moDCs, but not CD11b+ cDC2s and CD103+ cDC1s (figure 6K). Collectively, these data 
show that ω-1 can suppress AAI with a similar pattern of immune characteristics as observed for egg-
mediated protection from AAI.
figure 5. egg treatment impairs the lung modc, but not cdc, compartment. (a) Total number of lung cells, 
and total number of lung DCs (CD11c+ MHCII+), assessed by FACS. Representative of 2 experiments, n=4-6. (b) 
Total number of moDCs (CD11c+ MHCII+ CD11b+ CD103- CD64+), CD103+ cDC1 (CD11c+ MHCII+ CD11b- CD103+ 
CD64-) and CD11b+ cDC2s (CD11c+ MHCII+ CD11b+ CD103- CD64-) in the lung, assessed by FACS. Representative of 
2 experiments, n=4-6. (c) Concentration of CCL2 in BAL fluid measured by CBA. Summary of 2 experiments, n=9-10. 
Significant differences were determined by one-way ANOVA following Dunnett’s multiple comparisons test and as 
indicated with * p < 0.05, *** p < 0.001.
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figure 6. the suppressive effect of s. mansoni egg on aaI can be reproduced by one of the major egg 
antigens, the glycoprotein ω-1. (a) Schematic representation of the experimental model. (b) Total number of cells, 
percentage of eosinophils and total number of eosinophils in BAL fluid as assessed by FACS. (c) Total number of 
neutrophils (Neu), dendritic cells (DC), T cells and B cells in BAL fluid as assessed by FACS. (d) Representative images 
of haematoxylin and eosin (H&E) staining from PFA-fixed lung sections, and scores for severity of cellular infiltration 
around the airways on a scale of 0-4. Scoring was performed blinded by two different individuals, the average of both 
scores is displayed. Bars = 200µm (e) OVA-specific IgG1 and OVA-specific IgE antibodies in serum measured by ELISA. 
(f) ω-1-specific IgG1 and ω-1-specific IgE antibodies in serum as measured by ELISA. (G) Cytokine concentration 
in BAL fluid measured by CBA. (h) Cytokine concentration in medLN cell supernatants after 4d re-stimulation with 
OVA (10µg/mL) measured by CBA. (I) Cytokine concentration in medLN cell supernatants after 4d restimulation with 





In this study, we sought to further characterize the potential of S. mansoni to protect from allergic 
asthma, despite profound egg-specific Th2 responses, by using both isolated S. mansoni eggs in 
a setting without adult worms and the egg glycoprotein ω-1. We show that S. mansoni eggs are 
capable of protecting against experimental AAI, which is in line with previous reports 16, 43 and in 
contrast to earlier work postulating that protection can only be achieved in the absence of female, egg-
laying worms. We found that protection from AAI can also be achieved by eggs isolated from infected 
mice instead of hamsters (data not shown), excluding confounding factors from a contamination 
of egg preparations with traces of hamster tissue. Importantly, the protective effect of eggs can be 
replicated by ω-1 as single, egg-derived antigen. Data on the administration of isolated eggs, and 
the cellular mechanisms eggs can induce in the context of an allergic inflammation, are still very 
limited. Moreover, a protective effect of ω-1 on AAI has not been reported previously. This study aims 
to advance the current knowledge by providing new insight into the putative mechanism of protection 
in the presence of egg-specific Th2 responses. 
We show that egg treatment induces a fully developed Th2 response to egg antigens, while 
the OVA-specific Th2 response, normally induced by alum, is completely absent. This is in line with 
earlier observations in chronic S. mansoni infections 14 and after treatment with excretory-secretory 
products of T. suis 44. Mangan et al. describe a ‘helminth-modified pulmonary Th2 response’ in S. 
mansoni infection, characterized by elevated pulmonary IL-10 and IL-13, but reduced IL-5 13, 45. We 
found the production of OVA-specific Th2 cytokines to be reduced upon egg treatment, which 
argues against a putative ‘modified Th2 response’ in our egg-treatment model and is similar to 
what has been described in humans. People in schistosome-endemic areas, for which a negative 
association between chronic infection and allergic sensitization has been shown, often have elevated 
Th2 responses to the eggs alongside reduced allergic symptoms 7, 8. However, a recent study on 
a fishing community in Uganda, with a low prevalence of allergy-related diseases, found a positive 
correlation between S. mansoni-specific Th2 cytokines and atopy, and S. mansoni-specific IgE and 
atopy, respectively. A significant inverse associations was observed in relation to wheeze, keeping with 
the original hypothesis 46.
Previous reports describe Treg cells, Breg cells and IL-10 to be important for protection by natural 
S. mansoni infections 14, 16-19. We observed that the number of pulmonary Treg cells was increased in 
the BAL fluid of allergic mice during the challenge phase, which has similarly been reported by others 44, 47, 
but returns to baseline rather than continues to rise in treated animals. Following allergen challenge, 
egg-treated mice did not induce Treg cell numbers or enhance the expression of regulatory activity 
markers in the lung compartment compared to untreated, allergen-challenged mice. In addition, 
IL-10 in BAL fluid of egg-treated animals was unchanged following egg treatment. The fact that Treg 
cells did not exceed the baseline levels of naïve control mice, combined with the lack of any activity 
markers, suggests that there is no active suppression by Treg cells during the allergen challenge phase. 
Mice depleted of CD25-expressing Treg cells during egg treatment and allergic sensitization display 
a similar degree of AAI suppression, despite the inflammation being generally increased upon Treg 
depletion, which is probably as a result of a dysregulated Treg to effector T cell balance. This suggests 
that egg-induced Treg cells do not play a decisive role in egg-mediated protection from AAI in our 
geometric mean expression of CTLA-4 on Foxp3+ CD25+ Treg cells as assessed by FACS. (K) Total number of lung cells, 
total number of lung DCs (CD11c+ MHCII+) as well as total number of moDCs (CD11c+ MHCII+ CD11b+ CD103- CD64+), 
CD103+ cDC1s (CD11c+ MHCII+ CD11b- CD103+ CD64-) and CD11b+ cDC2s (CD11c+ MHCII+ CD11b+ CD103- CD64-) in 
the lung, assessed by FACS. Summary of 2 experiments, n=9-12. Significant differences were determined by one-way 
ANOVA following Dunnett’s multiple comparisons test and are indicated with * p < 0.05, ** p < 0.01, *** p < 0.001.
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hands. These findings seem, at least in part, contrary to a previous report on the putative role of Treg 
cells in a similar model of egg administration 16, 19.  Discrepancies in the results may be related to factors 
like the length of exposure to parasitic products (infection versus isolated injections) or the use of 
different mouse strains.
To study the role of B cells in protection, we treated both WT and µMT mice with S. mansoni 
eggs. µMT mice lack mature, conventional B2 B cells 34. Most studies report that µMT mice mount an 
allergic response similar to their WT counterparts 48-50. In line with these data, we also found the allergic 
response to be unaffected in µMT mice, apart from a significant reduction in the allergen-specific Th2 
cytokine production by medLN cells. This could be, at least in part, due to the amount of allergen 
used, as we have previously reported an important role for B cells in low dose HDM-induced AAI 35. 
Despite the difference in OVA-specific Th2 responses, egg treatment equally protects from AAI both 
in WT and µMT mice, indicating that mature B cells are not crucial for protection. While this does not 
formally exclude a role for all Breg cell subsets, which can be present in both the B1 and B2 B cell 
compartment 51-53, we believe they are unlikely to play a major role. We have previously studied 
the induction of Breg cells by S. mansoni infection, SEA and the single egg molecule IPSE/alpha-1, and 
predominantly identified Breg cells within the splenic marginal zone (MZ) B cell compartment as well 
as the pulmonary B cell compartment 54. Both MZ B cells, which belong to the B2 B cell lineage, and 
pulmonary B cells are absent in µMT mice and thus unlikely crucial for protection. Additionally, µMT 
mice are also unable to mount an allergen-specific antibody response 53, excluding a role of inhibitory 
antibodies in protection.
DCs play a central role in the induction of adaptive immune responses in the context of AAI. Both 
CD11b+ cDCs and moDCs can drive allergic Th2 responses in a model of HDM allergy, with moDCs 
being sufficient in models of high-dose allergen exposure 40. Moreover, Schistosoma infection has 
been shown to functionally impair myeloid DCs in humans 36. Here, we show that, during the challenge 
phase of OVA/alum-induced AAI, control mice depict a sharp influx of moDCs as well as increased 
numbers of CD103+ cDC1 and CD11b+ cDC2s. Interestingly, egg treatment selectively affects the lung 
moDC compartment, whereas both cDC populations remained unchanged. The reduced concentration 
of CCL2 in BAL fluid of egg-treated mice suggests that the recruitment of moDCs into the lung is 
impaired. During allergic sensitization with alum-supplemented allergen by i.p. injection, inflammatory 
monocytes are recruited to the peritoneal cavity within hours and ingest allergens in a uric acid-
dependent manner. They migrate to the lung-draining medLNs and there develop into moDCs that 
contribute to the development of a Th2 response 55. It is unclear whether this inflammatory monocyte 
response to allergic sensitization in the peritoneal cavity was targeted by egg treatment, or whether 
the reduced pulmonary moDC levels are the consequence of reduced inflammation and reduced 
CCL2 levels. Preliminary data suggest that moDCs isolated from allergic and egg-treated mice behave 
similar and both have a poor T cell stimulatory capacity (data not shown). This may suggest that 
the observed reduced number of moDCs is the consequence rather than the cause of reduced AAI in 
egg-treated mice.
While protection from AAI by S. mansoni eggs has been described before, this is the first description 
of a suppressive effect of  ω-1 in a model of AAI. The only other Schistosoma spp. molecules described 
to inhibit AAI are the egg-derived S. japonicum molecule SjP40, which seems to induce splenic IFNγ 
production 56, and S. mansoni Sm22.6, Sm29 and PIII, all from life cycle stages other than eggs 32. 
Treatment with ω-1 resulted in a very similar pattern of AAI suppression as previously observed for egg 
treatment. Treatment with ω-1 did not induce medLN Treg cells, similarly to what we have observed 
for eggs. Treg depletion experiments in the context of ω-1 treatment will however be necessary to 




DC compartment as observed for egg treatment, but also in this case it is currently unclear whether this 
is a cause or consequence of reduced pulmonary inflammation. 
Using plant-derived ω-1 offers unique tools to further study the mechanisms of protection. While 
the recombinant ω-1 used here is the active protein carrying wild-type plant glycans, this expression 
system can be engineered to express the protein H58F mutant that lacks T2 RNase activity and/
or Lewis X (LeX) glycan motifs found on native ω-1 42. Ω-1 is internalized via its glycans by the MR 
expressed on macrophages, DCs and endothelial cells and conditions for Th2 polarization in an 
RNase-dependent manner 20. Using ω-1 lacking the ribonuclease enzymatic activity will allow to assess 
whether the absence of ω-1-mediated Th2 polarization influences protection. The comparison of ω-1 
carrying wild-type plant glycans versus glycans with engineered LeX glycan motifs will allow to discern 
whether the glycan composition is important for the observed protective effect. Furthermore, tracking 
experiments with labelled antigen should be carried out to assess which tissues ω-1 drains to after i.p. 
injection, and which cell types take up the molecule. The MR seems to be central in this process, but 
ω-1 has also been shown to bind to the CLR DC-SIGN (Dendritic Cell-Specific Intercellular adhesion 
molecule-3-Grabbing Non-integrin) and to induce DC IL-10 mRNA expression 42. In addition to ω-1, 
several other helminth antigens have been reported to bind to MR, which is often associated with 
the induction of an anti-inflammatory or Th2 response 57, 58. Studying the effect of ω-1 treatment on AAI 
in mouse lines deficient in MR or the murine DC-SIGN-equivalent SIGN-R1 will therefore be of interest 
to gain further insight into the mechanism of protection. 
In summary, the here presented data show that the suppressive effect of S. mansoni infection on 
allergic asthma can be replicated by isolated eggs. This effect occurs despite a strong Th2 response 
to the eggs itself and is likely independent of Treg and B cells. Egg treatment strongly and selectively 
affects the lung moDC compartment. The protective effect of eggs can moreover be replicated by 
the egg-derived glycoprotein ω-1. Understanding the complex interactions early during allergic 
sensitization, and how helminths interfere there, is critical for the development of preventative 
strategies for allergies and allergy-related diseases.
materIal and methods
mice
Female C57BL/6 mice (Harlan) were housed under SPF conditions in the animal facility of the Leiden 
University Medical Center (Leiden, The Netherlands) and used for experiments at 6-12 weeks of age. 
All animal studies were performed in accordance with the Animal Experiments Ethical Committee 
of the Leiden University Medical Center. The Dutch Experiments on Animals Act is established 
under European Guidelines (EU directive no. 86/609/EEC regarding the Protection of Animals used 
for Experimental and Other Scientific Purposes). B6.129S2-Ighmtm1Cgn/J (µMT) mice (C57BL/6 
background) were kindly provided by B. Lambrecht, Ghent University (Belgium) and originally purchased 
from Jackson Laboratory (Bar Harbor, USA). 
Preparation of s. mansoni eggs and recombinant ω-1
Eggs were isolated from trypsinized livers of hamsters infected for 50 days with a Puerto Rican-strain of 
S. mansoni, washed with RPMI medium containing 300U/mL penicillin, 300µg/mL streptomycin (both 
Sigma-Aldrich) and 500µg/mL amphotericin B (ThermoFisher Scientific) and frozen at -80ºC until use. 
To investigate whether freeze-thawed eggs still release a comparable protein content to that of freshly 
cultured eggs, excretory-secretory product (eggES) of freeze-thawed and fresh eggs was compared 
by silver staining after 48h of egg culture. Recombinant ω-1 was produced as previously described 
in plants 42. Briefly, ω-1 was expressed in Nicotiana benthamiana and purified from apoplast fluid by 
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cation exchange chromatography. Purity was routinely assessed by SDS-PAGE and Coomassie brilliant 
blue staining, and protein concentration assessed by BCA assay.
aaI model, egg and ω-1 treatment, and treg cell depletion
Mice were sensitized by i.p. injection of OVA (10µg/mL; Invivogen) emulsified in alum adjuvant (2mg/
mL; ThermoFisher Scientific) on day 0 and 7. Seven to 10 days after the last injection, mice were 
challenged for 3 consecutive days by either exposure to OVA aerosols (10mg/mL in PBS, 30mins) or 
by intranasal (i.n.) administration of 50µg OVA/50µL PBS. Mice were sacrificed 24 hours after the last 
challenge. Animals in the treatment group received two i.p. injections of 5000 S. mansoni eggs or 50µg 
ω-1 diluted in sterile PBS on day 11 and day 4 prior to allergic sensitization. To deplete Treg cells from 
egg-treated mice, mice were treated i.p. with anti-CD25 depleting (clone PC61) or control (anti-β-
galactosidase, clone GL113) antibody (500µg/mouse) 6 days prior to the first egg injection, and again 
6 days prior to the first allergic sensitization (2 days before second egg injection) 59.
tissue preparation
BAL fluid was collected by flushing the lungs with 1mL PBS/2mM EDTA (Invitrogen), followed by 
additional two lavages to collect remaining cells. The 1st BAL flush was kept separate for cytokine 
analysis in cell-free supernatant, the cells from all flushes were pooled for flow cytometry. Perfused 
lungs were cut into small pieces and digested using collagenase III (100U/mL; Worthington) and DNAse 
(2000U/mL; Sigma-Aldrich) for 1 hour at 37ºC. Digested lungs were homogenized through 70µm cell 
strainers (BD Biosciences) and remaining red blood cells lysed. In some cases, one side of the lung was 
tied off with surgical suture and removed, and the other side inflated with and collected into 3.9% PFA/
PBS. Mediastinal lymph nodes and spleens were homogenized through 70µm filters, and spleens were 
subjected to red blood cell lysis. Blood for assessment of Treg cells was collected from the tail vein 
6 days after the first injection of anti-CD25 or control antibody, and red blood cells were lysed. For 
serum collection, blood was collected by heart puncture, spun down and the serum stored at -20ºC 
until further analysis.
flow cytometry
The cellular composition of BAL fluid was determined by staining with fluorescently labelled antibodies 
against B220 (RA3-6B2), CD3 (17A2), CD11b (M1/70), CD11c (HL3), Gr-1 (RB6-8C5), MHCII (M5/114.15.2) 
and Siglec-F (E50-2440) directly ex vivo. Treg cells in BAL fluid, medLNs and blood were identified by 
staining with live/dead fixable aqua dead cell stain kit (ThermoScientific) and fluorescently labelled 
antibodies against CD3 (17A2), CD4 (GK1.5), CD25 (PC61.5), CTLA-4 (UC10-4B9), Foxp3 (FJK-16s) and 
GITR (YGITR 765). DCs in lung tissue were identified by staining with live/dead fixable aqua dead cell 
stain kit (ThermoScientific) and fluorescently labelled antibodies against CD3 (17A2), CD11b (M1/70), 
CD11c (HL3), CD19 (MB19-1), CD64 (X54-5/7.1), CD103 (2E7), Gr-1 (RB6-8C5), MHCII (A5/114.15.2), 
Nk1.1 (PK136) and Siglec-F (E50-2440). For all stainings, FcγR-binding inhibitor (2.4G2, kind gift of 
L. Boon, Bioceros) was added. Flow cytometry was performed using a FACS Canto II and FACSDiva 
software (BD Biosciences) followed by data analysis using FlowJo. 
histology
Lungs were collected into 3.9% PFA/PBS and the tissue transferred into 70% ethanol after 1-2 days. 
Lungs were then embedded in paraffin, sliced and stained for inflammatory cell infiltration using 
haematoxylin and eosin (H&E; both Klinipath). Stained slices were analysed under a Olympus BX41 
light microscope (Olympus). Peribronchial inflammation as assessed by H&E staining was scored on 





OVA- and SEA-specific IgG1 and IgE antibodies were measured in serum. 96-well Nunc Maxisorp 
plates (ThermoFisher Scientific) were coated with 25µg/mL of the respective antigen diluted in buffer 
(1M sodium carbonate) at 4ºC overnight and subsequently incubated with serial dilutions of sera, 
biotinylated detection antibodies against IgG1 and IgE (BD Biosciences) and horseradish peroxidase-
conjugated streptavidin (BD Biosciences). Optical densities were measured after addition of TMB 
peroxidase substrate (KPL). The concentration of the cytokines IL-5, IL-10, IL-13 and IFN-γ were 
detected in cell-free supernatants of BAL fluid and cell cultures using either ELISA kits or BD cytometric 
bead array (CBA) Flex-set kits (BD Biosciences) followed by flow cytometry measurement on a FACS 
Canto II (BD Biosciences). The chemokine CCL2 was also measured using a CBA Flex-set kit. 
statistical analysis
Statistical analysis was performed with GraphPad Prism (version 7.02) using unpaired t-test for 
comparison of 2 groups, one-way ANOVA for comparison of more than two groups, and two-way 
ANOVA for comparison of more than two groups while correcting for a batch effect between different 
experiments. All data are presented as mean ± standard error of the mean (SEM). P-values < 0.05 were 
considered statistically significant. 
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figure s1. (a) Eggs were isolated from the liver of infected hamsters, washed extensively and either separated into 
immature and mature eggs following by culture, or frozen at -80°C prior to culture. Freshly isolated and freeze-
thawed eggs were cultured at a density of 200.000 eggs/mL in medium for 48h before egg-free culture supernatant 
was collected and subjected to silver staining. (b) Total number of cells, percentage of eosinophils and total number 
of eosinophils in lung tissue  as assessed by FACS. Representative of 2 experiments, n=4-6.  (c) FACS gating strategy 
for the analysis of cells in BAL fluid. All single cells were gated for the identification of eosinophils (SiglecF+ CD11c-), 
alveolar macrophages (alvMFs; SiglecF+ CD11c+), neutrophils (SiglecF- CD11c- CD11b+ Gr-1+) and DCs (SiglecF- CD11c+ 
MHCII+). A lymphocyte gate was used to identify T cells (CD3+ B220-) and B cells (CD3- B220+). 
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figure s2. Cytokine concentration in medLN cell supernatants after 4d re-stimulation with SEA (10µg/mL), n=5. 
Significant differences were determined by one-way ANOVA following Dunnett’s multiple comparisons test and are 
indicated with *** p < 0.001.
figure s3. (a) Mice were treated with anti-CD25 depleting antibody (clone PC61) as described in Figure 4. Five days 
after the first antibody injection, tail blood was collected and the percentage of Foxp3+ Treg cells of all CD4 T cells 
and of all cells assessed by FACS. Representative of two experiments, n=6. Significant differences were determined 
by one-way ANOVA following Dunnett’s multiple comparisons test and are indicated with *** p < 0.001. (b) FACS 
gating strategy for the analysis of Treg cells. Treg cells were identified as single, live CD3+ CD4+ Foxp3+ CD25+ cells. 




figure s4. Cytokine concentration in BAL fluid measured by ELISA, n=3-6. Significant differences were determined 
by one-way ANOVA following Dunnett’s multiple comparisons test and are indicated with * p < 0.05, ** p < 0.01. 
figure s5. FACS gating strategy for the analysis of DC subsets in lung tissue. Single, live cells were identified, and all 
SiglecF, CD3, CD19, NK1.1 and Gr-1 expressing cells excluded. DCs were identified as CD11c+ MHCII+, and subdivided 






what was already Known 
Helminths, being well-known inducers of type 2 immune responses, also promote immune regulatory 
networks. The resulting immune modulation conveys ‘spill-over’ suppression to hyper-inflammatory 
conditions such as allergy 1. 
Schistosomes, which establish chronic infection in both humans and mice, have been widely used 
to dissect the mechanisms underlying the development and activation of regulatory B (Breg) cells, 
a prominent member of the immune regulatory network. It is widely recognized that Breg cells are 
induced by schistosomes in both humans and mice 2, 3. Breg cells comprise a heterogeneous group of 
cells of different cellular origin as well as phenotypical and functional characteristics. Multiple stimuli 
are known to contribute to Breg cell activation, of which most-well described are signalling via the B 
cell receptor (BCR), CD40 and Toll-like receptors (TLRs). Schistosome antigens have been described to 
induce Breg cells 4-6, but the molecular identity of the stimulus and the signalling pathways engaged 
remain to be characterized.
Hyper-inflammatory conditions such as allergy are less common in helminth-endemic areas. This 
relationship has both been studied in humans and in animal models. Human studies have yielded 
heterogeneous results over the years 7, suggesting that many factors including helminth species, time, 
location, intensity and chronicity of infection as well as host genetics influence helminth-mediated 
immunomodulation. Advances in understanding helminth-mediated protection from allergy have been 
made in animal models, where antigen mixtures and single molecules have been shown to protect from 
experimental allergic airway inflammation (AAI) in the absence of infection. A range of mechanisms 
mediating protection have been described, including the induction of various components of 
the immune regulatory network and suppression of pro-inflammatory responses 8. The description of 
single, schistosome-derived molecules that mediate protection against AAI are however limited.
how dId our studIes advance the fIeld
molecular signals for schistosome-induced breg cell development
Although Breg cells have been most well-characterized in the murine spleen, B cells with regulatory 
properties can also be found at other sites. We show that B cells with regulatory properties, protecting 
mice from AAI, can be found in the lung of chronically S. mansoni-infected mice (chapter 2). While we 
and others have previously shown that S. mansoni-induced splenic Breg cells exert their suppressive 
function through interleukin (IL)-10 production and induction of regulatory T (Treg) cells 2, 4, we found 
these schistosome-induced pulmonary B cells to be phenotypically different from splenic Breg cells 
and to suppress in an IL-10- and Treg cell-independent manner, rather displaying a reduced T helper 
2 (Th2)-driving function. This study suggests that B cells with inhibitory properties exist at the site of 
inflammation, which are phenotypically and functionally different from ‘classical’ Breg cell subsets 
described in the spleen. Our study contributes to the body of evidence that Breg cells reside not 
only in lymphoid organs, but can also be found at other sites including human adipose tissue 9 and 
nasal polyps 10. 
While it is well-established that helminths induce Breg cells, no single helminth-derived molecule 
had been described that mediates this effect. We show that the egg glycoprotein IPSE/alpha-1 
induces splenic Breg cells in vitro, as assessed by IL-10 production and Treg cell induction, following 
direct interaction (chapter 3). Importantly, SEA depleted of IPSE/alpha-1 is also capable of Breg cell 
induction, highlighting that there are other, yet unidentified factors in SEA that induce Breg cells. We 
found IPSE/alpha-1 to also induce IL-10 production in human CD1d+ B cells, thus identifying IPSE/
alpha-1 as the first helminth molecule with direct Breg cell-inducing capacity in both mice and humans. 




the molecule, as previously described for the S. mansoni egg glycoprotein omega-1 (ω-1) 11, is an 
important point of departure for further investigations into the therapeutic potential of this molecule.
We could identify IPSE/alpha-1, previously mainly recognized for its capacity to activate 
basophils 12, 13, as one Breg cell-inducing factor within SEA in vitro, but in vivo multiple signals likely 
synergize to induce Breg cells. To study the molecular signals required for Breg cell induction in 
schistosomiasis more globally, we analysed the transcriptome of splenic MZ and FO B cells from 
chronically S. mansoni infected mice (chapter 4). We found marginal zone (MZ) and follicular (FO) B 
cells to display clearly distinct transcriptional profiles, both at steady-state and after infection. Both cell 
types moreover clearly responded to infection. We analysed genes, pathways and upstream regulators 
that are more unique to one B cell subset or the other, and identified interesting leads for further 
investigation. Amongst those, the cytokines IL-1β and IL-6, as well as members of the type I interferon 
(IFN-I) family, seem to preferentially activate MZ B cells, which is interesting as initial observations in 
the literature suggest their involvement in Breg cell induction 14, 15. Furthermore, our data suggest TLR7 
and TLR9 as upstream regulators that are more active in MZ than FO B cells, which also aligns with 
the literature 16, 17 and overall suggests the involvement of several innate signals in MZ B cell activation.
As IFN-I have been suggested as one upstream regulator of the transcriptional changes that MZ 
B cells undergo in S. mansoni infection, we further investigated whether IFN-I also provide signals for 
Breg cell induction in the context of S. mansoni (chapter 5). Schistosomes 18, 19 and other helminths 20, 21 
induce IFN-I, and a recent report shows that IFN-I provide signals for the induction of human Breg 
cells 15. We found Breg cell IL-10 production in response to S. mansoni antigens to be enhanced by 
IFN-I in vitro, but not in vivo. Stimulation with S. mansoni-derived antigens might provide a pre-
activation signal in vitro, but the identification of optimal conditions for Breg cell expansion in vivo 
warrants further investigation.
In conclusion, our studies contribute to the understanding of how Breg cells develop and are 
activated in response to S. mansoni. S. mansoni actively secretes molecules to target host immunity, 
including molecules that directly bind and induce Breg cells such as IPSE/alpha-1. In vivo, multiple 
signals synergize leading to optimal Breg cell induction and activation, which seem to be a combination 
of both helminth-derived and host-derived factors. The further identification of such factors, their 
synergistic effects and the role of tissue-specific niches warrants further investigation.
Identification of single, schistosome-derived molecules for the inhibition of aaI
As discussed in the 2014 review (chapter 6), various helminths and helminth-derived molecules have 
been described to modulate allergic disease, and a range of different mechanisms of suppression have 
been suggested. However, the role of schistosome eggs in AAI protection was not well defined and 
hardly any protective, single molecules had been described. We subsequently showed that isolated 
S. mansoni eggs, in the absence of infection, protect from AAI when administered during the allergic 
sensitization phase (chapter 7). In contrast to several other studies that previously reported helminth- 
and, more specifically, Schistosoma spp.-mediated protection to be dependent on Treg and/or 
Breg cells, we still observed protection in the absence of Treg and B cells, respectively. Interestingly, 
protection from the allergic type 2 response occurred despite a strong antigen-specific type 2 response 
to the eggs. We could reproduce the protective effect of eggs on AAI by treatment with a plant-derived, 
recombinant version of the single, egg-derived glycoprotein ω-1, for which no such role had been 
described before. As for S. mansoni eggs, protection by ω-1 also seemed independent of regulatory 
lymphocytes and occured despite a strong antigen-specific Th2 response. Protein mutants lacking T2 
RNase activity and protein variants with modified glycosylation pattern will help to further assess e.g. 
the importance of the ribonuclease activity of ω-1 and consequently the (partial) breakdown of mRNA 22 
in mediating protection. Moreover, tracking experiments as well as mouse lines with mutation in ω-1-
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binding receptors mannose receptor (MR) and SIGN-R1 will help to understand which tissues and cells 
take up ω-1, potentially allowing further insight into the mechanism of protection.
Collectively, our work on the protection from AAI by schistosome-derived eggs or single molecules 
has contributed to revealing the diversity in mechanisms involved in mediating bystander suppression 
in hyper-inflammatory settings such as allergic asthma. This adds to the expanding realization that 
helminths have developed various mechanisms of modulating host immunity which go beyond 
the development of regulatory lymphocytes.
dIrectIon for future research
molecular signals for schistosome-induced breg cell development
It is currently unclear whether Breg cells develop from a committed precursor, or whether any B cell 
can acquire suppressive capacity in response to environmental stimuli. It becomes more and more 
clear that B cells at different stages of maturation and differentiation (from transitional B cells 23, 24 to 
plasma cells 25-27), and B cells at different sites (from secondary lymphoid organs 28, 29) to the peritoneal 
cavity 30 and the lung 31 in mice, and in human adipose tissue 9 and nasal polyps 10) possess suppressive 
capacities, which argues against a committed precursor. Most recently, natural regulatory plasma cells 
have been identified that develop at steady-state and respond by IL-10 production within hours of 
stimulation 27. 
Breg cells comprise a heterogeneous group of cells that lack a specific marker. The markers 
currently used to identify Breg cells are likely not specific enough to selectively target them in cellular 
immunotherapy. Novel technologies such as mass cytometry will allow a better characterization of 
Breg cell heterogeneity in both animal models and humans, similarly to studies already performed for 
Treg cells 32.
Breg cell activation in vivo is more complex than the in vitro Breg cell-activating stimuli which have 
been extensively studied. A variety of receptors including BCR, CD40 and TLRs have been described to 
be involved in Breg cell activation in different models both in vitro and in vivo. While an inflammatory 
environment seems a shared feature between all models and central to Breg cell induction, it has been 
suggested that different Breg cell subsets require different additional stimuli for their development 
and activation. Innate-like Breg cells may require the ligation of TLRs, while other Bregs especially 
in autoimmunity seem to require BCR and CD40 ligation 33. Work from us and others suggests that 
Breg cells induced during infection - and in particular during schistosome infections - might be of 
the innate-like type that develop in response to inflammatory cytokines and TLR ligation. 
With respect to stimuli that might contribute to Breg cell activation in vivo, the gut microbiome 
is of particular interest. A recent study shows changes in the gut microbiome following 
S. mansoni infection 34. Some studies moreover suggest that gut microbiota can support Breg cell 
induction 14, 35, 36, whereas others describe the development of regulatory plasma cells to be microbiota-
independent 27. Although changes in the composition of the lung microbiome have both been shown 
to promote airway disease 37 and to induce Treg cells that can suppress AAI 38, the influence of the lung 
microbiota on local B cells has so far not been addressed. It will be of special interest to further define 
whether and how changes in microbiome composition, and the subsequent interaction with the host 
immune system, contribute to Breg cell induction.
The importance of Breg cell antigen-specificity for maximal and focussed suppressive function, 
or for minimizing side effects due to non-specific immune suppression, needs to be addressed in 
more detail. It is clear from animal models that BCR signalling is one of the critical stimuli for Breg cell 
development at least in models of autoimmunity, as mice with a BCR fixed for a non-relevant antigen 
or with impaired BCR signalling harbour less Breg cells and cope less well with EAE 39, 40. However, 




affinity BCR ligation induces regulatory properties rather than the strong signal provided by anti-IgM. 
Whereas the importance of B cell specificity in autoimmune models has been acknowledged, the nature 
of the antigen(s) remains to be defined. Interestingly, the frequency of IL-10- and IgG4-producing Breg 
cells specific for the bee venom allergen phospholipase A2 (PLA) was increased in patients allergic 
to bee venom after successful allergen immunotherapy, and reached levels comparable to tolerant 
beekeepers, whereas B cells not specific for PLA produced only little IL-10 and IgG4 and did not 
respond to allergen immunotherapy 42. In this study, B cells specific for a defined antigen are the ones 
to acquire regulatory properties. In helminth infection, the importance of antigen-specificity for Breg 
cell development is less defined. 
Helminths release a multitude of antigens, which can potentially activate B cells through the BCR 
and innate receptors like TLRs simultaneously. While signalling through TLRs has been repeatedly 
reported to induce Breg cells in helminth infection, the relative contribution of BCR signalling should 
be further defined by using e.g. mouse models with fixed BCRs as done in the field of autoimmunity. 
In addition, studies on Breg cell antigen-specificity are possibly hampered by technical challenges, 
such as low abundance of these cells and the co-staining of other, non-specific B cells with labelled 
antigens. This could potentially be overcome in the future through advancements in the field of single 
cell analysis.
It is furthermore not well understood whether Breg cells acquire suppressive capacity in a tissue-
dependent manner, and what their migration pattern is. Many studies assess splenic Breg cells after 
intraperitoneal injection of a stimulus, which does not resemble the physiological situation well. 
Studying Breg cells at the site of inflammation and/or tracking B cell residency and migration would 
help to understand the role of the tissue micro-environment in Breg cell development and activation. 
Interestingly, it has been shown that tumour-infiltrating B cells acquire suppressive capacity upon 
exposure to metabolites of the 5-lipoxygenase pathway and growth factors in the tumour micro-
environment 43, 44, suggesting an important role of local signals for Breg cells. Lipoxygenase derivatives 
were found in the lipidome of several S. mansoni life-cycle stages 45, and it would be interesting to 
further investigate those in the context of Breg cell induction during schistosome infections. 
In view of potential therapeutic applications of Breg cells in conditions such as allergy and 
autoimmunity, it is important to identify conditions for optimal Breg cell activation and to study if 
suppression by Breg cells is a lasting phenotype, or whether these cells require frequent (re)stimulation 
to exert their function. To this end, the study of Breg cells should always include the characterization 
of their suppressive capacity e.g. by adoptive transfer into animal models of allergy or autoimmunity. 
This might pose challenges as active suppression via IL-10 is likely a transient feature, with recent cell 
activation necessary for active cytokine secretion 46. In addition, proof of suppressive capacity might be 
more challenging to confirm in humans as it largely relies on in vitro assays 47, 48 that only yield limited 
information about in vivo suppressive capacity.  
B cells are important therapeutic targets in many diseases with an immune component, including 
autoimmunity and cancer. Most prominently, B-cell depletion by anti-CD20 monoclonal antibody 
(rituximab) has been approved for the treatment of certain forms of leukaemia and rheumatoid 
arthritis (RA), and is under investigation for e.g. treatment of multiple sclerosis (MS) 49. Treatment 
with anti-CD20 affects the balance of CD20-expressing and non-expressing B cells. It preferentially 
leaves immature, transitional B cells - a population that contains progenitor Breg cells 50, 51 - intact, 
thus targeting the Breg cell compartment indirectly. Another monoclonal antibody that, in addition 
to inhibiting pro-inflammatory B cells, might affect the Breg cell compartment is an IL-6R antagonist 
(tocilizumab), which has been shown to increase the TGF-β expression of CD25+ Breg cells when used 
in RA patients 52. Finally, IFNβ therapy commonly applied in patients with certain types of MS increases 
IL-10 production not only by monocytes and T cells 53, 54, but also by B cells and plasmablasts 55, 56. 
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None of these treatments have been developed to directly target Breg cells and the results are merely 
off-target effects. Proof-of-concept studies in mice have shown that suppressive Breg cells can be 
expanded, either in vivo by agonistic anti-CD40 antibody 23, or ex vivo by stimulation with CD40L, IL-4 
and IL-21 57. More research is however necessary to understand the conditions that lead to optimal 
Breg cell activation and targeted suppressive function especially in vivo before novel therapies based 
on Breg cells can be developed. 
With respect to applying treatment that targets the Breg cell compartment in allergy or asthma, 
any such treatment would have to be advantageous, meaning be of higher efficacy or lower side 
effects, compared to the currently applied options including anti-IgE therapy and allergen-specific 
immunotherapy. Anti-IgE treatment targets IgE produced by pro-allergic B cells as one of the central 
players in allergy and asthma, but is only short-lived 58. Allergen-specific immunotherapy (AIT) aims to 
restore tolerance to the allergen by shifting the Th2 and IgE-dominated response to a more balanced 
one including IgG4 isotype switch and regulatory cells like Treg and Breg cells, achieving more long-
lasting effects 59, 60. Drawbacks of AIT are that it takes 3-5 year before AIT treatment reaches its full 
beneficial effect, and that this curative effect gradually declines over time 61. Furthermore, the question 
remains how much of the symptom suppression is dependent on the induction of a long-lasting pool 
of (memory) Breg cells. Nevertheless, an interesting strategy could be to develop a new generation 
of allergen immunotherapeutics including an (helminth-derived) adjuvant component that specifically 
boosts the Breg cell compartment to perhaps shorten treatment time and increase the timespan of 
the curative effect. 
Identification of single, schistosome-derived molecules for the inhibition of aaI
Although some of the clinical trials using Trichuris suis eggs (TSO) to treat patients with allergic 
and autoimmune conditions initially showed promising results, the progress in the field has slowed 
down in recent years. Larger trials have failed to confirm the early results, and efforts to use live 
infections as treatment strategies have diminished. Single, well-defined helminth-derived molecules 
circumvent the risks that full infections bear and are therefore advantageous. The identification of such 
immunomodulatory candidate molecules benefits from systemic approaches using computational 
tools and screening in high-throughput assays, such as already applied for the excretory-secretory 
products of H. polygyrus and S. mansoni adult worms 62-64. The search for candidate molecules can by 
guided by the immunological activity of parasite-derived antigen mixtures such as excretory-secretory 
products, followed by molecule identification using e.g. fractionation, screening assays or proteomics 
approaches. Additionally, molecules of interest can also be identified  in the absence of data from 
antigen mixtures, by e.g. identifying cytokine and chemokine homologues or family member of proteins 
already known to be of interest, such as proteases and protease inhibitors, members of the venom-
allergen-like (VAL) family and lectins 65-68. Notably, potential immunomodulatory molecules do not only 
include (glyco)proteins, but also lipids 69, 70, short chain fatty acids 71, and exosomes containing proteins, 
lipids and nucleic acids 72-74. 
A growing body of literature shows that helminths including S. mansoni modulate allergic asthma via 
various mechanisms that are not limited to the induction of regulatory lymphocytes 75. Bioinformatics-
guided approaches such as dual transcriptomics and genomics databases such as WormBase ParaSite 
will not only aid the identification of immunomodulatory candidate molecules, but can also support 
the prediction of functional characteristics, interactions with host immunity and ultimately the putative 
mechanisms of action based on the presence of known homologues, predicted folding structures and 




Helminth parasites do not only directly interact with host immune cells to modulate immune 
responses, but also do so indirectly by their effect on the intestinal microbiome. Rodent intestinal 
nematodes have been shown to change the microbiome composition and thereby reduce AAI severity, 
or confer protection to respiratory syncytial virus (RSV) infection 20, 81, 82. Whether helminths, and in 
particular Schistosoma spp. residing in the vasculature, alter the intestinal microbiome in humans, 
e.g. by the release of eggs in the intestinal lumen, is currently less well understood as studies come to 
conflicting conclusions 34, 83-86. Future studies should therefore address the role of the microbiome in 
Breg cell induction in more detail.
Studies investigating the role of single, helminth-derived molecules are often limited by 
the amount and purity of the natural, isolated protein, and heterologous expression systems often lead 
to unintended alterations in the glycan composition. The development of a plant-derived expression 
system for schistosome molecules allows to produce large amounts of recombinant, helminth-
glycosylated proteins 11, and the generation of protein mutants and variants with altered glycosylation 
will help to understand the role of protein activity and glycosylation pattern in protection. 
There are multiple factors that might explain the mixed results obtained in clinical trials so far, 
and that thus are crucial points of consideration for the development of helminth-based therapies 
in the future, such as the timing, intensity/dose and localization of helminth infection or exposure to 
helminth-derived products. The body of evidence from studies in both animal models and humans 
suggest that, while exposure to helminths is able to prevent disease onset, treatment of established 
allergic disease is much harder to achieve. The importance of early-life exposure to microbial agents is 
supported by studies showing that growing up in a traditional farming environment with exposure to 
certain bacteria and fungi 87, 88 as well as unprocessed farm milk 89 protects against allergies and asthma. 
These studies suggest that stimuli shaping the immature immune system are critical for the protection 
against allergy and asthma later in life, and that in consequence also helminth-based therapies might 
have the most impact at a stage where the immune system can still be shaped. Supporting evidence also 
comes from studies on the impact of maternal helminth exposure on the offspring’s susceptibility to 
allergy and asthma 90, 91. As a prophylactic application of helminth-based therapies to the general public 
is likely not feasible and bears risks of side effects, such approach would require the identification of 
people at risk of developing allergy or asthma later in life, e.g. because of their genetic pre-disposition 
or aberrant immune reactions to allergens.
Most clinical trials so far have assessed helminth infections or their products that are restricted 
to the intestine, such as T. suis OVA. While intestinal exposure might be sufficient to alleviate local 
inflammation such as observed in inflammatory bowel disease, it might prove insufficient to induce 
systemic immunomodulation and suppress inflammation at distal sites such as the lung. With 
respect to treatment based on helminth-derived molecules, the choice of administration route could 
potentially overcome questions of local versus systemic exposure. Regarding the dose of treatment, 
animal studies naturally use higher infection or molecule doses than found in humans, where strict 
ethical regulations require dose escalation studies to determine that maximum tolerated dose and to 
minimize side effects 92. The intraperitoneal administration of large doses of compound as employed in 
the majority of animal studies, in which the principles guiding human clinical trials are rarely applied, 
therefore provide only very limited guidance for translation into the human situation. Furthermore, 
once immunomodulatory candidate molecules are identified, it has to be assessed whether they can 
directly be applied in humans or whether alternative strategies are needed. For example, reproduction 
by small molecules or modified molecules that contain only the active motifs needed for interaction 
with host cells 93, 94 might be warranted to minimize side effects due to high immunogenicity of 
foreign, parasite-derived proteins in the human host. It however remains to be established whether 
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immunogenicity is a concern, as there are examples of pathogen-derived molecules where this is 
not the case. The hookworm molecule AIP-2 is an example of a helminth product that is minimally 
immunogenic in mice 95, and the bacteria-derived product streptokinase has been successfully used in 
humans despite its immunogenicity 96.
Additional efforts to fully understand the multiple variables at interplay that determine the effect of 
helminth infections and helminth-derived products on hyper-inflammatory conditions such as allergy 
may provide valuable leads for the development of novel pharmaceutical agents for the treatment of 
allergic disorders.
concludInG remarKs
The human immune system successfully distinguishes between benign and harmful agents, and 
mounts the appropriate response, in the majority of cases. It is however not without error, as apparent 
from e.g. allergic and autoimmune disorders. The rapid pace at which our living environments change, 
faster than any evolutionary adaptation can take place, poses challenges for the immune system. 
A deeper understanding of fundamental immunological processes, including immunomodulation such 
as induced by parasitic agents, might open up opportunities to develop novel treatment options based 
on targeted intervention in immune processes. 
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The immune system is our body’s defence, protecting us from potentially harmful pathogens such 
as bacteria, viruses and parasites. It thereby has to differentiate between different microorganisms 
that can cause disease and should be expelled, and harmless substances that also enter the body 
but are not dangerous, such as food we eat or substances in the air we breathe. The immune system 
has developed a range of different responses, and most of the time mounts the appropriate reaction. 
Sometimes however, it fails to clear pathogens before they can do harm to the body, or it overreacts 
to harmless substances like pollen in the air or even or own body, causing e.g. asthma or autoimmune 
diseases. Asthma is a chronic inflammatory disease of the lung, which in characterized by symptoms 
such as breathlessness, chest tightness and wheezing. Allergic asthma, a common form of asthma 
and subject of this thesis, is caused by a reaction of the immune system to certain inhaled substances 
(allergens) such as dust mite or pollen.
The parasitic worm Schistosoma (commonly known as bilharzia), is a flatworm which can be 
found in freshwater snails and penetrates the host through the skin. Adult worms live and mate in 
the blood vessels of the intestine or bladder. There they lay eggs that are excreted with the faeces or 
urine. Worm parasites including Schistosoma are a unique class of parasites, as they usually remain 
in the human body for extended periods of time. These chronic infections do not only have adverse 
effects for the human host, but can in certain circumstances also be beneficial. Worms down-modulate 
the host immune response to promote their own survival, thereby providing protective effects 
against a spectrum of diseases with an overactive immune system, such as aforementioned asthma 
and autoimmune diseases. Worm parasites modify various aspects of the immune system, including 
the promotion of immune cells that act tolerogenic, such as regulatory B cells. While ‘normal’ B cells 
produce antibodies and protect us from invading microorganisms, regulatory B cells are immune cells 
that help to down-modulate the immune system when it is too active. A better understanding of 
how these cells get activated and how they work might enable us to make use of these cells for 
the treatment of e.g. asthma and autoimmune diseases. 
research conducted in this thesis
The first part of this thesis focusses on the role of regulatory B cells in protection from allergic asthma 
by chronic S. mansoni infections, as well as on the identification of molecular signals required for 
schistosome-induced development of regulatory B cells.
Chronic S. mansoni infection induces regulatory B cells both in the spleen and the lung. While 
splenic B cells are known to protect from allergic asthma by producing the immunomodulatory 
molecule interleukin (IL)-10, lung B cells act independent of IL-10. We further characterized these lung 
B cells with regulatory properties and show that they are phenotypically and functionally different 
from classical regulatory B cells in the spleen (chapter 2). This work therefore suggests the presence of 
distinct regulatory B cell subsets, even if induced by the same type of worm parasite. 
Chronic S. mansoni infections are known to induce regulatory B cells. Single molecules that are 
produced and secreted by the worm to influence surrounding immune cells and mediate this protective 
effect had however not been identified yet. Moreover, the cellular mechanisms driving regulatory B 
cell development remained to be defined. We showed that a subset of B cells in the spleen, which 
preferentially develop into regulatory B cells, directly bound molecules released by the worm. No 
neighboring cells were necessary for these B cells to respond to the worm molecules. We could also 
identify a single worm protein, called IPSE/alpha-1, that can induce IL-10 production, both in B cells 
of mice and humans. We moreover found evidence that there are additional molecules which can also 
have this effect (chapter 3). 
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The induction of regulatory B cells by a chronic S. mansoni infection can thus also be achieved 
by a single worm molecule such as IPSE/alpha-1. This induction of regulatory B cells by isolated 
molecules is however less strong compared to the full infection, which suggests that there are several 
components working together in the case of an infection. To identify more signals and processes that 
contribute to the induction of regulatory B cells in an infected host, we compared which genes are 
expressed in the different B cell subsets from chronically S. mansoni-infected mice. We could identify 
several interesting signals and processes that seem more important for one of the B cell subsets than 
the other and might therefore play a role in the development of regulatory B cells. Amongst those 
were members of the type I interferon cytokine family, but also several elements of the innate immune 
system (chapter 4). 
Type I interferons were thus suggested to be preferentially important for the activation of regulatory 
B cells in chronic S. mansoni infection. It had also been reported that different worms can trigger 
the production of these type I interferons, and that they are important in the activation of regulatory 
B cells in humans. We therefore further investigated whether type I interferons also provide signals 
for the induction of regulatory B cells in the context of S. mansoni. We found that type I interferons 
enhance regulatory B cell IL-10 production in response to S. mansoni molecules in a culture plate, but 
that they are not important in the body (chapter 5). Further research is therefore needed to identify 
the conditions that do lead to an optimal development and activation of regulatory B cells, and to 
better understand which role type I interferons play in parasitic worm infection. 
The second part of this thesis focuses on the identification of S. mansoni-derived molecules 
that are protective in experimental models of allergic asthma. chapter 6 summarizes and discusses 
the scientific literature with respect to earlier findings for worm-induced protection from allergic asthma 
and the mechanisms of protection. In addition, studies are described that have identified protective 
worm molecules as well as their implications for the development of novel treatment strategies for 
allergic asthma. 
Chronic S. mansoni infection had been shown to protect from allergic asthma in animal models, 
and infected humans are less likely to have allergies or asthma. We could show that isolated S. mansoni 
eggs, in the absence of infection, protect from experimental allergic asthma when administered to 
mice before they are exposed to allergenic substances for the first time. We could also reproduce 
the protective effect of eggs on allergic asthma in mice by a similar treatment with the worm-derived 
protein omega-1, for which no such role had been described before (chapter 7).
In conclusion, the work presented in this thesis shows that both the induction of regulatory B 
cells, as well as the protection from allergic asthma by a chronic worm infection can also be achieved 
by single molecules isolated from the worm. This work however also shows that immunological 
processes in response to a chronic worm infection are complex and often act in synergy. This thesis 
contributes to the understanding of how regulatory B cells are induced, and how molecules secreted by 
the parasite provide protection against allergic asthma. A deeper understanding of these fundamental 
immunological processes is necessary and will open up opportunities to develop new treatment 





Continu krijgen we allerlei stoffen en microben binnen via bijvoorbeeld het voedsel dat we eten of 
de lucht die we inademen. Ons afweersysteem beschermt ons lichaam tegen mogelijk schadelijke stoffen 
of ziekteverwekkers zoals bacteriën, virussen en parasieten. Om dit te kunnen bewerkstelligen heeft 
het afweersysteem verschillende strategieën ontwikkeld om onderscheid te maken tussen schadelijke 
deeltjes, die ziekten veroorzaken, en onschadelijke deeltjes en goede bacteriën. Meestal kiest het 
afweersysteem de juiste respons. Soms slaagt het er echter niet in om ziekteverwekkers te elimineren 
voordat ze schade aan het lichaam kunnen toebrengen, of reageert het juist te heftig op onschadelijke 
stoffen of zelfs op het eigen lichaam. Hierdoor kunnen bijvoorbeeld astma of auto-immuunziekten 
ontstaan. Astma is een chronische ontsteking van de longen, waarbij klachten zoals benauwdheid 
en een piepende ademhaling voorkomen. Allergisch astma, een veel voorkomende vorm van astma 
en onderwerp van dit proefschrift, wordt veroorzaakt door een reactie van het afweersysteem tegen 
bepaalde ingeademde stoffen (allergenen) zoals uitwerpselen van de huisstofmijt of stuifmeelkorrels. 
Schistosoma (in de volksmond bekend als bilharzia), is een parasitaire platworm die in 
zoetwaterslakken te vinden is en waarvan de larven de gastheer via de huid binnendringen. 
De volwassen wormen leven en paren in het bloedvatenbed van de darm of blaas. Hier leggen zij 
vervolgens tientallen eieren per dag die uitgescheiden worden via de feces of urine. Wormen zoals 
Schistosoma zijn unieke parasieten omdat ze een zeer lange tijd in het menselijk lichaam kunnen 
verblijven. Deze langdurige infecties hebben echter niet alleen nadelige effecten voor de menselijke 
gastheer, maar kunnen soms ook juist een gunstige werking hebben. Wormen onderdrukken namelijk 
de afweerreacties van de gastheer om hun eigen overleving te veilig te stellen. En passant worden 
ook andere afweerreacties onderdrukt waardoor bescherming wordt geboden tegen een spectrum 
van ziekten veroorzaakt door een overactief afweersysteem. Hieronder vallen de hierboven genoemde 
astma en auto-immuunziekten. Parasitaire wormen beïnvloeden het afweersysteem op verschillende 
manieren, waaronder de aanmaak van afweercellen die tolerantie opwekken, zoals regulatoire B cellen. 
Terwijl ‘normale’ B-cellen antilichamen produceren en ons tegen binnendringende micro-organismen 
beschermen, onderdrukken regulatoire B cellen het afweersysteem. Een beter begrip van de activatie en 
functie van deze cellen kan helpen om de behandeling van bijvoorbeeld astma en auto-immuunziektes 
te optimaliseren.
onderzoek in dit proefschrift
Het eerste deel van dit proefschrift richt zich op de rol van regulatoire B cellen in de bescherming 
tegen allergisch astma tijdens chronische Schistosoma mansoni infecties. Tevens wordt geprobeerd 
de signalen en moleculen afkomstig van de schistosoma worm parasieten te ontrafelen die 
de ontwikkeling van regulatoire B cellen verder aansturen.
Een chronische infecties met S. mansoni bevordert de aanmaak van regulatoire B cellen zowel in 
de milt als in de longen. B cellen uit de milt onderdrukken de ontwikkeling van allergisch astma door 
het uitscheiden van het tolerantie-opwekkend molecuul interleukine (IL)-10, terwijl B cellen uit de long 
dit onafhankelijk van IL-10 lijken te doen. Wij hebben de eigenschappen van deze long B cellen verder 
gekarakteriseerd en vonden dat zij zowel qua uiterlijke kenmerken als in hun afweer onderdrukkende 
werking verschillend zijn van de klassieke regulatoire B cellen uit de milt (hoofdstuk 2). Dit werk toont 
het bestaan aan van verschillende typen regulatoire B cellen die opgewekt kunnen worden door een 
en dezelfde parasiet.
Hoewel bekend is dat chronische S. mansoni infecties regulatoire B cellen opwekken, zijn de worm-
specifieke moleculen die dit beschermende effect kunnen bewerkstellingen nog niet geïdentificeerd. 
Bovendien is het niet bekend in hoeverre andere cellen betrokken zijn bij de ontwikkeling van 
regulatoire B cellen. Wij tonen aan dat de ontwikkeling van regulatoire B cellen in de milt tot stand 
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komt door direct contact met moleculen die door wormeieren worden uitgescheiden. Wij hebben 
geen betrokkenheid van andere afweercellen kunnen vinden, die nodig zijn om op de wormmoleculen 
te kunnen reageren. Tevens hebben we één worm-specifiek eiwit, IPSE/alpha-1, geïdentificeerd dat 
kan aanzetten tot de productie van het kenmerkende IL-10 in B cellen afkomstig van zowel muizen als 
mensen. We hebben ook aanwijzingen dat er nog meer moleculen zijn die dit kunnen (hoofdstuk 3).
De aanmaak van regulatoire B cellen wordt dus niet alleen tijdens een chronische worminfectie 
aangedreven, maar kan ook tot stand komen door één enkel molecuul zoals bijvoorbeeld IPSE/
alpha-1. De ontwikkeling van regulatoire B cellen als reactie op geïsoleerde wormmoleculen is 
echter minder sterk in vergelijking met die als reactie op een volledige infectie. Om de bijdrage van 
verschillende signalen en routes in de aanzet van regulatoire B cellen te onderzoeken, hebben wij 
de genen in kaart gebracht die tot expressie komen in de verschillende typen B cellen van muizen met 
een chronisch S. mansoni infectie. Wij laten zien dat de ontwikkeling van regulatoire B cellen wordt 
gedreven door verschillende categorieën genen. Wij vonden aanwijzingen voor de betrokkenheid van 
de type I interferon-cytokinefamilie evenals bepaalde elementen van het aangeboren afweersysteem 
(hoofdstuk 4).
In navolging van de bevindingen in hoofdstuk 4 onderzochten wij de relatieve bijdrage van type 
I interferonen in de activering en aanmaak van regulatoire B cellen tijdens een chronische S. mansoni 
infectie. Eerder onderzoek heeft aangetoond dat verschillende typen wormen de productie van deze 
type I-interferonen in gang kunnen zetten en dat ze belangrijk zijn voor de aanzet van menselijke 
regulatoire B cellen. Wij laten zien dat de aanwezigheid van type I interferonen de IL-10 productie 
door regulatoire B cellen als reactie op moleculen van S. mansoni wormen verbetert, wanneer dit 
wordt getest met behulp van celkweken.  Echter, in muizenstudies lijkt het vooralsnog geen belangrijke 
bijdrage te leveren (hoofdstuk 5). Verder onderzoek is daarom nodig om de exacte omstandigheden 
te identificeren die leiden tot een optimale ontwikkeling en activering van regulatoire B cellen in 
het lichaam. 
Het is bekend dat chronische S. mansoni infecties kunnen beschermen tegen allergisch astma in 
proefdiermodellen en dat ook geïnfecteerde mensen minder kans op het ontwikkelen van allergieën 
of astma lijken te hebben. Het tweede deel van dit proefschrift richt zich op de rol van moleculen 
afkomstig van S. mansoni wormen die bescherming bieden tegen de ontwikkeling van allergisch 
astma in proefdiermodellen. hoofdstuk 6 is een samenvatting en discussie van de wetenschappelijke 
literatuur met betrekking tot worm-gerelateerde bescherming tegen allergisch astma, met in het 
bijzonder de hierbij betrokken beschermingsmechanismen. Daarnaast worden studies beschreven 
die beschermende wormmoleculen hebben geïdentificeerd, evenals de rol van deze moleculen in 
de ontwikkeling van nieuwe behandelstrategieën voor allergisch astma.
In hoofdstuk 7 tonen wij aan dat geïsoleerde eieren van S. mansoni, bij afwezigheid van een 
natuurlijke infectie met wormen, beschermen tegen de ontwikkeling van allergisch astma wanneer zij 
worden toegediend voorafgaand aan de blootstelling aan allergische stoffen. Daarnaast laten wij zien 
dat een vergelijkbaar beschermend effect bereikt kan worden door de behandeling met alleen het eiwit 
omega-1. Dit eiwit wordt uitgescheiden door eieren van S. mansoni. Een dergelijke rol voor omega-1 
is nog niet eerder beschreven.
Concluderend laat het werk in dit proefschrift zien dat zowel de aanmaak van regulatoire B 
cellen als de bescherming tegen allergische astma door een chronische worminfectie ook bereikt kan 
worden met individuele moleculen die door de eieren van S. mansoni wormen worden uitgescheiden. 
Tevens laat dit werk zien dat immunologische processen in reactie op een chronische worminfectie 
complex zijn en vaak in synergie optreden. Dit proefschrift draagt bij aan het begrip hoe parasiet-
uitgescheiden moleculen enerzijds regulatoire B cellen kunnen opwekken en anderzijds bescherming 
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